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Abstract 
 
Enterohaemorrhagic Escherichia coli (EHEC) O157:H7 is a formidable pathogen that uses a 
type-III secretion system to inject bacterial ‘effector’ proteins directly into host cells. Most 
effectors that are encoded within the locus of enterocyte effacement (LEE) have been studied 
extensively. This study aimed to characterise a selection of recently discovered non-LEE-
encoded effectors using a variety of model systems. Firstly, a β-lactamase translocation assay 
was used to demonstrate translocation of novel effectors into host cells. The localisation of 
selected effectors was then investigated using mammalian cells and a yeast cell model. The 
effector EspM2 was shown to induce the formation of actin stress fibres in transfected HeLa 
cells and caused growth retardation when expressed in yeast. A number of NleG effectors also 
caused growth retardation and morphological changes when expressed in yeast. Growth 
retardation caused by the effector NleG8-2 was shown to be dependent on three conserved 
cysteine, aspartic acid and histidine residues. Transcriptomics and a high copy yeast gene 
suppression screen revealed that NleG8-2 may disrupt yeast physiology by affecting the 
secretory pathway. This study confirms that the effector repertoire of EHEC O157:H7 is 
much larger than previously imagined and provides insight into the function of selected novel 
effectors.   
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CHAPTER ONE 
Introduction 
 
  
1 
 
1. Introduction 
 
1.1. Escherichia coli 
 
Escherichia coli is a Gram-negative bacterium that lives as a commensal in the lower-gut of 
humans and animals [4]. The bacterium is a useful model organism and is often used as a 
workhorse for molecular biology. However, E. coli is very diverse and numerous strains 
have the ability to cause disease. Diseases such as neonatal meningitis and urinary tract 
infections are caused by extra-intestinal pathogenic E. coli (ExPEC) whereas enteric disease 
is caused by diarrhoeagenic E. coli [5]. Infections with pathogenic E. coli costs millions of 
pounds in lost work time and hospital visits every year [6]; research into these pathogens is 
therefore important.    
 
Diarrhoeagenic E. coli strains are grouped into six distinct pathogenic variants (pathovars) 
based on  clinical presentation, virulence factors and epidemiology [7]. The pathovars 
include enteroaggregative E. coli (EAEC), enterotoxigenic E. coli (ETEC), 
enteropathogenic E. coli (EPEC), enterohaemorrhagic E. coli (EHEC), enteroinvasive E. 
coli (EIEC) and diffusely adherent E. coli (DAEC) [8]. The characteristics of each are 
summarised in table 1.1. Shigella has been shown to be taxonomically indistinguishable 
from EIEC at the species level. However, the distinction between E. coli and Shigella is 
maintained due to the clinical significance of Shigella [8]. 
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Pathovar Characteristics 
DAEC Possesses fimbrial adhesins that cause the formation of 
cellular extensions which wrap around the bacteria [9]. 
Causes diarrhoea in children >12 months old [10]. 
 
EAEC 
 
Possesses enterotoxin and cytotoxin. Forms biofilms and 
autoaggregates in a distinctive ‘stacked brick’ pattern [5]. 
Causes outbreaks of secretory diarrhoea [11]. 
 
EHEC Possesses one or more Shiga toxins. Intimately adheres to 
and effaces enterocytes. Affects children and elderly people 
in developed countries. Causes severe bloody diarrhoea [5]. 
 
EIEC Invades host cells [12].  Causes watery diarrhoea. Closely 
related to Shigella. 
 
EPEC Intimately adheres to and effaces enterocytes [13]. Causes 
diarrhoea in children in developing countries [14]. 
 
ETEC Possesses heat stable (ST) and heat labile (LT) toxins [15].  
Causes watery diarrhoea in children and travellers in 
developing countries [5]. 
Table 1.1: Diarrhoeagenic pathovars of E. coli 
3 
 
1.2. EHEC 
 
Enterohaemorrhagic E. coli strains form a subgroup of Shiga-toxin-encoding E. coli (STEC) 
[16]. EHEC O157:H7 was first recognised as a cause of human disease in 1982 when it was 
identified as the cause of two outbreaks of haemorrhagic colitis in the USA [17, 18]. Shiga 
toxin and/or Shiga-toxin-producing E. coli in the stools of affected patients were also linked 
to sporadic cases of haemolytic-uraemic syndrome (HUS) [19]. EHEC is characterised by 
the ability to cause HUS and haemorrhagic colitis [5]. HUS is defined by three features: 
acute renal failure, thrombocytopenia and microangiopathic haemolytic anaemia [20]. HUS 
is especially dangerous in young children where it causes death in 5% of cases [20]. 
Haemorrhagic colitis is characterised by severe abdominal cramps, bloody stools, lack of 
fever, colonic mucosal oedema and haemorrhage.  
 
EHEC O157:H7 is a formidable pathogen. The infectious dose may be <100 organisms and 
treatment of infection with antibiotics may exacerbate disease [21]. There is currently no 
vaccine to prevent infection with EHEC O157:H7. Outbreaks of EHEC O157:H7 are often 
associated with consumption of contaminated meat products, particularly undercooked beef 
products [22]. The largest-ever outbreak occurred in Sakai City, Japan in 1996; it caused 
>6000 cases and three deaths [23] [24]. The EHEC strain isolated from the Japanese 
outbreak (RIMD 0509952) is known as EHEC O157:H7 Sakai – the genome of this strain 
was sequenced in 2001 [25]. Most outbreaks of EHEC in the USA, UK and Japan are 
caused by the EHEC O157:H7 serotype whereas non-O157 serogroups such as O26 and 
O111 are important in other countries [5] [26].  
4 
 
Cattle and other ruminants are the main reservoir of EHEC O157:H7 [27] [28] [29]. EHEC 
O157:H7 colonises the terminal rectum of cattle [30]. EHEC O157:H7 is released into the 
external environment in bovine faeces [31] and can persist in the farm environment for 
many months in water/feed troughs, making it difficult to prevent infection of other animals 
[32] [33] [34]. A major cause of EHEC infection is direct or indirect contact with ruminant 
faeces [35]. A number of infections, mainly in children, have been attributed to farm visits 
[36].  
 
Infection of the gastrointestinal tract of adult cattle and weaned calves with EHEC O157:H7 
serotype is asymptomatic [37] although intimate adherence to cattle intestinal epithelia and 
induction of a mild inflammatory response has been documented in some cases [38]. This is 
in contrast to infection with other serotypes such as EHEC O26 which cause significant 
morbidity and mortality in cattle [39]. In fact, one could argue that EHEC O157:H7 should 
no longer be considered a commensal of cattle as originally proposed [40]. Infection of 
susceptible calves with EHEC O157:H7 produces diarrhoea, epithelial damage and 
neutrophil infiltration of the lamina propria and intestinal lumen [41]. The relationship 
between EHEC O157:H7 and cattle is therefore complex with the outcome (i.e. 
disease/asymptomatic carriage) depending on many factors including the age of the animal 
[41]. Recent publication of the genome sequence of cattle may help researchers understand 
the relationship between EHEC O157:H7 and cattle [42]. 
 
An increasing number of EHEC O157:H7 outbreaks have been linked to vegetable and salad 
products [43]; for example, radish sprouts were implicated in the Sakai outbreak [24] and 
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ready-to-eat spinach was identified as the cause of a recent outbreak in the US [44]. Recent 
research has shown that EHEC O157:H7 and other pathogens such as Salmonella are able to 
survive on and colonise plant surfaces using type III secretion systems [45-47]. This has 
implications for food safety as techniques such as washing that are currently used to 
decontaminate plant material may need to be more stringent.  
 
1.3. EHEC virulence factors 
 
A wide variety of virulence determinants are used by EHEC O157:H7 to cause disease 
including Shiga toxin and the Esc-Esp type III secretion system (T3SS) encoded by the 
locus for enterocyte effacement (discussed in later sections). Examples of other EHEC 
O157:H7 virulence factors are shown in table 1.2. Space does not permit a full discussion of 
each – the reader is directed to a review of EHEC virulence factors by Nataro et al [5].  
 
EHEC strains produce one or more types of Shiga toxin [48]. The toxin belongs to the AB5 
group of toxins and is thought to be the main factor in the development of HUS in infected 
patients. The toxin binds to globotriaosylceramide-3 (Gb3) receptors on host cells using the 
B subunits [49]. The toxin is then endocytosed by the cell [50] and the catalytic A domain 
acts as a glycosidase to depurinate ribosomes. This causes irreversible inhibition of protein 
synthesis and death of the cell [51] [52]. Interestingly, Shiga toxin has been shown to 
significantly enhance the survival of EHEC O157:H7 and E. coli K-12 in the presence of 
predatory bacterivorous protozoa [53]. Therefore, it is possible that the Shiga toxin gene is 
maintained in the EHEC genome to protect the bacterium against predators in the host gut.  
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EHEC O157:H7 
virulence factor 
Example Characteristics 
Endotoxin O157 LPS Induces cytokine expression through TLR4. O-
antigen-specific antibodies are elicited in calves 
infected with EHEC O157:H7 but this does not result 
in clearance of the bacteria [37]. Vaccines based on 
the O157 LPS elicit specific antibody responses in 
humans and mice but mice were not protected against 
intestinal colonisation by EHEC O157:H7 [54] [55] 
[56].  
Capsule Group 4 capsule Temporal expression of a group 4 capsule (co-
ordinated with T3SS expression) is required for 
colonisation of the host intestine [57].  
Adhesins Intimin 
 
 
ToxB 
 
 
 
Fimbriae 
 
 
 
 
 
 
Binds T3SS effector Tir to mediate intimate adherence 
to host enterocytes [58]. 
 
Encoded on pO157, influences expression of T3SS 
and promotes adherence to host cells but is not 
required for colonisation of young calves [59] [60]. 
 
EHEC O157:H7 encodes 14 fimbrial operons [61]. 
Fimbriae are involved in initial attachment of bacteria 
to host cells but may interfere with T3SS mediated 
intimate attachment [62]. Type I fimbriae are not 
expressed in EHEC O157:H7 due to a deletion in the 
fimA promoter [63]. Long polar fimbriae (LPF1) may 
contribute to colonisation in vivo [64] [65].  
Pili Type 4 pili Long bundles of T4P form haemorrhagic coli pili 
(HCP) that mediate interbacterial, bacterial-epithelial 
cell and bacterial-extracellular matrix interactions. 
This contributes to colonisation of the host [66].  
Toxins Stx 
 
 
EhxA 
Shiga toxin depurinates rRNA leading to inhibition of 
protein synthesis and induction of apoptosis [51] [52]. 
 
Enterohaemolysin  causes cell lysis of erythrocytes 
and leukocytes [67]. 
 
Flagellar T3SS Flagella Used for bacterial motility/chemotaxis [68]. Also 
increases bacterial adhesion to epithelial cells in vivo 
[69] [70]. Flagellin binds TLR5 which activates IL-8 
expression and an inflammatory response [71]. 
Proteases EspP 
 
 
 
 
StcE 
Type V secreted serine protease encoded on pO157 
that cleaves human coagulation factor V [72]. 
Required for adherence to and colonisation of bovine 
intestine [73]. 
 
Metalloprotease, C1-esterase inhibitor, disrupts 
complement cascade [74]. 
 
Table 1.2: EHEC O157:H7 virulence factors (excluding nf-T3SS) 
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1.4. Type III secretion 
 
Secretion of proteins is important for bacterial pathogens as it allows them to transport a 
variety of virulence determinants from their cytosol to the external milieu and host cells. 
The Gram-negative cell envelope consists of an inner membrane, a thin peptidoglycan layer 
(contained within the periplasm) and an outer membrane [75]. Gram-negative bacteria 
including pathogenic E. coli are able to move proteins across the cell envelope using at least 
six different secretion systems.  Each system uses its own dedicated structural machinery 
and auxiliary proteins, such as chaperones, to support the different modes of secretion. 
Secretion may occur in a single step as in types I, III and IV or in multiple stages as in types 
II and V. Table 1.3 summarises each secretion system. 
 
There are two main classes of type III secretion system (T3SS), the flagellar and the non-
flagellar. The subsystems are homologous and monophyletic i.e. they have evolved from a 
common ancestor [76-78]. Each system is comprised of over 20 proteins and they form 
some of the most complex bacterial structures characterised to date. The flagellar T3SS is 
involved in flagellar biosynthesis [79]. Flagella are used by bacteria for swimming and 
swarming. The non-flagellar T3SS (nf-T3SS) is used by both commensal and pathogenic 
bacteria to deliver bacterial ‘effector’ proteins directly into eukaryotic cells through a 
‘molecular syringe’ [80]. This may enable bacteria to colonise, disseminate and survive 
within the mammalian/plant/insect host. T3SSs are versatile – they are not limited to a 
particular bacterial species, host environment or disease spectrum. The work presented in 
this thesis concentrates on the nf-T3SS; subsequent reference to T3SS refers to the nf-T3SS 
unless otherwise stated.  
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Table 1.3: Secretion systems used by Gram-negative bacteria. 
System Example Mechanism 
 
Type I 
(T1SS) 
 
α-haemolysin secretion by 
uropathogenic E. coli [81] 
 
One-step Sec-independent secretion. Substrates are 
secreted across the cell envelope using an ABC 
transporter, a membrane fusion protein and a pore-
forming outer membrane protein to cross the inner 
membrane, periplasm and outer membrane 
respectively [82]. Substrates possess a C-terminal 
signal peptide that is not cleaved during secretion. 
 
Type II 
(T2SS) 
Pullulanase secretion by 
Klebsiella oxytoca [83]. 
Two-step Sec-dependent secretion of proteins.  
Proteins cross through the inner membrane using a 
multi-subunit translocon (general secretory 
pathway). Proteins then cross the outer membrane 
through a ring-shaped secreton complex [84]. 
Substrates have an N-terminal signal peptide that is 
cleaved during secretion. 
 
Type III 
(T3SS) 
Yop secretion by Yersinia 
pestis [85] 
One-step Sec-independent secretion of proteins 
through a central channel that spans the cell 
envelope. A hollow filament extends from the outer 
membrane. The filament is either used to deliver 
bacterial proteins into eukaryotic cells or for 
locomotion depending on the type of system 
(flagellar/non-flagellar) [86]. 
 
Type IV 
(T4SS) 
Pertussis toxin secretion by 
Bordetella pertussis [87] 
One-step Sec-independent secretion mechanism. 
The apparatus is similar to T3SS in structure and 
function i.e. substrates are secreted into host cells 
through a pilus. However, substrates can include 
DNA as well as proteins [88].  
  
Type V 
(T5SS) 
IgA protease secretion by 
Neisseria gonorrhoeae [89] 
Two-step Sec-dependent secretion. Proteins are 
secreted across the inner membrane by the general 
secretory pathway as in T2SS. The C-terminal β-
barrel domain of the substrate (Type Va) or its 
partner (Type Vb) then forms a pore in the outer 
membrane allowing the substrate to pass through 
the outer membrane [90]. Substrates have an N-
terminal signal peptide that is cleaved during 
secretion.   
 
Type VI 
(T6SS) 
Haemolysin-coregulated 
protein (HCP) secretion by 
Vibrio cholerae [91] 
A newly identified system. The structure, function 
and localisation of many components of the system, 
are poorly understood although there is evidence 
that proteins are translocated directly into host cells 
as in T3SS and T4SS [92]. Substrates have no N-
terminal secretion signal.   
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The T3SS requires several types of protein: 
 Structural proteins – form an injectisome. The injectisome comprises two rings (one 
in each bacterial membrane) joined by a short rod (periplasmic) and a needle that 
extends from the outer membrane ring. Bacterial proteins pass through the 
injectisome from the bacterial cytosol to the eukaryotic cytoplasm in one step. The 
structure of the Esc-Esp T3SS is shown in figure 1.1.  
 Translocator proteins – located at the tip of the needle; allow passage of effector 
proteins into the host cell. 
 Effector proteins – secreted into eukaryotic cells by the T3SS; subvert normal host 
cell processes to the benefit of the bacteria. 
 Chaperones – assist in the unfolding and secretion of effector proteins. 
 Regulatory proteins – control expression of the T3SS and secretion of translocators 
and effectors. 
 
Phylogenetic analysis of the ATPases of injectisomes reveals that there are seven families of 
T3SS [76] [86]. The families of T3SS with examples of the organisms that possess them are 
shown in table 1.4. Individual species of bacteria can contain more than one type of T3SS. 
For example, Burkholderia pseudomallei contains two plant pathogen-like T3SS (TTS1 and 
TTS2) [93] and one animal pathogen-like T3SS (Bsa) [94]. Salmonella possesses two 
T3SSs; T3SS-1 and T3SS-2 which are used for initial invasion of host cells [95] and for 
survival and replication within host cells respectively [96].  
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Figure 1.1: Graphical representation of the Esc-Esp T3SS. EM; eukaryotic 
membrane, OM; outer membrane, PG; peptidoglycan layer, IM; inner membrane. 
Image used with permission from Pallen et al., 2005 [1]. 
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T3SS Family Organisms Examples 
 
Ysc 
 
Yersinia  
Pseudomonas aeruginosa 
Aeromonas salmonicida 
 
Includes the Ysc T3SS found in Yersinia spp 
(where it is necessary for survival within 
macrophages [97, 98] [99]) the Psc T3SS of 
Pseudomonas aeruginosa and the Asc T3SS 
of Aeromonas sp. 
 
Inv-Mxi-Spa 
 
Shigella 
Salmonella 
 
Includes the Inv-Mxi T3SS found in Shigella, 
the Inv-Spa T3SS of Salmonella and the Bsa 
system in Burkholderia pseudomallei. These 
T3SSs are involved in uptake of the bacteria 
by host cells to promote intercellular 
dissemination within the host [100] [101] 
[102]. 
 
Ssa-Esc 
 
E. coli 
Salmonella 
 
EPEC and EHEC use the Esc-Esp T3SS to 
intimately attach to and efface host cells 
[103]. Salmonella uses the SPI-2 encoded Ssa 
T3SS to interfere with phagosome maturation 
in macrophages to allow bacteria to multiply 
within host cells [104]. 
 
Rhizobiales 
 
Symbiotic bacteria of plants 
such as the nitrogen-fixing 
Rhizobiaceae family 
 
This system is necessary for the establishment 
of a beneficial symbiosis between the 
bacterium and plant host e.g. by inducing root 
hair deformation and nodule formation [105] 
[106] [107]. 
 
Chlamydiales 
 
Chlamydia 
 
T3SS used to modulate host cell cytokine 
release and to support intracellular survival 
and growth [108]. 
 
Hrc-Hrp1 and 
Hrc-Hrp2 
 
 
Plant pathogens including 
Pseudomonas syringae, 
Xanthomonas campestris  
 
T3SS play a significant role in colonisation of 
the plant surface and in the formation of 
lesions [109-111]. T3SS enables bacteria to 
cause disease on susceptible hosts [112] but 
induces the hypersensitive response in non-
susceptible hosts [113]. 
 
Table 1.4: Families of T3SS 
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Both flagellar and nf-T3SSs play an important role in bacterial virulence and symbiosis (the 
flagellar system also has an important role in motility) [114] [115]. Our understanding of 
these processes therefore depends upon understanding both types of T3SS and the functions 
of nf-T3SS effector proteins. The study of T3SSs is also important as the T3SS provides an 
attractive target for novel vaccines/drugs [116]. For example, EspA-based vaccines have 
been designed to reduce colonisation of cattle by EHEC O157:H7 as the EspA filament is 
exposed to host immune cells during infection [117]. Also, screening of small molecule 
inhibitors in Yersinia [118], Chlamydia [119, 120], EPEC [121] and Salmonella [122] has 
identified several compounds capable of inhibiting the T3SS without affecting bacterial 
replication [122]. The T3SS may also provide an attractive drug/vaccine delivery tool – 
biologically active cytokines and antigens have been delivered into eukaryotic cells using 
T3SSs of attenuated Shigella [123] and Salmonella [124].    
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1.5. T3SS effectors 
 
Effector proteins are bacterial T3SS proteins that function primarily inside the host cell 
[125]. It is predicted that effectors are secreted in a denatured/partially denatured state 
although it is unclear as to how (or whether) effectors depend upon host cell molecules to 
fold into a functional state after secretion. Studies of BopE (B. pseudomallei effector) 
suggest that effectors may be capable of spontaneously folding into a functional state after 
translocation into the host cell cytoplasm [126]. 
 
Translocation of effectors into the host cell leads to subversion of the host cell [127]. 
Effectors may cause local (e.g. cytoskeletal) or systemic (e.g. immune response) changes in 
the host. Therefore, subversion can have a variety of outcomes for example, invasion of the 
host cell [128], evasion of the host immune system [85] or development of a beneficial 
symbiosis between the host and bacterium [107]. Examples of T3S effectors from various 
T3S organisms are shown in table 1.5.  
 
Local disruption of the cytoskeleton allows invasive bacteria to both survive/multiply within 
host cells and also to move intra/intercellularly to disseminate within the host and avoid host 
immune surveillance [129]. For example, many Shigella and Burkholderia pseudomallei 
T3SS effectors are involved in subversion of the actin and microtubule cytoskeleton of host 
cells, pathogen escape from endocytic vesicles and intercellular spread [128] [102]. T3SS 
effectors and actin-based motility are central to the pathogenicity of these pathogens [130] 
[131] [132].  
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Systemic changes are caused by numerous effectors – many modulate the host immune 
response e.g. effectors may affect IL-8 synthesis to cause or prevent attraction of neutrophils 
[133] [134]. P. aeruginosa induces IL-8 production using T3SS effector ExoU. ExoU 
activates JNK resulting in activation of AP-1 (a transcription factor) which up-regulates IL-
8 synthesis [135]. Activation of the immune system in this way might aid pathogen 
colonisation by decreasing the number of resident gut microflora (as occurs in Citrobacter 
infections [136]). Down regulation of the immune response (as shown by EPEC [134]) may 
enable bacteria to reach a critical mass, disseminate/cause disease and spread to other 
organisms.  
 
Many local and systemic changes in the host are controlled by small GTPases. These highly 
conserved molecular switches are involved in many aspects of eukaryotic cell biology [137] 
e.g Rho GTPases regulate actin cytoskeleton and microtubule dynamics as well as the cell 
cycle [138]. Their central role in eukaryotic biology and their ancient/conserved nature 
means that GTPases are often targeted by T3SS effectors [139] [140]. GTPases are 
regulated by GEFs (GTP exchange factors) and GAPs (GTPase activating proteins) that 
activate and inactivate GTPases respectively [137]. Activation of GTPases can have a 
variety of outcomes including up/down regulation of the immune response via the MAPK 
signalling pathway [141]. Numerous effectors mimic GAP/GEFs and activated forms of 
GTPases (see table 1.5). 
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Eukaryotic 
target 
Effectors Function Outcome 
Actin 
cytoskeleton 
Tir (Citrobacter 
rodentium) 
 
VopL (Vibrio) 
 
Binds Nck to activate N-WASP 
and recruit Arp2/3 [142]. 
 
Arp2/3-independent actin assembly 
[143]. 
 
Actin polymerisation and 
pedestal formation. 
Intestinal colonisation [144] 
Disrupts actin homeostasis 
of host cells [145]. 
Microtubule 
cytoskeleton 
VirA (Shigella) Disrupts microtubules [146].  Enhanced intra- and 
intercellular spread [147]. 
    
Tight junctions SopE (Salmonella) Rho GEF [148]. Disruption of tight junction 
structure and function – 
contributes to diarrhoea 
[149]. 
    
Cell cycle Cif (EPEC) Inhibits mitosis inducer CDK 1 by 
preventing degradation of CDK 
inhibitors [150].  
Inhibition of cell cycle at 
G2/M phase transition [151]. 
    
Mitochondria Map (EPEC) Disrupts mitochondrial membrane 
potential and morphology [152]. 
Mitochondrial swelling, 
damage and dysfunction 
[153] [154]. 
    
Signalling 
(Ubiquitination) 
SseL (Salmonella) 
 
IpaH9.8 (Shigella) 
Deubiquitinase [155]. 
 
Ubiquitin E3 ligase [156]. 
Macrophage death [155]. 
 
Disruption of host MAPK 
signalling pathways [156]. 
    
Signalling (Rho 
GTPases and 
MAPKs) 
YopE (Yersinia) 
 
 
IpgB2 (Shigella) 
 
SptP (Salmonella) 
SopE2 
(Salmonella) 
Map (EPEC) 
 
 
YopJ (Yersinia) 
 
 
VopA (Vibrio) 
 
OspF (Shigella) 
 
ExoT 
(Pseudomonas 
aeruginosa) 
Rho GAP [157] [158]. 
 
 
Rho mimic [159]. 
 
Rho GAP [160]. 
Rho GEF [160]. 
 
Cdc42 mimic [159]. 
 
 
MAPKK acetyltransferase [161]. 
 
 
MAPKK acetyltransferase [162]. 
 
MAPK phosphothreonine lyase 
[163]. 
 
Rho GAP [164]. 
Inhibits Rac1 to inhibit 
phagocytosis and superoxide 
anion production [165]. 
Induces formation of actin 
stress fibres [159]. 
See text. 
Bacterial uptake [148]. 
 
Actin cytoskeleton 
rearrangement (filopodia) 
[159]. 
Decreased chemokine 
production, apoptosis [166, 
167]. 
Decreased cytokine 
production, apoptosis [162] 
Blocks activation of NF-κB 
responsive genes [168]. 
 
Disrupts cytokinesis [169]. 
Table 1.5: Examples of T3SS effectors. 
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Effectors may function individually, synergistically or antagonistically with other effectors 
within the host cell to perturb normal cell processes. For example, EHEC Tir and TccP act 
together to disrupt and manipulate the actin cytoskeleton whereas others e.g. Salmonella’s 
SopE and SptP counteract each other. Such interactions between effectors can be important 
in the progression of infection through various stages. The antagonistic action of SptP 
(represses the activation of cellular GTPases caused by SopE [170]) restores normal 
cytoskeletal function thus preventing the expulsion of internalised bacteria. This promotes a 
transition between the invasive and intracellular growth stages of the Salmonella infection. 
T3SS effectors can also act alongside other secretion system proteins e.g. autotransporter 
proteins during infection processes such as dissemination. For example, B. pseudomallei 
uses the Bsa T3SS to invade host cells [102] and escape into the cytoplasm (via lysis of the 
endosomal membrane [102]). It then uses the T5SS protein BimA (induces actin 
polymerisation at the pole of the cell [171]) to facilitate cell-to-cell spread and 
dissemination within the host [171]. 
    
Individual T3SS effectors often exhibit multiple functions; for example, EPEC EspF targets 
mitochondria, the tight junction proteins Nexin-9 and occludin, and inhibits PI-3 kinase 
[172] [173]. Functional redundancy between effectors has also been demonstrated: EspF 
targets mitochondria, an organelle also targeted by another EPEC effector, Map [174].  
 
Effector proteins, in contrast to T3SS structural proteins, are very diverse and do not show a 
high degree of sequence similarity between species [175] [176]. Similar strains of the same 
species can possess different repertoires of effectors. Over 300 different effectors are known 
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to exist [2]. However, despite T3SS effector diversity, there are common themes in the 
nature of the host cell processes that effectors manipulate and exploit. Many effectors target 
the host cell cytoskeleton and host cell signalling pathways. These are often the most 
conserved processes and pathways of eukaryotic cell biology. This is perhaps due to an 
ancient, long standing interaction between bacteria and eukaryotic cells. There is increasing 
evidence that T3SS may have evolved, not as virulence factors for bacterial pathogenesis in 
animals, but for other roles in microbial ecology such as survival within predatory amoebae 
[177]. Recently, the Salmonella T3SS encoded by SPI-2 was found to be essential for 
survival within Acanthomoeba polyphaga [177]. Other virulence factors including T2SS and 
T4SSs (in Legionella pneumophila [178] [179]) and toxins (Stx of EHEC O157:H7 [53]) 
have been shown to increase survival of bacteria in predatory protozoa. 
 
The study of T3SS effectors allows us to better understand the interface between T3S 
organisms and their host, and may ultimately provide opportunities for therapeutic 
intervention [180] and vaccine design [181]. An increasing number of T3SS effectors and 
translocator proteins have been identified as T cell immunogens (i.e. vaccine candidates). 
For example, the B. pseudomallei effector BopE induced a BopE-specific T cell response in 
immunised mice [182] (although it provided incomplete protection against infection). 
Yersinia effector YopE also elicited a T3SS-specific T cell response in mice challenged with 
this effector [183].  
 
T3SS effectors have also proved to be useful tools in the study of eukaryotic cell biology – 
allowing the molecular dissection of complex signalling pathways and cytoskeletal 
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processes [184]. In particular, our understanding of actin assembly in eukaryotic cells has 
greatly improved through the use of T3SS effectors [185]. For example, the minimal 
requirements for actin assembly in structures such as lamellipodia and filopodia can be 
defined using T3SS effectors from organisms such as Shigella and Burkholderia [186]. 
Novel connections and new classes of enzymes have also been discovered using T3SS 
effectors e.g. investigations into Salmonella effectors that modulate GTPase activity 
identified a novel connection between the Cdc42 and Slt2 mediated cell integrity pathway in 
yeast [160]. Structural studies of the Shigella effector IpaH led to the discovery of a novel 
class of E3 ubiquitin ligases [156, 187, 188]. 
 
1.6. T3SS in EHEC mediated disease 
 
EHEC O157:H7 was shown by Tzipori et al to adhere to intestinal epithelia in a similar 
manner as EPEC and cause attaching and effacing (A/E) lesions in the intestines of infected 
piglets [189]. Knutton et al subsequently showed that the A/E lesion was characterised in 
vitro by bacterial microcolonies intimately adhering to the surface of cultured cells with 
cytoskeletal actin accumulation beneath the adherent bacteria [190] [191] [192] (see figure 
1.2). Actin polymerisation beneath the site of adherence caused protrusions of the host cell 
plasma membrane known as pedestals [13]. Knutton et al used the actin-rich nature of the 
pedestals to devise a diagnostic test for EPEC infection using fluorescently labeled 
phalloidin (a toxin that binds filamentous (F)-actin) [13]. The fluorescent actin staining 
(FAS) test allowed infection with the EPEC pathotype to be diagnosed more quickly and 
easily than did O:H serotyping [13]. Formation of the EPEC A/E lesion was subsequently 
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shown by Jerse et al to be dependent on a gene, eae (E. coli attaching and effacing) [193] 
that was also found in EHEC O157:H7 [194]. McDaniel et al then showed that the eae gene 
was encoded within a 35-kb pathogenicity island and that this island was found in many 
enteric pathogens [195]. The pathogenicity island was shown to encode genes for 
attachment, a T3SS and T3S effector proteins [103, 195] and was termed the locus for 
enterocyte effacement (LEE) [196]. The LEE-encoded T3SS is an important virulence 
factor of EHEC and other A/E pathogens (e.g. Citrobacter rodentium, EPEC) [196]. The 
LEE is required for full virulence and for efficient colonisation of cattle by EHEC O157:H7 
[197] and other EHEC serotypes [198]. The next section describes the LEE and associated 
T3SS effectors.   
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Figure 1.2: The attaching and effacing lesion. Scanning electron 
micrograph of EHEC O157:H7 intimately adhering to enterocytes. The 
LEE-encoded T3SS is required for the formation of the A/E lesion. Image 
used courtesy of Dr R. Shaw, University of Birmingham.    
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1.7. Locus of Enterocyte Effacement 
 
1.7.1. The LEE is a pathogenicity island 
 
T3SS are often encoded by pathogenicity islands; for example the Salmonella pathogenicity 
island SPI-1 encodes a T3SS required for invasion of intestinal cells [199]. PAIs are a 
subclass of genomic island that encode virulence factors and share many features [200] 
[201]. These features will be discussed with reference to the LEE:  
 PAIs carry genes that encode virulence factors (e.g. adhesins, toxins, secretion 
systems); the LEE encodes a T3SS, T3SS effector proteins and an adhesin that 
produce the A/E lesion.  
 PAIs are present in the genome of pathogenic bacteria but not in the genome of 
similar non-pathogenic members of the same species [201]. The LEE is found in 
attaching and effacing E. coli but not in non-pathogenic lab-strains of E. coli [202] 
[195].  
 PAIs are relatively large: 10-100kb. The EHEC O157:H7 LEE is approximately 
43kb in length [203].  
 PAIs differ in G+C content and codon usage from the rest of the host genome. The 
EHEC O157:H7 LEE has a G+C content of approximately 40% whereas the rest of 
the chromosome has an average G+C content of 50.8% [201].  
 PAIs are often flanked by directly repeated DNA sequences. The 5’ end of the 
EHEC LEE contains a directly repeated sequence from a P4-like prophage [203]. 
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 PAIs are often associated with tRNA genes. The EHEC O157:H7 LEE is inserted 
into the selC tRNA locus. However, pheU and pheV loci are also used in other E. 
coli strains [204-207]. 
 PAIs often carry mobility factors (although these are sometimes non-functional) e.g. 
integrases, transposases, insertion (IS) elements. The EHEC O157:H7 LEE carries a 
P4-like prophage element (933 L). The C. rodentium LEE contains many IS 
elements [201]. 
 PAIs represent unstable regions of DNA i.e. easily deleted/transferred/transmitted. 
Previous autonomous mobility of the LEE is suggested by the IS600-like insertion 
elements found at the ends of the LEE and a transposase-like peptide encoded by a 
small CDS [203]. The position of the LEE within A/E pathogen genomes also 
varies; suggesting that the LEE has been acquired independently, a number of times, 
by A/E pathogens [76, 208]. 
 
PAIs are acquired by horizontal gene transfer (HGT) [209]. HGT of PAIs via transduction, 
conjugation or transformation is significant – along with modification and loss of existing 
genes, acquisition of new genes is an important process in the evolution of bacterial 
pathogens [201]. Acquisition of PAIs enables bacteria to make a ‘quantum leap’ towards 
pathogenicity. This has been demonstrated by functional transfer of T3SSs encoded on 
pathogenicity islands. For example, transfer of the ‘high pathogenicity island’ of a virulent 
Yersinia enterocolitica strain to a less virulent strain resulted in increased virulence in the 
recipient strain [210]. Similarly, transfer of the EPEC LEE to E. coli strain K-12 conferred 
the ability to form A/E lesions on enterocytes [211]. There is evidence to support the 
hypothesis that the LEE was acquired independently via horizontal gene transfer by EPEC 
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and Citrobacter rodentium [208]. The insertion site of the EPEC LEE (inserted in the selC 
tRNA gene) is different from the insertion site in C. rodentium which is flanked by plasmid 
sequences [208]. The presence of plasmid sequences suggests that the LEE may have 
resided on a horizontally transferable plasmid [208]. Horizontal transfer of plasmids among 
A/E pathogens is plausible – plasmids pCRP3 of C. rodentium and p9705 of EHEC 
O157:H7 are very similar [208].  
 
Many E. coli strains, including EHEC O157:H7, contain a PAI that encodes a degenerate 
T3SS [212] [213]. This PAI is known as E. coli type III secretion system 2 (ETT2). 
Although the secretion system encoded by ETT2 cannot be used for secretion of proteins 
due to frameshifts in the secretion apparatus genes [213], ETT2 retains a regulatory role in 
the secretion of proteins through the LEE-encoded T3SS [3].  
 
1.7.2.     Structure of the LEE 
 
The EHEC O157:H7 Sakai LEE contains 54 coding sequences (CDS). 41 of these are 
common to the EPEC and C. rodentium LEE. The EHEC Sakai LEE is located at the selC 
tRNA gene [208]. The 13 CDSs found only in EHEC belong to a P4-like prophage that is 
inserted near the selC locus. The genes of the EHEC O157:H7 Sakai and EPEC LEE often 
show more than 98% homology and the order and orientation of the loci in both pathovars 
are identical [203]. The proteins encoded in the LEE include: T3SS structural proteins; 
translocators; the adhesin intimin; regulatory proteins; chaperones of effectors and a small 
number of effectors [214, 215]. LEE genes are ordered into 5 large polycistronic operons 
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(LEE1-5) and several smaller transcriptional units. Most of the structural proteins that make 
up the injectisome are encoded in LEE1 and LEE2. LEE3 encodes the ATPase (EscN), an 
effector protein (EspH) and a number of Sep proteins that are important in the control of 
secretion hierarchy. A variety of protein types are encoded in LEE4 including the effector 
EspF, the chaperone CesD2 and the translocator proteins, EspA, EspB and EspD. LEE5 
encodes Map, Tir, the Tir chaperone CesT and intimin. The 41 LEE CDS common to EHEC 
and EPEC are shown in figure 1.3. 
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Figure 1.3: 41 CDS common to both EHEC and EPEC LEE regions. The function of 
proteins encoded by each CDS is indicated by colour. Operons LEE1-5 are also indicated. 
A B
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1.7.3. LEE-encoded translocators 
 
The needle of the Esc injectisome, unlike other type III needles has a long flexible filament 
attached to the tip. The filament is composed of EspA and assists in initial attachment of 
bacteria to enterocytes [216-219]. EspA is probably homologous to flagellin [1] [218] [220] 
and polymerises to form a filament at the distal end of the needle with a channel of 25-Å 
diameter [221]. EspA is required for colonisation of the calf intestine by EHEC O157:H7. 
Due to its role in colonisation and its exposure on the surface of EHEC O157:H7 cells, 
EspA has been tested as a vaccine to prevent infection of cattle. However, results showed 
that despite the induction of a high-titre antigen-specific IgG and IgA response to EspA, 
calves were not protected against colonisation by EHEC O157:H7 [222]. Translocators 
EspB and EspD lie at the end of the EspA filament and form a pore in the host cell 
membrane through which effector proteins pass into the host cell [223] .  
 
1.7.4. LEE-encoded chaperones 
 
The LEE also encodes several chaperones that are required for efficient secretion of 
effectors and translocator proteins [224]. T3SS chaperones have various functions 
including; delivery of substrate to the secretion apparatus, prevention of substrate 
degradation and efficient secretion of the substrate [224, 225]. Chaperones may also 
maintain substrates in a secretion competent state (e.g. prevent polymerisation of EspA 
[226]), aid protein entry into the secretion machinery [225], and control the hierarchy of 
effector secretion [227] [228]. T3SS chaperones are divided into several classes. Class I 
chaperones are small acidic proteins that associate with effector proteins. There are three 
27 
 
class I chaperones encoded within the LEE; CesF [229], CesT [196] and Orf12 [Pallen, 
unpublished]. The effectors Tir, EspH, EspZ and Map require CesT for secretion [230] 
whereas EspF requires CesF [230]. Class II chaperones contain three tetratricopeptide repeat 
motifs and assist in the secretion of translocator proteins [231] [232]. The LEE-encoded 
protein CesD is a class II chaperone; CesAB and CesD2 appear to form two distinct classes 
of their own [233]. An additional chaperone of EspA encoded by LEE gene L0017 was 
recently characterised [234]. 
 
1.7.5. Regulation of LEE gene expression 
 
Coordinated control of virulence gene expression in response to environmental changes is 
vital to pathogen survival [235]. T3SSs are costly in terms of the amount of substrates (e.g. 
amino acids) used in their construction; transcriptional regulation of T3SS expression is 
therefore tightly controlled. T3SSs are only expressed under specific environmental 
conditions or in response to certain stimuli e.g. quorum sensing [236]. For example, 
Aeromonas salmonicida A449 expresses its T3SS in response to a rise in temperature or salt 
concentration [237]. Regulation of the LEE is complex and a full discussion is beyond the 
scope of this introduction – the reader is directed to recent reviews for more information on 
transcriptional regulation of the LEE [236, 238]. Figure 1.4 provides a summary of LEE 
regulation. At least four regulatory inputs influence expression of LEE genes. These 
include:  
 a regulatory hierarchy within the LEE involving LEE-encoded regulators Ler [239], 
GrlR and GrlA [196].  
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 global regulators and responses e.g. H-NS, IHF, FIS, quorum sensing and responses 
to host hormones e.g. noradrenaline [236].  
 regulators encoded on mobile genetic elements [3]. 
 Post-transcriptional processing. Experimental evidence demonstrates that post 
transcriptional processing of LEE4 may allow differential regulation of SepL and 
Esp protein production [240].  
 
In EHEC O157:H7, environmental factors such as temperature, nutrient availability, ion 
concentrations and butyrate are evaluated by sensing systems [241] [242]. This results in 
expression of transcriptional regulators which then activate or repress virulence gene 
expression [243] [244]. For example, the stringent response in EHEC O157:H7 
differentially regulates expression of phage/PAI encoded perC-homologous (pch) genes 
[245]. Pch genes are positive regulators of the LEE [246]. Activation of transcription of the 
LEE1 operon by such regulators results in expression of Ler [246]. Ler is itself a 
transcriptional regulator that activates transcription of other LEE operons by antagonising 
repression caused by H-NS [247]. GrlA and GrlR are LEE-encoded regulators that act with 
Ler to regulate transcription of various LEE operons to coordinate construction of the T3SS 
[248]. Ler and GrlA are also involved in the regulation of non-LEE-encoded virulence 
factors e.g. enterohaemolysin [249] [250]. Cross regulation of T3SS and flagella in EHEC 
O157:H7 by GrlA/GrlR has also been demonstrated [251]. Other transcriptional regulators 
encoded on mobile elements such as EtrA and EivF that are encoded within the ETT2 locus 
in EHEC O157:H7 have been shown to negatively regulate transcription of the LEE [3]. 
Also, proteins encoded on pO157 including ToxB and Efa-1’ are required for the expression 
of LEE genes and secretion of type III secreted proteins in EHEC O157:H7 [60]. 
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Figure 1.4: Regulation of the EHEC O157:H7 LEE. Transcription of the LEE is 
regulated by LEE encoded proteins, regulators encoded on mobile elements and global 
regulatory systems. QS, quorum sensing; NE, noradrenaline. Arrowheads indicate 
positive influences, crossbars indicate negative influences. Figure adapted from Zhang 
et al., 2004 [3].
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1.7.6. LEE-encoded effectors 
 
A small number of T3SS effectors are encoded within the LEE [196]. They include: Tir 
[58], EspF [252], EspG [253], EspH [254], EspZ [255], and mitochondrial associated 
protein (Map) [153]. The translocator EspB is also translocated into host cells [256].  
 
The translocated intimin receptor (Tir) was the first T3SS effector of A/E pathogens to be 
characterised [58]. This effector is essential for formation of the A/E lesion [59] [257]. 
Without it, A/E pathogens are less able to colonise the host [196] [258]. As its name 
indicates, Tir acts as a receptor for the bacterial adhesin intimin, which is also encoded 
within the LEE [58]. After translocation into the host enterocyte, Tir inserts into the apical 
host cell membrane. Here it adopts a hairpin–like structure with both the amino- and 
carboxy-termini of the protein facing the host cell cytoplasm and the mid section of the 
protein exposed to the external milieu. The mid section forms the receptor for intimin 
present on the bacterial surface. The N-terminus of Tir interacts with cytoskeletal proteins 
such as α-actinin and cortactin [259, 260]. The C-terminus of Tir may be phosphorylated at 
a specific tyrosine residue (Y474) and bind Nck to indirectly activate host N-WASP or 
remain unphosphorylated and bind Tir cytoskeleton coupling protein, TccP [261, 262]. 
Alternatively, Tir may bind both Nck and TccP to activate N-WASP [263]. N-WASP then 
recruits host protein Arp2/3 which leads to actin polymerisation beneath the adherent 
bacterium and pedestal formation [261]. EHEC O157:H7 Tir binds TccP to activate N-
WASP. However, pedestals were detected beneath an adherent EHEC O157:H7 TccP 
mutant in calves. Colonisation of the calves by the mutant was also unaffected whereas 
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pedestal formation in vitro was affected [257]. This suggests that, in vivo, actin assembly 
may occur by a distinct mechanism.  
 
Map contains an N-terminal mitochondrial targeting sequence and causes mitochondrial 
swelling, damage and dysfunction by interfering with the mitochondrial membrane potential 
[153]. Map also binds EBP50/NHERF1 via a C-terminal TRL motif to induce filopodia 
formation and disruption of tight junctions [264].  
 
EspF is a potent multifunctional effector. Studies have shown that it is able to disrupt host 
intestinal barrier function [265], coordinate host membrane trafficking [266] and cause 
apoptosis [267] [268]. EspF also inhibits sodium exchanger 3 activity [269], activates N-
WASP [266] and causes redistribution of aquaporins [270]. 
 
EspG is homologous to VirA of Shigella [253]. The main function of EspG is disruption of 
microtubules [271] [272] [273]. Pertubation of microtubules by EspG has been shown to 
have various effects on the host cell including a decrease in the level of the anion exchanger 
DRA in host cell apical plasma membrane, mislocalisation of enterocyte aquaporins AQP2 
and AQP3 [274] and alteration of paracellular permeability [275]. Disruption of chloride 
transport in the intestinal luminal membrane and redistribution of aquaporins may contribute 
to diarrhoea [276].  
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EspH modulates the actin cytoskeleton and when overexpressed causes elongation of 
pedestals and represses formation of filopodia [254].  
 
EspZ is a hypervariable effector that, contrary to initial reports, does not mediate uptake of 
bacteria into host cells or affect phosphorylation of Tir [255]. EspZ is delivered at high 
levels (comparable with Tir) early in the infection process [230].  
 
1.8. Non-LEE-encoded effectors 
 
1.8.1. The LEE is not self-contained 
 
Transfer of the EPEC LEE [211] but not the EHEC O157:H7 LEE [277] to E. coli K-12 is 
sufficient to confer the A/E phenotype on this non-A/E strain. This shows that the EHEC 
O157:H7 LEE is not self contained and that non-LEE-encoded effectors are required for 
A/E lesion formation. Whilst characterising the C. rodentium LEE, Deng et al discovered 
seven non-LEE-encoded effectors (Nle A-G) that were translocated through the LEE-
encoded T3SS [196]. Other non-LEE-encoded effectors have since been discovered; TccP 
[278], EspJ [279], EspG2 and Cif [151]. This shows that the EHEC O157:H7 LEE, like 
other T3SS PAIs, does not act in isolation. For example, Salmonella encode many T3SS 
effectors outside their T3SS PAIs [280] and the plant pathogen Pseudomonas syringae 
encodes over 200 T3SS effector proteins outside the Hrp locus [281] [176].  
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The occurrence of numerous T3SS effector genes encoded outside the T3SS pathogenicity 
islands of many T3S organisms prompted Pallen and his research group (in collaboration 
with Toru Tobe and Gad Frankel) to investigate the presence of non-LEE effector genes in 
EHEC O157:H7. The rest of this section describes the work carried out by the 
aforementioned groups (author was a member of the Pallen group) in the search for non-
LEE-encoded T3SS effectors in EHEC O157:H7 Sakai. The work documenting the 
discovery of novel non-LEE effectors was published in 2006 and is subsequently referred to 
as work by Tobe et al [2]. The genomic context of the novel effector genes is discussed. The 
final section of this chapter provides a discussion of model systems that have been used to 
investigate T3SS effector localisation and function to provide a background to the 
experimental work presented in subsequent chapters.  
 
1.8.2. Non-LEE-encoded effectors in EHEC O157:H7  
 
T3SS effector genes do not have common amino acid sequences such as secretion signal 
peptides (as found in other secretion systems such as T2SS) [282].  This means that T3SS 
effectors cannot be identified by simple analysis of protein sequences - one is forced to rely 
on the detection of homology to known effectors using more advanced sequence analysis 
such as Basic Local Alignment Sequence Tool (BLAST) and Position Specific Iterative 
(PSI)-BLAST.  
 
PSI-BLAST is a powerful tool used to find distant homologies to an input query sequence 
[283] [284]. The original BLAST program calculates similarity and produces alignments 
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between a query sequence and sequences contained within a database [285]. BLAST also 
provides a statistical estimate as to the likelihood of two sequences being related by chance 
alone [285]. PSI BLAST is similar to BLAST except that a position-specific scoring matrix 
(PSSM) is used in place of the query sequence in an iterative process [283]. The PSSM 
allows patterns to be developed from an alignment of significantly similar sequences to the 
original query sequence. This is achieved by weighting the amino acid residues of each 
sequence according to the information provided by the residue [286]. The PSSM (pattern) is 
then used in subsequent iterations of PSI-BLAST to find more distant homologies. Tobe et 
al used PSI-BLAST and a query set of 300 known T3SS effectors from organisms such as 
Shigella and Pseudomonas to identify over sixty novel non-LEE-encoded T3SS effector 
genes in the EHEC O157:H7 Sakai genome [2]. 
 
Thirteen of the novel EHEC effectors were predicted to be pseudogenes. Pseudogenes 
encode proteins that are not functional due to alterations such as premature stop codons 
(resulting in a protein <80% length of functional counterpart), insertions, or frameshifts 
(altering more than 20% original amino acid sequence) [287].   
 
1.8.3. Distribution of non-LEE-encoded effectors 
 
The novel EHEC O157:H7 effectors were encoded in more than 20 exchangeable effector 
loci (EEL). EEL are found in many T3SS organisms. The loci contain different collections 
of effector genes in different strains of the same species and contain the hallmarks of 
horizontally transferred genes i.e. they contain phage genes, transposable elements, plasmid-
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related sequences and usually show significantly different G+C content to the rest of the 
host genome [176]. For example, the EEL of P. syringae strains contain completely 
different collections of effector genes in each strain; this is in contrast to the conserved 
effector locus (CEL) that contains the same effectors in all strains and is necessary for 
pathogenesis [176] [288]. The EHEC EEL (containing novel effectors) included 14 non-
phage EEL and nine EEL within lambdoid prophages [2].  
 
Phage-encoded effectors were located within the passenger compartments of phage 
genomes.  These compartments, known as ‘morons’ are downstream of phage tail fibre 
genes and can be transcribed independently from the rest of the phage genome owing to the 
presence of promoter and terminator regions [289].  It was found that EHEC phage EEL 
always contained more than one effector gene (Sp9 EEL harbours eight effector genes) and 
effectors typically showed low G+C content (ca. 30%) compared to their host phage. The 
location and structure of the EHEC O157:H7 phage EEL that contain novel T3SS effectors 
are shown in figure 1.5.  
 
Non-phage EEL in EHEC contained one or a small number of effectors and were mainly 
lineage specific insertions. It is speculated that non-prophage encoded EEL represent 
ancient phage remnants or ETT2 substrates [2].  
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1.8.4. Novel effectors give insights into EHEC evolution 
 
As discussed earlier, the acquisition of PAIs is an important process in the evolution of 
bacterial pathogens. PAIs and prophages are a major source of genomic diversity within E. 
coli [7] [290]. Much of the 1.4Mb of the EHEC O157:H7 genome that is absent from the E. 
coli K-12 genome [291] is comprised of horizontally transferred PAIs and prophages [292] - 
the lethal Shiga-like toxins of EHEC O157:H7 are encoded on lambdoid prophages [293]. It 
has been suggested that T3SS effectors present in EHEC O157:H7 prophages belong to a 
dynamic phage-based metagenome [2]. This hypothesis is supported by evidence of 
recombination between prophage of Sakai and EDL strains of EHEC O157:H7 i.e. both 
strains contain the same prophage at the same loci, but internally the phages are distinct 
[294]. As the number of sequenced EHEC genomes increases it is becoming clear that 
horizontal gene transfer, including HGT of T3SS effector genes, has been important in the 
evolution of EHEC [294]. 
 
1.8.5. Novel effector nomenclature 
 
Novel EHEC effectors were classified into 20 families; the largest being NleG with 13 
members.  A scalable nomenclature similar to that used for Pseudomonas syringae effectors 
[281] was devised for the novel effectors. This was based on effector family and followed 
the E. coli secreted protein nomenclature (Esp) i.e. families were named EspK – EspR. Two 
further families were EspY (all effectors with a WEX5F motif) and EspX (all SopA-like 
effectors). Subfamilies and their individual members were defined using a numerical suffix 
e.g. NleG8-2 [2]. Novel effectors were found to include, amongst others, homologues of 
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effectors from plant pathogens e.g. Pseudomonas syringae effector HopPtoH; and 
homologues of Shigella ‘Osp type’ effectors. 
 
Non-LEE-encoded effectors including those discovered by Deng et al have been 
investigated individually using various models. However, their functions remain poorly 
characterized with most having only been identified as being necessary for colonization of a 
murine infection model (Table 1.6). This study aimed to use a standardised approach to 
characterise novel EHEC O157:H7 Sakai effectors (focusing on those discovered by Tobe et 
al) using a range of model systems.  
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Figure 1.5: Exchangeable effector loci (EEL) of EHEC O157:H7 Sakai. 
Non-LEE T3SS effectors are indicated by tall arrows. The location of EELs 
within the EHEC (Sakai) genome is also shown. G+C content is indicated by 
colour. Figure used with permission from [2]. 
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Table 1.6: Selected Non-LEE-encoded effectors (for a full 
list see Tobe et al.[2]). 
Non-LEE effector Function 
NleA Localises to the Golgi apparatus. Required for virulence in a mouse model [295] 
 
NleB Associated with non-O157 EHEC outbreaks and HUS [296]. Necessary for 
colonisation and mortality of mice [297]. 
 
NleC Not required for A/E lesion formation or colonisation [298]. 
 
NleD Not required for A/E lesion formation or colonisation [298]. 
 
NleE Required for colonisation and mortality of mice [299].  Associated with 
outbreaks (and HUS) of non-O157 EHEC [296].  
 
NleF Required for colonisation of mouse and piglet colon [299] [300]. 
 
NleG Unknown. 
 
NleH Homologous to Shigella effector OspG. Involved in activation of NF-κB in host 
cells to optimise host gut inflammatory response [301]. Required for 
colonisation of mice [302]. 
 
EspJ Homologous to Pseudomonas syringae effector HopF. Required for clearance 
of C. rodentium from the mouse colon [279]. Not required for A/E lesion 
formation in vitro or ex vivo [279].   
 
EspK Homologous to Salmonella T3SS effector GogB. Not required for A/E lesion 
formation [303]. Shows a diffuse cytoplasmic localisation in eukaryotic cells 
[303]. 
 
EspG2 Similar to EspG. Disrupts microtubule network [272] [304]. Alters paracellular 
permeability [275]. 
 
Cif Inhibits cell cycle at G2/M-phase transition [305] [306]. Recruits focal adhesion 
plaques causing stress fibre formation [151]. 
 
TccP Tir cytoskeleton coupling protein [307]. Promotes Nck independent actin 
assembly [278]. Required for actin assembly beneath adherent EHEC O157:H7 
in vitro but dispensable for A/E lesion formation  in vivo [257].  
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1.9. Models of infection  
 
Human challenge with live EHEC O157:H7, Stx or other EHEC virulence factors is 
unethical. Therefore, epidemiological evidence and models must be relied upon in order to 
investigate EHEC O157:H7 and its virulence factors. Unfortunately, there is no animal 
model that accurately represents the disease process of human infection with EHEC 
O157:H7 [308]. However, models have been developed that mimic, at least in part, the 
infection process of A/E pathogens – these, along with other model systems that have been 
used to investigate individual T3SS effectors of T3S organisms are discussed in the 
following sections.   
 
1.9.1. Vertebrate models 
1.9.1.1. Murine infection model 
Citrobacter rodentium is an attaching and effacing pathogen of mice [309]. Possession of 
the LEE and other virulence factors also found in EHEC make this model system ideal for 
investigating EHEC pathogenesis [310]. Susceptible strains of mice die soon after infection 
with C. rodentium. However, colonisation and development of colonic hyperplasia can be 
investigated using resistant mouse strains or a streptomycin-treated mouse model [311]. 
Therefore, although clinical outcome of infection differs from EHEC O157 the effect of 
virulence factors can be assessed by monitoring disease progression. C. rodentium can be 
engineered to overexpress EPEC and EHEC effectors so that their effects can be monitored 
in vivo. Murine models have also been used in the study of other T3S pathogens including 
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B. pseudomallei – the T3SS translocator BipD and the effectors BopA and BopB were 
shown to be required for full virulence [94]. Modern techniques such as real-time 
bioluminescence imaging (BLI) can be employed when using a murine model to monitor 
tissue tropism and infection dynamics in vivo [301] [312].    
1.9.1.2. Rabbit infection model 
Rabbit EPEC (REPEC) is a natural rabbit pathogen. This infection model, in particular the 
use of infant rabbits, has been useful for characterising formation of the A/E lesion and 
localisation of EPEC colonisation. The model was used to demonstrate that intimin and Tir 
are both essential virulence factors [313].  
1.9.1.3. Porcine infection model 
Piglets have been used in the study of EHEC O157:H7 virulence factors (e.g. intimin). 
Intimin-based vaccines have also been tested using this model [314]. Caecal explants have 
recently been used to investigate the effects of noradrenaline on colonisation of the caecum 
and colon by EHEC O157:H7. Noradrenaline was shown to increase initial loose (T3SS-
independent) attachment of EHEC O157:H7 to the porcine caecal mucosa [315].  
1.9.1.4. Bovine infection model 
As the main reservoir of EHEC O157:H7, cattle are an important part of research into 
EHEC O157:H7 disease and epidemiology. Due to the lack of effective treatment for 
infection with EHEC O157:H7, reducing carriage and transmission of the organism within 
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cattle is an important area of research. Preventing infection of cattle may help to prevent 
human infection with EHEC O157:H7 by decreasing contamination of meat, vegetable 
products and the farm environment [38]. Many important discoveries have been made 
regarding colonisation, mucosal immune response and significance of A/E lesion formation 
in the cattle intestine using the bovine infection model and bovine in vitro organ culture 
(bIVOC). Cattle have also been used in studies of vaccines that protect against colonisation 
by EHEC O157:H7 [117] [222]. Significantly, the cattle genome was recently sequenced 
[42] thus providing another resource for understanding the complex interaction between 
cattle and EHEC O157:H7. 
 
Several studies using a bovine infection model have revealed mechanisms of colonisation of 
cattle by EHEC. For example, non-O157 serotypes demonstrated greater interaction with 
calf intestinal epithelium than EHEC O157:H7 [60] [316]. Efa-1 was found to mediate 
colonisation of the bovine intestine by non-O157 EHEC strains [60]. Signature-tagged 
transposon mutagenesis (STM) of EHEC O157:H7 has also been used in conjunction with 
the bovine infection model to identify bacterial factors (including LEE-encoded proteins) 
required for colonisation of the bovine intestine [317]. The site of specific adherence of 
EHEC O157:H7 to bovine intestinal epithelium was also determined using this model – 
EHEC O157:H7 bacteria were found to reside in the terminal rectum where they induced 
the formation of A/E lesions on, and cytokine release from, enterocytes [197] [40].  
 
Bovine intestinal loops were found by Gerdts et al (2001) to be a valuable model for 
investigating the mucosal immune response [318]. Bovine ligated ileal loops have been used 
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to analyse the secretory and inflammatory response to different EHEC serotypes [60] and to 
identify host/bacterial factors that modulate such responses [319]. In accordance with results 
from bovine infection studies, non-O157 serotypes caused more fluid accumulation and 
neutrophil infiltration in the intestinal epithelium than EHEC O157:H7 [320]. This response 
was not affected by Tir, intimin or Stx-1 [321]. 
 
The use of large animal (bovine/ovine/porcine) models is expensive and, like other 
vertebrate models, time consuming and controversial. The use of vertebrate models is 
subject to legislation contained within the Animals (Scientific Procedures) Act 1986. Codes 
of practice and licences issued by the Home Office must be followed when using vertebrate 
models. There is therefore a need for alternative laboratory models.   
 
1.9.2. Invertebrate models 
1.9.2.1. Caenorhabditis elegans 
C. elegans is a small free-living soil nematode that feeds on bacteria. C. elegans has 
tractable genetics and has been used to investigate several bacterial pathogens including 
Salmonella and Pseudomonas aeruginosa. Paralysis and death of worms can be monitored 
to indicate toxicity of strains or toxins. More recently C. elegans has been used to identify 
virulence factors e.g. tryptophanase in EHEC and EPEC, and to demonstrate that EPEC 
requires the LEE for full virulence [322]. 
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1.9.2.2. Galleria mellonella 
The greater wax moth caterpillar Galleria mellonella is used as a model to study the insect 
immune system [323]. Proteins encoded in PAIs of Photorhabdus asymbiotica and 
Pseudomonas aeruginosa T3SS effectors have been screened using G. mellonella [324] 
[325]. The T3SS effector study found that the G. mellonella system was as reliable as the C. 
elegans model and that there was a high correlation between cytopathology assays using G. 
mellonella and Chinese hamster ovary (CHO) cells [325]. 
 
1.9.3. Eukaryotic organ and cell culture 
1.9.3.1. In vitro organ culture 
IVOC has been described as ‘the gold standard for investigating EPEC infection of the 
human intestinal mucosa’ [326] and has been used to study interactions of EPEC, EHEC 
[327] [328] [329] and Salmonella [330] with human intestinal tissue. Intact intestinal biopsy 
tissue is cultured in either petri dishes on foam supports or in specifically designed plates to 
maintain the luminal and serosal compartments [331]. The mucosal side of the tissue is then 
infected with the A/E pathogen. Inflammatory responses and changes associated with 
disease can then be monitored through sampling of the growth medium (cytokine release 
etc.) and immunofluorescence/electron microscopy [326]. IVOC has advantages over in 
vitro cell culture models as intestinal membrane integrity is maintained i.e. cells maintain a 
3-dimensional tissue architecture with cell-cell and cell-matrix interactions that are more 
representative of tissues in vivo. This allows research into the significance of apical and 
basolateral distributions of bacterial and host cell proteins during infection. A major 
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disadvantage of the human IVOC model is the difficulty of obtaining sufficient tissue 
samples to perform experiments [330]. Bovine IVOC models have been developed [332] 
[333] and used to investigate A/E lesion formation by EHEC O157:H7 and non-O157 
EHEC strains [258] on bovine intestinal epithelium. The bIVOC model provides a more 
practical alternative to the bovine infection model as it allows the study of bacterial 
pathogenesis, host response and host specificity without requiring the specialist 
infrastructure (and associated cost) needed to accommodate large animals at high 
containment [258].        
1.9.3.2. Cell culture 
Cell culture is one of the most convenient and widely used model systems for investigating 
T3SS effectors. Numerous studies have used infection and transfection of various 
immortalised human and murine cell lines to investigate T3SS effector function and 
localisation [255]. Cell culture was instrumental in the development of the fluorescent actin 
staining (FAS) test for EPEC and EHEC infection [13]; observation of actin accumulation 
beneath adherent bacteria on cultured cells allowed A/E pathogens to be easily identified 
and diagnosed. Epithelial cell types can be used to investigate how T3SS effectors affect the 
cytoskeleton and cell signalling pathways. Polarised enterocytes such as Caco-2 cells can 
provide insights into overall intestinal ‘barrier function’ during infection as well as 
information regarding changes in transepithelial resistance and position of tight junction 
proteins [174]. The use of cultured epithelial cells revealed that LEE-negative STEC use an 
autoagglutinating adhesin (Ssa) and a novel type IV pilus in adherence to eukaryotic cells 
[334] [335].   
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1.9.4. Saccharomyces cerevisiae 
 
The budding yeast Saccharomyces cerevisiae has been used as a model of eukaryotic 
cellular processes for many years. Much of our knowledge of fundamental processes such as 
transcription, translation, cell signalling and cytoskeletal dynamics has been gained through 
the use of this organism [336]. Yeast is both easy to genetically manipulate and easy to 
grow in the laboratory making it an ideal model organism – even compared to other popular 
model organisms such as Drosophila melanogaster and Caenorhabditis elegans, yeast 
represents a simple system.  
 
Over the past decade, researchers have increasingly used the yeast cell model to investigate 
the functions of T3SS effectors from a variety of T3SS organisms [336] [337]. As 
mentioned earlier, T3SS effectors have a diverse range of effects within mammalian and 
plant cells but tend to target conserved eukaryotic cell processes and protein assemblages 
such as the cytoskeleton, small GTPase regulated signaling cascades and ion transport 
[140]. As these processes are conserved throughout eukaryotes, yeast can be used as a 
model of these processes without the need for expensive and time consuming mammalian 
organism/cell culture [157]. Yeast can also be used to study effector targets involved in the 
immune system. Many of the signalling pathways that regulate unique multicellular 
processes such as the immune response are conserved in yeast. This means that even though 
it is a single-celled organism, yeast can give us insights into multicellular specific processes 
[336] [163]. An increasing volume of research also shows that bacterial virulence factors 
may be directed against predatory protozoa and single-celled organisms [53] – EHEC 
O157:H7 virulence factor targets may therefore include yeast and yeast cell processes.  
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1.10. Aims of this thesis 
 
Given the identification of a previously unsuspected T3SS effector repertoire in EHEC 
O157:H7, two important tasks remained: confirming that putative effectors are indeed 
translocated and identifying and characterising their effects on eukaryotic cells. 
The aims of the research described in this thesis therefore are: 
a) To confirm that selected putative effectors of EHEC O157:H7 Sakai are translocated 
into eukaryotic cells, using a beta-lactamase translocation assay. 
b) To characterise the effects of selected effectors on eukaryotic cells (mammalian and 
yeast cells), focusing on: 
(i) Effects on cell growth. 
(ii) Effector localisation and effects on cell shape (as determined by 
microscopy). 
(iii) Disruption of cellular physiology (as determined by transcriptomics and a 
suppression screen). 
c) To dissect sequence-activity relations for selected effectors. 
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CHAPTER TWO 
General Materials and Methods 
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2.1. Suppliers 
 
Chemicals, media and reagents were supplied by Sigma, Oxoid or Invitrogen unless 
otherwise stated.  
 
2.2. Bacterial media 
 
All media were sterilised at 121°C, 15psi for 15 minutes unless otherwise stated. Antibiotics 
and sugar solutions used to supplement media were sterilised by filtration through a 0.22 
µm filter (Millipore, UK). 
 
Luria-Bertani (LB) broth/agar was used for the routine culture of all E. coli strains.  This 
media consisted of 10g tryptone, 5g yeast extract, 10g NaCl dissolved in 1 litre distilled 
water.  One litre LB agar contained 15g bacto-agar in addition to the ingredients stated 
above. SOC broth was used for the recovery of bacteria after transformation.  This media 
consisted of 2% (w/v) tryptone, 0.5% (w/v) yeast extract, 10mM NaCl, 2.5mM KCl, 10mM 
MgCl2, 10mM MgSO4 and 20mM glucose. 
 
For the expression of the LEE-encoded T3SS, bacteria were cultured in low-glucose 
Dulbecco’s modified Eagles medium (DMEM) (Invitrogen, UK) supplemented with 
appropriate antibiotics. 
 
50 
 
Antibiotics were added to the media as required to a final concentration of: ampicillin 100 
µg/ml; kanamycin 50 µg/ml; chloramphenicol 34 µg/ml; tetracycline 10 µg/ml. 
 
2.3. Yeast media 
 
YPD complete medium was used for the growth and maintenance of S. cerevisiae strains 
FY833 and BY4741.  This consisted of 10 g Bacto-yeast extract, 20 g Bacto-peptone, 20 g 
glucose dissolved in 1 l dH2O. 20 g Bacto-agar was added to make solid medium. 
 
Synthetic complete media (SC) lacking uracil (SC-Ura) or SC lacking uracil and leucine 
(SC-Ura-Leu) were used for the selection, growth and maintenance of transformed S. 
cerevisiae. SC-Ura consisted of 6.7 g bacto-yeast nitrogen base without amino acids 
(Appleton Woods, UK) and 1.92g of yeast synthetic drop-out media supplement without 
uracil (Sigma) dissolved in 900 ml dH2O. SC-Ura-Leu consisted of 6.7g bacto-yeast 
nitrogen base without amino acids, 1.4 g yeast synthetic drop-out media supplement without 
histidine, leucine, tryptophan and uracil (Sigma), 20 mg histidine and 20 mg tryptophan 
dissolved in 900ml H2O. For solid media, 20 g bacto-agar was also added. Media were 
supplemented with sterile water to a final concentration of 2% (v/v) glucose, galactose or 
raffinose as appropriate after autoclaving. 
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2.4. Bacterial and Yeast strains 
 
2.4.1.  Bacteria 
 
TOP10 chemocompetent E. coli cells (Invitrogen, UK) were used for the routine 
propagation of bacterial plasmids including entry vectors and recombined destination 
vectors.  DB3.1 chemocompetent E. coli were used for the propagation of original 
destination vectors. The genotypes of each strain are listed in table 2.1. Other bacterial 
strains are listed in the appropriate chapter.  
Strain Genotype Source 
TOP10 F
- 
 mcrA  Δ(mrr-hsdRMS-mcrBC)  φ80lacZΔ  M15  ΔlacX74 recA1 
ara Δ139  Δ(ara-leu)7697 galU galK rpsL (StrR) endA1 nupG 
Invitrogen™ 
DB3.1 F- gyrA462 endA1 Δ(sr1-recA) mcrB mrr hsdS20(rB-, mB-) supE44 
ara-14 galK2 lacY1 proA2 rpsL20(SmR) xyl-5 λ- leu mtl1 
Invitrogen™ 
 
Table 2.1: Bacterial strains used in this study. 
 
2.4.2.  Yeast 
 
Saccharomyces cerevisiae strains FY833 and BY4741 were used in this study. Details of the 
strains are listed in table 2.2.  
Strain Genotype Source 
FY833 MATα his3Δ ura3Δleu2Δ lys2Δ trp1Δ 
GAL2  
S. Dove, University of Birmingham 
BY4741 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 S. Dove, University of Birmingham 
 
Table 2.2: Yeast strains used in this study.  
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2.5. Growth conditions 
 
2.5.1.  Bacterial growth conditions 
 
E. coli was grown aerobically in liquid culture or on solid agar. For liquid cultures, the 
culture vessel was at least 5 x volume of the media. Cultures were incubated at either 30°C 
or 37°C on an orbital shaker or shaking waterbath. For growth on solid media, plates were 
incubated in a static incubator overnight at 37°C. Liquid cultures were stored long term at -
80°C in cryovials, which contained 250 µl of 60 % (v/v) glycerol and 750 µl of an overnight 
liquid culture. 
 
2.5.2.  Yeast growth conditions 
 
Broth cultures were grown aerobically at 30°C in a shaking waterbath (200 rpm). Culture 
vessels were at least 5 x the volume of the media to ensure good aeration. For yeast growth 
on solid media plates were sealed with parafilm (Millipore) to prevent desiccation. Plates 
were incubated at 30°C in a static incubator. Liquid cultures were stored long term at -80°C 
in cryovials, which contained 250 µl of 60 % (v/v) sterile glycerol and 750 µl of an 
overnight liquid culture. 
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2.6. Human cell culture 
 
HeLa cells were grown in minimal Eagle’s medium (MEM) without antibiotics, foetal calf 
serum 10% (v/v) was used to supplement the media. Cells were grown in 75 cm
2
 tissue 
culture flasks by incubating at 37°C in 5% CO2 until 80% confluence was achieved. 
 
2.7. Gateway system 
 
2.7.1.  High-throughput cloning 
 
A high-throughput DNA cloning system was required to increase throughput and efficiency 
when characterising effectors using numerous model systems. This study makes use of the 
Gateway system of cloning (Invitrogen). This system allows a gene of interest (GOI) to be 
amplified and easily cloned into a myriad of expression vectors for use in various systems. 
Many types of destination vectors are available including bacterial, mammalian and yeast 
expression plasmids. This means that the Gateway system is very versatile. The use of the 
system gives the potential to explore the localization and function of the novel effectors in 
diverse systems and model organisms. The Gateway system of cloning differs from 
conventional cloning in that the GOI is amplified once and is transferred to expression 
vectors through a process of recombination rather than through restriction digestion and 
ligation. An overview of the system is shown in figure 2.1. 
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2.7.2.  Polymerase chain reaction 
 
PCR was used to amplify genes of interest (GOI) for cloning. Primers were designed to 
have similar melting temperatures and to contain approximately 50 % G/C. As per the 
requirements of the Gateway cloning system, forward primers were designed with a CACC 
oligonucleotide motif at their 5’ end. Primers were synthesized by Eurogentec (Belgium) or 
Alta Biosciences (UK) and were supplied at a concentration of 100 µM. Those primers used 
in Quikchange reactions were purified by high performance liquid chromatography (HPLC). 
Primers used in this study are listed in appropriate chapters. For the amplification of EHEC 
O157:H7 Sakai effector genes PCR mixtures consisted of 1 x ExTaq buffer, 1.5 mM MgCl2, 
2 nM dNTPs, 1 µM each primer, genomic DNA (EHEC O157:H7 Sakai) and 2 U of ExTaq 
polymerase in 50 µl total volume (dH2O was used to make up reaction volume). Reaction 
mixtures were vortexed and centrifuged briefly. Amplification of DNA took place in a 
Primus thermocycler. The thermocycling program used is shown below. PCR products were 
then analysed by gel electrophoresis. 
95°C 2 minutes 
95°C  30 seconds 
Annealing temperature (40-60°C) 30 seconds 
72°C 30 seconds 
72°C  2 minutes 
4°C until use 
 
Cycle 
x 30 
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Figure 2.1: Overview of the Gateway system of cloning. GOI; gene of interest. 
  
Amplify GOI with 5' CACC motif 
by PCR
TOPO®-clone GOI into a suitable 
Gateway® entry vector 
Transfer GOI from entry vector to 
a suitable destination vector(s) 
using Gateway® LR recombinase 
Express GOI from destination 
vector in chosen system
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2.7.3.  Electrophoresis of DNA 
Buffers for DNA electrophoresis 
TAE buffer: A 50 x stock solution of TAE buffer was prepared and diluted fifty-fold to 
create a working solution. The stock solution consisted of 242 g Tris base, 57.1 ml glacial 
acetic acid and 100 ml 0.5 M EDTA (pH 8.0) per litre of dH2O.  
Sample loading buffer: a 6 x buffer contained 0.25% (w/v) Bromophenol blue, 0.25% (w/v) 
xylene cyanol FF and 30% (v/v) glycerol in dH2O. 
DNA electrophoresis 
DNA was analysed by electrophoresis on 0.8% agarose gels. Agarose was dissolved in TAE 
buffer and melted. Ethidium bromide was added (100 ng/ml) once the agar had cooled to 
50°C. Gels were prepared using Hybaid moulds and combs. The gel was submerged in TAE 
buffer in a Hybaid electrophoresis tank. Samples were mixed with DNA loading buffer and 
5 µl was added to each well. 5 µl hyperladder I (Bioline) was added to the left-most lane as 
a size and quantity marker. Samples were run at 90 volts. DNA was then visualised using an 
ultra-violet transilluminator of a Biorad gel documentation system.  
Gel extraction and purification of DNA 
DNA was visualized in the agarose gel after electrophoresis using a UV transilluminator and 
was excised from the gel using a clean scalpel. DNA was purified using the QIAquick Gel 
Extraction kit (Qiagen) according to the manufacturer’s instructions.   
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2.7.4.  TOPO cloning 
 
A schematic of the TOPO cloning process is shown in figure 2.4. The PCR product 
containing the GOI is cloned into the ‘entry vector’ using TOPO cloning. Entry vectors 
were obtained from Invitrogen (UK) and are shown in figures 2.2 and 2.3. Entry vectors 
used in this study are listed in the appropriate chapter. The entry vector contains a 3’ GTGG 
overhang that is covalently attached to Vaccinia topoisomerase I protein.  The overhang of 
the entry vector invades the 5’ end of the PCR product. The 5’ hydroxyl group of the PCR 
product then attacks the phosophotyrosyl bond between the vector DNA and topoisomerase 
enzyme which releases the enzyme.  The GTGG motif of the entry vector anneals to the 
complementary CACC motif of the PCR product and the PCR product is stabilised in the 
entry vector in the correct orientation.  
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Figure 2.2: pENTR-SD/D-TOPO. Gateway entry vector (with Shine-Dalgarno sequence). 
TOPO indicates Vaccinia topoisomerase I. 
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Figure 2.3: pENTR-D-TOPO. Gateway entry vector.  
TOPO indicates Vaccinia topoisomerase I. 
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Figure 2.4: Directional cloning of an effector gene into a TOPO entry vector.  
Covalently bound topoisomerase 1 is represented in a red oval. Figure adapted from Invitrogen 
[338].
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Insertion of the GOI PCR product into the entry vector was performed: 1 µl of TOPO entry 
vector (Invitrogen), 10-40 µg PCR product, 1 µl salt solution (1.2M NaCl, 0.06 MgCl2) and 
H2O (added to a make a final volume of 5 µl) was incubated at room temperature for 5 
minutes. The reaction mix was then incubated on ice or stored at -20°C until used in 
transformation of competent E. coli. 
 
2.7.5.  Transformation of E. coli 
Heat shock transformation 
10 µl chemically competent TOP10 E. coli cells (Invitrogen) were transformed with 1 µl 
desired plasmid by incubating the mixture on ice for 30 minutes. The cells were then heat 
shocked in a water bath at 42°C for 30 seconds. 200 µl SOC medium was then immediately 
added to the cells and the cells grown statically at 37°C for one hour. Transformants were 
then plated out onto LB agar (supplemented with appropriate antibiotics) and grown 
overnight at 37°C. 
Electroporation 
Electrocompetent E. coli were first prepared: an overnight culture of E. coli was diluted 1 in 
100 into fresh LB broth (supplemented with appropriate antibiotics) and grown at 37°C until 
mid-log phase (OD600 between 0.5 and 0.7). Bacteria were chilled on ice. The culture was 
then centrifuged at 3000 x g for 10 minutes. The supernatant was discarded and the cells 
resuspended in 24 ml sterile, ice cold 10 % (v/v) glycerol. Cells were washed twice more, 
each time the volume of glycerol solution used to resuspend the cells decreased by half (i.e. 
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12 ml then 6 ml). After the final centrifugation, the cells were resuspended in 200 µl sterile 
dH2O. For electroporation, 50 µl cell suspension was aliquoted into ice cold, sterile 
electroporation cuvettes (Geneflow). 2 µl of plasmid was then added to the cuvette. Cells 
were incubated on ice for 30 minutes. Cells were electroporated with a Biorad 
electroporator using 2.5 kV. Immediately after electroporation, 250 µl SOC medium was 
added to the cuvette and cells were transferred to a microfuge tube. Cells were incubated 
with shaking (200rpm) at 37°C for 1 hour before being plated onto LB agar containing the 
appropriate antibiotic/s. Plates were incubated overnight at 37°C.        
 
2.7.6.  Isolation of DNA from bacterial cells 
 
Single colonies of transformed E. coli were picked and grown overnight in 5 ml LB 
(containing appropriate antibiotic) at 37°C with shaking (200 rpm). The bacterial culture 
was then centrifuged at 13,000 rpm for 5 minutes. Plasmid DNA was obtained by a standard 
alkaline-lysis method using commercially available miniprep kits following the 
manufacturer’s instructions (Qiagen). 
 
 
  
63 
 
2.7.7.  DNA sequencing 
 
Plasmid DNA was extracted as above using miniprep kits (Qiagen).  The orientation and 
sequence of the GOIs in entry vectors (and destination vectors) was confirmed by automated 
DNA sequencing.  The single primers used in the sequencing of each destination vector are 
listed in the appropriate chapter. The universal primers M13 Forward (-20) and M13 
Reverse were used to sequence entry vectors. Plasmid products were sequenced by the 
Functional Genomics Laboratory, School of Biosciences, University of Birmingham. 
Sequencing reactions contained 300 nM primer and 200 – 500 ng of plasmid template DNA 
in a final volume of 10 µl (made up with dH2O). The sequencing process used a Big Dye 
Terminator kit (Applied Biosystems) and an MWG Primus HT 96 well PCR machine. The 
sequences of products were analysed by capillary electrophoresis on an ABI Prism 3700 
DNA analyser. FinchTV software was used to analyse sequence data. 
 
2.7.8.  LR recombination reaction 
 
Once the sequence and orientation of the GOI in the entry vector had been confirmed, 
expression constructs containing the GOI were generated by performing an LR 
recombination reaction between the entry vector and Gateway destination vector of choice. 
Destination vectors used in this study are listed in the appropriate chapter. 
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Stocks of non-recombined destination vectors were made by transforming non-recombined 
destination vectors into E. coli strains (i.e. DB3.1) that are resistant to the effects of CcdB 
encoded by the ccdB gene contained within the destination vector. Transformation of 
commercially available chemo-competent E. coli DB3.1 (Invitrogen, UK) with non-
recombined destination vectors was via the heat-shock transformation protocol as described 
above. 
 
Bacteriophage λ recombinase was used to transfer the GOI from the entry vector into the 
destination vector through recombination. Recombination replaces a chloramphenicol 
resistance cassette and the lethal ccdB gene (contained between the attR sites in the 
destination vector) with the GOI (contained between attL sites in the entry vector).  
Depending on the destination vector used this creates an in-frame translational fusion to a 
detectable protein tag e.g. GFP. Selection of vectors containing the GOI is possible using 
ccdB negative selection. 
 
The recombination reaction mix consisted of 100-300 ng entry clone, 150 ng destination 
vector, 2µl 5 x LR Clonase reaction buffer, 1 µl LR clonase enzyme II and 1 µl dH2O. The 
reagents were vortexed and incubated at room temperature for 1 hour. After incubation, 2 µl 
of Proteinase K solution was added to the mix and the mix incubated for 10 minutes at 
37°C. The mixture (containing recombined destination vectors) was then transformed into 
chemocompetent TOP10 E. coli cells. Transformants were plated onto LB agar plates 
supplemented with ampicillin (100 g/ml). Plasmid DNA was obtained from transformed 
bacteria as above. The sequence and orientation of the GOI within the destination vector 
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was confirmed by DNA sequencing as above. Stocks of successful transformants were 
stored at -80°C. Purified destination vectors were transformed or transfected into 
appropriate hosts as listed in the appropriate chapter.  
 
2.8. Protein analysis 
 
2.8.1.  SDS-Polyacrylamide gel electrophoresis 
Buffers and solutions for SDS-PAGE 
Resolving buffer contained 1.5 M Tris-HCl and 0.4% (w/v) sodium dodecyl sulphate (SDS) 
adjusted to pH 8.8. Stacking buffer contained 0.5 M Tris-HCl and 0.4% (w/v) SDS adjusted 
to pH 6.8. SDS-running buffer (10 x stock solution) contained 30.3 g Tris-HCl, 144 g 
glycine and 10 g SDS per litre H2O. The stock solution was diluted 10-fold to make a 
working solution i.e 50 ml of 10 x stock solution was added to 450 ml dH2O. Sample 
loading buffer (2x) consisted of 100 mM Tris-HCl (pH 6.8), 4% (w/v) SDS, 0.2% (w/v) 
Bromophenol blue and 20% (v/v) glycerol, 10% 2-mercaptoethanol. 
 
SDS-PAGE gels were stained with ProtoBlue Safe (National Diagnostics) colloidal 
Coomassie G-250 stain. A working solution for 1 mini-gel consisted of 2 ml absolute 
ethanol and 18 ml ProtoBlue Safe.  
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SDS-Polyacrylamide gel electrophoresis 
Gels were made using Ultrapure ProtoGel containing 30% w/v acrylamide and 0.8% w/v 
NN’-methylenebisacrylamide. Resolving gel consisted of 12.5 ml Ultrapure ProtoGel, 7.5 
ml resolving buffer, 150 µl 10% (w/v) ammonium persulphate (APS), 30 µl N, N, N’, N’- 
tetramethylethylenediamine (TEMED) and 10 ml dH2O (mix sufficient for 3 gels). Stacking 
gels consisted of 1.3 ml Ultrapure ProtoGel, 2.5 ml stacking buffer, 100 µl 10% (w/v) APS, 
20 µl TEMED and 6.1 ml dH2O. 
 
12% polyacrylamide gels (1mm thick) were used to separate proteins for analysis.  
Resolving gel was poured between two glass plates (Biorad) until 2.5 cm from the top of the 
plate. 200 µl butanol was added to the top of the gel to prevent oxygen (inhibits 
polymerisation) reaching the gel. Once the resolving gel had set, butanol was removed by 
washing with dH2O. Excess water was removed with filter paper and the stacking gel added 
on top of the resolving gel. An 8 or 15 well comb was inserted into the stacking gel to create 
wells (30 µl volume). Protein samples were mixed with SDS-loading buffer (10% β-
mercaptoethanol) and boiled for 10 minutes before being loaded into the wells of the 
stacking gel. Separation was achieved by the application of 200V for 45 minutes. After 
separation, gels were removed from the glass plates and washed twice in dH2O. 20 ml 
ProtoBlue Safe Coomassie stain was added to the gel in a small tub, the tub covered with 
film and gels left to stain overnight on a rotating platform (60rpm). Gels were then washed 
twice (10 minutes each) in dH2O to remove excess stain before being scanned using a 
computer.  
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2.8.2.  Immunoblotting 
Electrophoretic transfer of proteins 
Transfer buffer consisted of 5.8 g Tris-HCl, 2.9 g glycine and 0.37 g SDS in 20 ml methanol 
and 800 ml dH2O. Proteins were separated by SDS-PAGE as above, with a pre-stained 
protein marker run alongside. The SDS-PAGE gel, two sheets of 3 mm Whatman filter 
paper and two sponge pads were soaked in transfer buffer for 10 minutes. A gel-sized sheet 
of Hybond™-P polyvinylidene difluoride (PVDF) membrane (GE Life Sciences, UK) was 
washed in absolute methanol for 30 seconds and then washed in transfer buffer for 5 
minutes. A gel-membrane ‘sandwich’ was made by placing a sponge pad onto the clear side 
of the Biorad cassette, followed by one piece of filter paper, the membrane, the gel, another 
piece of filter paper and the final sponge pad. The cassette was closed and placed in a 
cassette holder in the tank. An ice pack was placed in the tank to prevent overheating. 
Transfer buffer was added to the tank until the cassette was submerged. Proteins were then 
electrophoretically transferred from the gel onto the membrane by application of 200 mV 
for 1 hour. Transfer buffer in the tank was stirred continuously during the transfer process 
by a magnetic stirrer.  
Western blotting 
Blocking buffer consisted of 1 g bovine serum albumin (1% w/v) dissolved in 100 ml 1 x 
phosphate buffered saline (PBS) supplemented with 0.05% (v/v) Tween-20. 
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After transfer, the membrane was washed twice in dH2O before being incubated at 4°C 
overnight in blocking buffer to block non-specific sites from reacting with antibody probes. 
Membranes were probed with primary antibody in fresh blocking buffer for 2 hours at room 
temperature with gentle shaking. Membranes were then washed three times (10 minutes 
each) in fresh blocking buffer before the secondary antibody (a horseradish peroxidase 
conjugate) was added (in 20 ml fresh blocking buffer). Membranes were incubated at room 
temperature for 1 hour with gentle shaking before being washed 3 times (10 minutes) in 
fresh blocking solution. Membranes were developed using chloro-1-napthal as a substrate 
for horseradish peroxidase using the Opti-4CN (Biorad) detection system. Developing 
solution consisted of 9 ml dH2O, 1 ml diluent and 200 µl substrate. Bands were allowed to 
develop at room temperature (up to 10 minutes). Membranes were then washed twice in 
dH2O and scanned using a computer.  
  
69 
 
CHAPTER THREE 
Translocation of candidate effectors into 
eukaryotic cells 
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3.1 Introduction 
 
3.1.1.  Background 
 
The work presented in this chapter describes a connected programme of research that 
spanned three research groups: the Pallen group in Birmingham, the Frankel group at 
Imperial College, London and the Tobe group at the University of Osaka, Japan. Before the 
experimental work described here was performed a bioinformatics-based survey of the 
EHEC O157:H7 Sakai genome within the Pallen group had identified 49 candidate T3SS 
effectors [2]. I exploited a β-lactamase translocation assay, one of four methods used to 
provide experimental evidence of type III secretion of the predicted EHEC O157:H7 T3SS 
effectors. This work contributed to a publication [2]. The introduction to this chapter 
describes the methods used by my collaborators to confirm effector status. The methods, 
results and discussion sections describe use of the β-lactamase translocation assay by myself 
and others in the Pallen and Frankel groups to confirm that selected putative effectors were 
translocated into eukaryotic cells. 
 
3.1.2.  Investigating type III secretion and translocation 
 
Several methods can be used to confirm secretion and translocation of T3SS effectors. For 
example, secretion of effectors into the growth medium can be revealed by SDS-PAGE and 
mass spectroscopy [2] whereas translocation of effectors into host cells can be detected by 
immunoblotting host cell lysates [339], immunofluorescence microscopy of infected cells 
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[340] and enzymatic-based translocation assays [341] [282] [230]. In this study, four 
methods were used to monitor type III secretion and translocation 
 EHEC O157:H7 secretome analysis,  
 an immunofluorescence-based translocation assay,  
 an adenylate cyclase translocation assay 
 a β-lactamase translocation assay.  
 
3.1.3.  Secretome analysis 
 
Our collaborators in the Tobe laboratory began experimental confirmation of the predicted 
effectors using a proteomics approach. They compared the proteins secreted into the growth 
media by a ΔsepL Sakai isolate with those proteins secreted by a non-type-III-secreting 
isogenic ΔsepL ΔescR Sakai isolate. A ΔsepL Sakai isolate was used as it secretes effectors 
into the culture supernatant at higher levels than wild type EHEC Sakai [196]. The Sakai 
strain used in this study also exhibited enhanced expression of the Esc-Esp T3SS due to 
high level expression of the LEE transcriptional activator PchA (provided on a multicopy 
plasmid). Proteins secreted into the culture supernatant by each isolate were separated by 
SDS-PAGE and slices of gel (representing the whole lane) were trypsinised. The peptides 
created by trypsinisation were then analysed by mass spectroscopy. Comparison of the 
proteins secreted by each strain allowed the identification of proteins that were secreted 
through the T3SS i.e. those proteins secreted by ΔsepL but not ΔsepL ΔescR isolates. 31 
proteins from the bioinformatics survey were found to be secreted by the T3SS using this 
method (thereby confirming the effector status of 31 predicted effectors) [2]. The validity of 
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this approach was confirmed by the presence of nine known T3SS proteins including Map, 
EspF and EspG in the EHEC O157:H7 T3SS secretome [2]. 
   
3.1.4 Immunofluorescent staining 
 
Our collaborators in the Tobe laboratory also used immunofluorescent staining to confirm 
the effector status of effector candidates. In this approach, candidate effectors were tagged 
with a small epitope tag (FLAG). Non-toxigenic EHEC O157:H7 Sakai and non-type-III-
secreting isogenic EHEC harbouring FLAG-fusion plasmids were used to infect Caco-2 
cells. Immunostaining using anti-FLAG antibodies enabled translocated effectors to be 
visualised within host cells by microscopy. Immunofluorescent staining of FLAG-tagged 
effectors in Caco-2 cells demonstrated that 12 of the candidate effectors were translocated 
via the T3SS [2].  
 
In studies of other putative T3SS effectors, translocation of individual effectors has been 
confirmed by immunofluorescent staining using antibodies to the effector in question e.g. 
confirmation of T3S of BopE  by B. pseudomallei [342].  However, the high cost associated 
with obtaining antibodies reactive for each putative effector in this study was prohibitive. 
The methods described so far also involve numerous time-consuming processes (e.g. 
secretome analysis requires SDS-PAGE, trypsinisation and mass spectroscopy [2] whereas 
immunofluorescence analysis requires cell fixation, permeabilisation and immunostaining 
[340]). Therefore, in order to maintain an efficient throughput during initial screening of 
effector translocation we decided to use enzymatic translocation assays.    
73 
 
3.1.5. Translocation assays 
 
T3SS permissible substrates such as small peptide tags (e.g. tetracysteine) or enzymatic 
reporter fusions can be used effectively to determine whether a protein is translocated into a 
host cell [282]. Translocation assays include FlAsH labelling (see below), the adenylate 
cyclase (CyaA) assay and the β-lactamase (TEM-1) fusion assay.  
FlAsH/tetracysteine labeling  
Fluorescein arsenical helical binding (FlAsH) labeling is a newly developed method that can 
be used to track effector translocation without the need for immunostaining [343]. FlAsH is 
a small biarsenical molecule that passively enters eukaryotic cells and binds specifically to a 
12-amino-acid tetracysteine motif [343]. The tetracysteine motif can be incorporated into 
effector genes on the chromosome so that effector gene expression occurs under 
physiological conditions [170]. Once bound to the tetracysteine motif, FlAsH emits a green 
fluorescence signal. Translocation of effectors carrying the motif can be monitored in situ 
and in real time using time-lapse fluorescence microscopy [170] [344]. FlAsH translocation 
assays were recently used to visualise real-time Salmonella effector delivery into HeLa cells 
[170]. 
Adenylate cyclase assay  
The adenylate cyclase (CyaA’) domain derived from Bordetella toxin CyaA causes an 
increase in the levels of cyclic AMP (cAMP) in eukaryotic host cells in response to host cell 
calmodulin [345]. In this assay, CyaA is fused to the protein of interest i.e. a T3SS effector. 
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Translocation of the fusion into host cells is detected by an increase in cAMP in the host cell 
[346] or loss of cell viability [347]. The increase in intracellular cAMP can be detected by 
enzyme-linked immunosorbent assay (ELISA) [2], radioimmunoassay [345] or 
colourimetric assay [347]. An increase in host cell cAMP confirms translocation of the 
CyaA’-fusion. This assay has been used successfully to confirm T3SS of effectors from P. 
syringae [348], EPEC [265], Erwinia chrysanthemi [111], R. solanacearum [349], 
Salmonella enterica [350] and to investigate the secretion signals of YscP of Yersinia 
enterocolitica [351]. Colleagues at Osaka University used the adenylate cyclase 
translocation assay with an ELISA based detection system to confirm the effector status of 
10 of the predicted EHEC O157:H7 effectors [2]. 
β-lactamase fusion assay 
The β-lactamase fusion assay was developed in 2004 to identify the secretion and 
translocation domain of the EPEC and EHEC T3SS effector, Cif [282]. This assay uses the 
fluorescent substrate CCF2/AM to demonstrate the action of a β–lactamase (TEM-1) fused 
to the protein of interest e.g. T3SS effector. CCF2/AM consists of a coumarin moiety and a 
fluorescein moiety joined together by a CCF2 β–lactam ring. CCF2/AM passively enters 
eukaryotic cells. Excitation at 409 nm results in fluorescence resonance energy transfer 
(FRET) from the coumarin to the fluorescein which causes the fluorescein moiety to emit a 
green fluorescence signal (520 nm). Translocation of the TEM-1 fusion protein into the 
eukaryotic cell induces catalytic cleavage of the CCF2 β-lactam ring. This disrupts FRET 
and causes emission of a blue fluorescence signal. Translocation of the TEM-1-effector 
fusion can easily be detected in live host cells by blue CCF2/AM fluorescence [282]. The 
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principle of this assay is summarised in figure 3.1. This assay has been successfully used to 
demonstrate translocation of EspJ [279], EspK [303], NleC and NleD [298] into HeLa cells. 
 
A β–lactamase fusion assay was used in this study to confirm the effector status of the 
candidate EHEC O157:H7 T3SS effectors. TEM-1-effector fusion plasmids were created 
and transformed into EPEC and an isogenic EPEC ΔescN mutant at the University of 
Birmingham. Seventeen translocation assays were performed by the author, S.A. Beatson 
and C. Bailey under the supervision of O. Marches at Imperial College, London.   
76
Figure 3.1: β-lactamase fusion assay used to study translocation of T3SS effectors. Non-
fluorescent CCF2/AM passively enters the eukaryotic cell where it is esterified by cellular esterases 
which results in charged, fluorescent CCF2. FRET from the coumarin moiety (triangle) to the 
fluorescein moiety (square) upon excitation at 409 nm leads to emission of a green fluorescence 
signal at 520 nm. Type III mediated translocation of a TEM1-effector fusion protein (expressed from 
pTEM-1) into the CCF2-loaded cell leads to cleavage of the β-lactam ring (circle) of CCF2. FRET is 
therefore disrupted causing the coumarin moeity to emit a blue fluorescence signal at 447 nm (upon 
excitation at 409 nm). Figure adapted from Charpentier et al [282].  
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3.2 Methods 
 
3.2.1. Gateway DNA cloning 
PCR 
Novel effectors were amplified by polymerase chain reaction by S.A. Beatson, A. Fivian, R. 
Younis and C.M. Bailey as described in chapter 2. Primers used are shown in table 3.1. 
TOPO Cloning 
Seventeen effectors were cloned into pENTR-SD/D-TOPO (performed by S.A.Beatson, A. 
Fivian and R. Younis) as described in chapter 2. Entry vectors used in this study are shown 
in table 3.2. 
LR recombination 
Seventeen effectors were recombined into pCX340gw (i.e. Gateway
 
compatible
 pCX340 β-
lactamase expression vector) via the LR recombination reaction by S.A.Beatson as 
described in chapter 2. Destination vectors created and used in this study are shown in table 
3.3. The author confirmed destination vectors by DNA sequencing as detailed in chapter 2 
using primers GatewayM13F (entry vectors) and TEM1_seqprimer2 (destination vectors). 
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Primer Sequence (5’-3’) 
DNA sequencing 
 
 
GatewayM13F GTAAAACGACGGCCAG 
TEM1_seqprimer2 GGCACTCGACCGGAATTAT 
  
Effector gene amplification 
 
 
ECs0061gwF CACCATGAAAGTATCAGTTCCA 
ECs0061gwR TTCAATAATTGCGTTGTC 
ECs0847.gwF2 CACCATGAAAATTCCCTCATTACAGTCC 
ECs0847.gwR2 TCATTGCTCATTGTGTTTGTCC 
ECs0850.gwF CACCATGCGCCCTACGTCC 
nsGW.0850r AAGCAATGGATGCAGTCTTACC 
ECs0876gwF CACCATGGATTGTTCAAAATGC 
ECs0876gwR CCATGCGTCTGGCGTCCA 
ECs1127gwF CACCATGAGCGGAACCTCAGGT 
ECs1127gwR CAAAAAAGATTGGGGAGG 
gw1567f CACCATGCCATTTTCAATC 
nsGW.1567r TTCTTTTGTGTTGTGTATCTC 
ECs1568.gwF CACCATGCTTCCTACATCG 
nsGW.1568r AGAATATTTATATGTGG 
ECs1814gwF CACCATGTTATCGCCCTCTTCT 
ECs1814_new_rev TTATATCTTACTTAATACTACAC 
ECs1815gwF CACCATGTTACCAACAAGTGGT 
ECs1815gwR TCCACATTGTAAAGATCC 
ECs2226gwF CACCATGCTTCAATTATCTTCA 
ECs2226gwR TTTACAATGCTGTTTCTG 
ECs3488gwF CACCATGGAGAGAAGGGCT 
ECs3488gwR TTAAGCATCACTTGCAAC 
ECs4561gwF CACCATGCCTATTGGTAATCTT 
ECs4561gwR GACGAAACGATGGGATCC 
ECs4564gwF CACCATGTCGTTATCAGGAGCG 
ECs4564gwR TAATACGCTATAAGAGGA 
ECs4571gwF CACCATGGAAGCAGCAAATTTA 
ECs4571gwR GGCATATTTCATCGCTAA 
ECs4590gwF CACCATGATACTTGTTGCCAAA 
ECs4590gwR AGTGTTTTGTAAGTACGT 
ECs4653gwF CACCATGGTCGCTAAATTAAAAC 
ECs4653gwR AGCCTGGGTTATATTTTG 
ECs5021gwF  CACCATGTTAGGTCATATCTCA 
ECs5021gwR AATACCTTTATTCTTTAT 
Table 3.1: DNA primers used in this study 
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Plasmid Details Source 
pCX340gw Gateway compatible TEM-1 
expression plasmid based on 
pCX340 [282]. 
  
Tobe et al [2]. 
pENTR-SD/D-TOPO Gateway entry vector.  Invitrogen (UK) 
 
Table 3.2: Gateway /Gateway-compatible entry 
 and destination vectors used in this study. 
 
 
 
Table 3.3: Entry vectors and TEM-1-effector expression vectors created and used in 
this study. 
  
Effector Sakai ID Entry vector 
(pENTR-SD/D-
TOPO) 
TEM-1 
destination vector 
(pCX340) 
Source 
EspY1 ECs0061 pSB9.47B pSB16.23A S.A. Beatson, this study 
NleC ECs0847 pRY2-ENTR pRY2-DEST R. Younis, this study 
NleD ECs0850 pRY3-ENTR pRY3-DEST R. Younis, this study 
EspX2 ECs0876 pSB10.4 pSB16.27 S.A. Beatson, this study 
EspV’ ECs1127 pSB9.41A pSB16.20A S.A. Beatson, this study 
EspO1-1 ECs1567 pAF14 pAF14D A. Fivian, this study 
EspK ECs1568 pAF5 pAF5D A. Fivian, this study 
NleH1-2 ECs1814 pSB9.46B pSB16.22A S.A. Beatson, this study 
NleF ECs1815 pSB10.11B pSB16.28A S.A. Beatson, this study 
NleG7’ ECs2226 pSB9.33B pSB16.13A S.A. Beatson, this study 
NleG6-3’ ECs3488 pRY12-ENTR pRY12-DEST R. Younis, this study 
Tir ECs4561 pSB9.13C pSB16.6A S.A. Beatson, this study 
EspH ECs4564 pSB9.15B pSB16.7A S.A. Beatson, this study 
EspZ ECs4571 pSB9.16B pSB16.8A S.A. Beatson, this study 
EspG ECs4590 pSB9.5A pSB16.2A S.A. Beatson, this study 
EspY4 ECs4653 pSB10.22B pSB16.32A S.A. Beatson, this study 
EspX4 ECs5021 pSB11.5A pSB16.35A S.A. Beatson, this study 
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Transformation of EPEC 
Electrocompetent EPEC 2348/69 and an isogenic non-type III secreting EPEC strain 
(EPECΔescN) were prepared by the method described in chapter 2. 2 µl purified destination 
vector was transformed into each strain by electroporation as described in chapter 2 
(transformation of wild type EPEC strain was performed by S.A. Beatson; the author 
performed transformation of EPECΔescN). Transformants were selected on LB agar 
containing 10 µg/ml tetracycline.  
  
3.2.2. Translocation assay 
Solutions  
The solutions used in the β-lactamase translocation assay are as follows: Hanks’ Balanced 
Salt Solution; HBSS (Invitrogen), Dulbecco’s modified eagles medium; DMEM (Sigma), 
Hepes modified DMEM (Sigma), CCF2/AM loading solution (Invitrogen, UK) comprising 
6 µl solution A, 60 µl solution B, 934 µl solution C. 
β-lactamase translocation assay 
The day before infection 4 x 10
4
 HeLa cells were seeded into each well of an 8-well labtek 
culture slide (BD Falcon). 500 µl DMEM was added to each well and the HeLa cells were 
grown overnight at 37
o
C with 5% CO2. 3 ml LB broth (supplemented with 10 µg/ml 
tetracycline) was inoculated with a fresh colony of the appropriate EPEC strain. The culture 
was incubated overnight at 37
o
C with shaking (200 rpm). The next day the bacterial culture 
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was diluted 1:100 in DMEM (Hepes modified) that had been preheated to 37
o
C. The culture 
was incubated statically at 37
o
C for 2.5 hours. DMEM was removed from the HeLa cells 
and replaced with 500 µl of the bacterial culture. Cultures were incubated for a further 30 
minutes at 37
o
C with 5% CO2. 1 mM IPTG was then added to each well to induce 
expression of TEM1-effector fusion and the cells incubated for one hour at 37
o
C 5% CO2. 
DMEM was removed from the cells and the HeLa cells were washed three times with 
HBSS. After removing the last wash, 200 µl of HBSS and 40 µl of the CCF2/AM loading 
substrate were added to the HeLa cells. The cells were incubated in the dark at room 
temperature for 90 minutes and then washed three times in HBSS. Excess HBSS was 
removed from the slide with Whatman 3 mm filter paper and the chamber partitions were 
removed from the slide. Wells were covered with two square (2 cm
2
) glass coverslips. Live 
cells were viewed using a Leica DMRE fluorescence microscope with a 4’,6’-diamidino-2-
phenylindole (DAPI) filter set (340 - 380 nm excitation and 425 nm long-pass emission). 
Images were taken using a true colour digital camera. 
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3.3 Results 
 
Thirteen EHEC O157:H7 T3SS effector candidates and 4 confirmed LEE encoded effectors 
were successfully cloned into the TEM-1 expression vector pCX340gw (performed by S. 
Beatson). Wild type EPEC 2348/69 and an isogenic non-T3S EPEC ΔescN were then 
transformed with the recombined TEM-1 fusion expression plasmids. The author together 
with S.A. Beatson and C.M. Bailey performed 17 β-lactamase translocation assays under the 
supervision of O. Marches at Imperial College, London.  
 
Figure 3.2 shows an example of the blue and green fluorescence seen in the translocation 
assays. Blue fluorescence was seen in HeLa cells infected with wild type EPEC expressing 
TEM-1-fusions of LEE encoded effectors Tir, EspH, EspZ and EspG. Blue fluorescence 
was also seen for 11 candidate effector proteins indicating translocation into eukaryotic cells 
(Table 3.4). Green fluorescence was seen in HeLa cells infected with EPEC ΔescN 
expressing the same effectors indicating that translocation of the putative effectors was 
dependent on the T3SS. This confirmed the effector status of 11 candidate effectors. Green 
fluorescence was seen in cells infected with EPEC expressing EspV’ and EspX4.  
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Figure 3.2: β-lactamase translocation assay. HeLa cells infected with 
EPEC2348/69 (a) or EPEC ΔescN (b) expressing TEM-1 EspO1-1.  Blue 
fluorescence indicates translocation of fusion protein. Green fluorescence 
indicates no translocation. Images used with permission from Tobe et al., 
2006 [2].  
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Effector Sakai ID Result 
EspY1 ECs0061 Positive 
NleC ECs0847 Positive 
NleD ECs0850 Positive 
EspX2 ECs0876 Positive 
EspV’ ECs1127 Negative 
EspO1-1 ECs1567 Positive 
EspK ECs1568 Positive 
NleH1-2 ECs1814 Positive 
NleF ECs1815 Positive 
NleG7’ ECs2226 Positive 
NleG6-3’ ECs3488 Positive 
Tir ECs4561 Positive 
EspH ECs4564 Positive 
EspZ ECs4571 Positive 
EspG ECs4590 Positive 
EspY4 ECs4653 Positive 
EspX4 ECs5021 Negative 
 
 
Table 3.4: Results of the β-lactamase translocation assays 
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Effector Sakai ID Evidence 
EspY1 ECs0061 B 
NleC ECs0847 B 
NleH1-1 ECs0848 SC 
NleD ECs0850 B 
EspX2 ECs0876 B 
EspX7 ECs1560 S 
EspN ECs1561 S 
EspO1-1 ECs1567 SCFB 
EspK ECs1568 SFB 
NleG2-1* ECs1810/1 S 
NleA ECs1812 S 
NleH1-2 ECs1814 SCFB 
NleF ECs1815 SB 
NleG ECs1824 SF 
EspM1 ECs1825 SF 
NleG2-2 ECs1994 SCF 
NleG6-1 ECs1995 SCF 
NleG5-1 ECs1996 SCF 
NleG5-2 ECs2154 S 
NleG6-2 ECs2155 S 
NleG2-3 ECs2156 S 
NleG7* ECs2226 B 
EspJ ECs2714 SC 
TccP ECs2715 S 
EspM2 ECs3485 SF 
NleG8-2 ECs3486 SCF 
EspW ECs3487 SC 
NleG6-3* ECs3488 B 
EspL2 ECs3855 SF 
NleB1 ECs3857 SCF 
NleE ECs3858 SF 
EspF1 ECs4550 S 
EspB ECs4554 S 
Tir ECs4561 B 
Map ECs4562 S 
EspH ECs4564 SB 
EspZ ECs4571 SFB 
EspG ECs4590 SB 
EspY4 ECs4653 B 
Table 3.5: Evidence supporting effector status. B = positive result in 
β-lactamase assay, S = present in EHEC O157:H7 Sakai T3S secretome, 
C = positive result in CyaA translocation assay, F = positive result in 
FLAG tag staining, * = predicted pseudogene. Table adapted from [2]. 
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3.4 Discussion 
 
Forty-nine novel T3SS effectors were discovered in the EHEC O157:H7 genome by a 
bioinformatics survey (performed by M. Pallen and S.A. Beatson). In order to confirm the 
effector status of the candidate effectors, T3S-dependent secretion and translocation of 
effectors needed to be demonstrated.  
 
Four independent methods were used to demonstrate the T3S-dependent secretion and 
translocation of the candidate effectors. Three approaches were carried out by colleagues at 
the University of Osaka, Japan. In the first approach 31 effectors were shown to be secreted 
into the culture supernatant by the T3SS using secretome analysis. In the second approach 
translocation of 12 novel effectors was demonstrated using FLAG tagged effectors and 
immunofluorescence. The third approach, an adenylate cyclase translocation assay, 
confirmed the translocation of 10 predicted effectors. Work carried out at the University of 
Birmingham and Imperial College, London demonstrated translocation of candidate 
effectors using a β-lactamase translocation assay. Predicted effectors were expressed as 
TEM-1 fusion proteins within wild type EPEC 2348/69 or an isogenic non-T3SS EPEC 
strain. HeLa cells were infected with EPEC strains (expressing novel effector-TEM-1 
fusions). Translocation of effectors was monitored using the fluorescent substrate 
CCF2/AM. Results showed that 11 novel effectors and 4 LEE encoded effectors were 
translocated into HeLa cells via the T3SS.   
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Table 3.5 shows the results of each assay for each effector. Results from this study confirm 
that the effector repertoire of EHEC O157:H7 Sakai is much larger than previously 
imagined. The total number of T3SS effectors in this strain now stands at 39. The results of 
the β-lactamase assay together with the results of assays performed by collaborators confirm 
that homologues of Shigella Osp-type effectors i.e. EspL (a homologue of OspD), EspO1-1 
(a homologue of OspE) and NleH1-2 (a homologue of OspG) are translocated by the LEE 
T3SS. Significantly translocation of EspW, a homologue of HopW from the plant pathogen 
P. syringae was confirmed in this study. This implies that effectors target conserved aspects 
of eukaryotic cell biology and that the association between type-III secretion and eukaryotic 
subversion is ancient [2].  
 
3.4.1 Non-prophage encoded effectors 
 
As discussed in chapter one, effector genes encoded in non-phage encoded EELs are 
predicted to be substrates of the ETT2 T3SS (a second T3SS defunct in the Sakai strain). 
Two such candidate effectors (EspY1 and EspY4) were shown to be translocated through 
the LEE encoded T3SS using the β-lactamase assay. This shows that these putative effectors 
are genuine effectors (or at least were effectors of the ETT2 T3SS). 
 
3.4.2 Pseudogenes encode T3SS-translocated proteins 
 
Interestingly two effectors (NleG6-3’ and NleG7’) encoded by pseudogenes caused blue 
fluorescence in HeLa cells indicating that they were translocated via the T3SS. This shows 
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that the cryptic T3SS secretion signal remains intact despite the prediction that these 
effectors can no longer function. It is possible however that these effectors modulate the  
function of other effectors and thus play a role in cellular subversion. This thesis 
concentrates on effectors that are not encoded by predicted psuedogenes. However, further 
studies into pseudogene-encoded novel effectors (especially those that are translocated into 
host cells) may provide valuable insight into EHEC pathogenesis and evolution. 
Translocation could not be demonstrated for two of the 17 effectors tested (EspV’ and 
EspX4). EspV’ is a pseudogene, it is likely that the T3SS secretion signal has been disrupted 
by a frameshift or by mutations thereby preventing T3S of this effector.  
 
3.4.3 Future T3SS effector discovery and confirmation 
 
In addition to expanding the repertoire of T3SS effectors in EHEC O157:H7, the results of 
this study confirm that homology searches can be used to predict T3SS effectors reliably. 
Homology searches of the recently sequenced EPEC 2348/69 genome have revealed the 
presence of 21 putative T3SS effector genes [352]. Previous experimental studies of T3SS 
effectors have often relied upon transposon mutagenesis and other laborious techniques to 
discover individual novel T3SS effectors [350]. This study highlights the effectiveness of an 
alternative approach in which bioinformatics and mid-throughput translocation assays are 
used to identify novel T3SS effectors and confirm their translocation into host cells. Such 
approaches are becoming more relevant as the availability of next generation sequencing 
technology means that there is likely to be a huge increase in the number of sequenced 
bacterial genomes (including many T3SS organisms) in the near future [353] [354]. To 
exploit the vast quantities of information provided by increased genome sequencing e.g. for 
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defining the effector repertoires of numerous strains of pathogens/clinical isolates, 
researchers will need to identify novel T3SS effectors quickly, easily and accurately [355] 
[356]. The approach to T3SS effector discovery and confirmation demonstrated by Tobe et 
al [2] will most likely enable this. 
  
The Gateway system of cloning enabled fast and efficient cloning of candidate effectors into 
a β-lactamase expression vector. Entry vectors created in this study can be used in 
recombination reactions with other destination vectors and other model systems in the future 
– thereby reducing the need for further amplification of effector genes by PCR. 
 
The β-lactamase translocation assay was relatively straightforward to perform and allowed 
translocation of T3SS effectors to be investigated in live cells. Results appear to be reliable 
as they are consistent with studies on the secretion/translocation of LEE-encoded effectors 
[196]. However, there are limitations to the approaches used. For example the reporter 
proteins (e.g. adenylate cyclase) fused to the effectors were large and may have interfered 
with secretion through the T3SS apparatus. This may have caused false negative results. 
Also, translocation of individual effectors was tested using EPEC. There is thus no 
hierarchy of secretion between EHEC effectors in this model – false negative results may 
have occurred if secretion of the effector in question relies upon or is regulated by another 
EHEC-specific effector or protein.  Translocation should therefore be tested using strains of 
EHEC in which individual effectors are deleted. This would provide a more physiologically 
relevant model of translocation of T3SS effectors during EHEC infection.   
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CHAPTER FOUR 
Expression of effectors in mammalian cells 
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4.1. Introduction 
 
The second aim of this thesis was to characterise the effects of novel EHEC O157:H7 T3SS 
effectors on eukaryotic cells. This chapter documents work carried out by the author and R. 
Shaw to define the localisation of selected novel effectors in mammalian cells.  
 
4.1.1. Localisation as a clue to effector function 
 
Following translocation into host cells, effectors are often targeted to specific organelles and 
cell structures where they perform their role in cellular subversion [357]. For example, 
EPEC Map is targeted to the mitochondria [152] whereas Tir localises to the plasma 
membrane to function as the receptor for intimin [58] [358]. Protein sequence analysis and 
predicted secondary structure e.g. transmembrane domains, may give clues as to effector 
targeting in host cells. Often however, no such clues are available – YopM of Yersinia 
localises to the host cell nucleus despite containing no classical nuclear localisation signal 
[359]. Numerous studies of T3SS effectors have investigated the localisation of individual 
effectors within mammalian cells [254] [359] [360]. In addition to following effector 
localisation directly, observation of cell processes such as cytoskeletal rearrangements and 
vesicle trafficking can also be useful for gaining an insight into effector function as 
disruption of these processes may indicate interference by the effector [254] [361]. For 
example, phalloidin, a toxin from the death cap mushroom that binds to filamentous actin 
[362] can be used to probe for actin stress fibres and other actin-rich cytoskeletal 
formations. Such changes in the actin cytoskeleton may indicate that the effector interacts 
with actin or disrupts small GTPase signalling [159].  
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T3SS effectors can be introduced into mammalian cells by infection or transfection [363] 
[364]. Localisation of the effectors may then be monitored by immunofluorescence 
microscopy or immunoblotting of cell fractions. 
 
4.1.2. Infection 
 
Infection of cells with type III-secreting pathogens allows effectors to be studied during the 
course of a physiologically representative infection i.e. all T3SS components (e.g. 
chaperones) are present. The advantages of this method include; delivery of effectors into 
host cells through the T3SS and maintenance of the correct hierarchy of secretion (may 
allow effectors to act in concert e.g. SopE and SptP of Salmonella). However, redundancy 
between effectors and the co-operative nature of many T3SS effectors means that it can be 
difficult to characterise the effects of one effector when that effector is translocated into host 
cells alongside other effectors through the same T3SS [357]. Transient transfection allows 
effectors to be expressed individually within the eukaryotic cell, making it easier to 
determine the contribution of a particular effector to cellular subversion [365]. This study 
used transfection of HeLa cells to examine the localisation of GFP-tagged EHEC O157:H7 
T3SS effectors. 
        
4.1.3. Transfection 
 
Transfection introduces nucleic acids into eukaryotic cells through a non-viral mechanism 
e.g. electroporation, microinjection [366], calcium phosphate [367], cationic polymer- and 
cationic lipid-mediated transfection [368]. The method of microinjection was considered for 
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this study whereby a microneedle is used to inject DNA directly into the eukaryotic cell. 
However, microinjection is a process that requires much skill and time as each cell is 
transfected individually [366]. Cells may be damaged by microinjection and throughput is 
very low [366]. Therefore, transfection mediated by cationic lipids was used as it provided a 
high-throughput system whereby effectors could be screened quickly and easily with 
existing laboratory equipment. In this method, DNA is delivered to the eukaryotic cell in the 
external milieu. Uptake of DNA by the eukaryotic cell is aided by cationic lipid molecules 
that bind to/condense DNA to produce a positively charged DNA-liposome transfection 
complex [369]. This complex interacts with the negatively charged host cell membrane 
[370]. Transfection complexes are then thought to be taken up by the eukaryotic cells by 
endocytosis [369]. Cells are not damaged by the delivery of DNA and the throughput is 
much higher than microinjection as many cells can be transfected simultaneously [368]. 
Transient transfection of mammalian cells has been used to investigate the functions and 
localisation of effectors from many T3SS organisms including Yersinia [371], Pseudomonas 
[361], EPEC [254], Salmonella [372] and Shigella [373].  
 
4.1.4. Protein tags 
 
Protein localisation within cells can be followed using antibodies to the protein of interest. 
However, when screening a large number of proteins it is laborious and expensive to obtain 
antibodies to each protein of interest. Therefore the protein of interest is often tagged with 
an epitope tag; usually a small peptide often derived from a viral protein e.g. myc, 
haemagglutinnin (HA), V5, or FLAG [374]. Antibodies for a range of tags are commercially 
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available at low cost. Therefore, protein tags provide an easier and more cost-effective 
method for following proteins of interest by immunofluorescent microscopy. 
 
Green fluorescent protein (GFP) is a 25kDa chromoprotein derived from the jellyfish 
Aequoria victoria [375]. GFP is photoactivatable, insensitive to pH and tolerates fusions – it 
is therefore a useful biological reporter protein and has been used to study protein 
expression, movement, localisation and protein interactions in a range of cell types [376] 
[377]. However, GFP cannot pass through the T3SS [225] so cannot be used in infection 
studies. GFP is useful in transfection studies of T3SS effectors where delivery of the 
effectors by the T3SS is not required. Fusion to GFP has also been shown to increase the 
overall stability of fusion proteins [378] [379].  
 
In this study, effector proteins were expressed as GFP fusions within HeLa cells. The 
Gateway vector pcDNA-DEST53 (Invitrogen) was used for transfection of mammalian cells 
with effector genes. Recombination between entry vectors and pcDNA DEST53 allowed 
expression of GFP–effector fusion proteins. The localisation of GFP-effector fusion proteins 
within HeLa cells was followed by fluorescence microscopy. Fluorescent 
tetramethylrhodamine isothiocyanate (TRITC) phalloidin was also added to transfected cells 
following fixation to probe for actin stress fibres and other actin-rich cytoskeletal 
formations.  
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4.1.5. Site-directed mutagenesis 
 
Another aim of this thesis was to dissect sequence-activity relations for selected effectors. 
To investigate the significance of individual amino acid residues in individual effectors, in 
vitro site-directed mutagenesis was used. Site-directed mutagenesis is a useful technique as 
it allows specific amino acid residues/motifs of a protein to be mutated [380]. This study 
made use of the commercially available QuikChange II Site-Directed Mutagenesis Kit 
(Stratagene, USA) to quickly, easily and reliably mutate effector genes. This method uses a 
double-stranded methylated DNA vector with the insert of interest (effector gene) as a 
template. Mutagenic primers containing the desired mutation are then used to generate a 
mutated plasmid through thermocycling and extension of the primers by PfuUltra DNA 
polymerase. The methylated parent plasmid is digested using Dpn I (an endonuclease 
specific for methylated DNA). The mutated plasmid is selected for as it is not methylated 
and therefore not affected by Dpn I. Mutated plasmids are then transformed into and 
propagated within E. coli [381]. 
 
4.1.6. Targeting residues of EspM2 for mutagenesis 
 
Amino acids that are highly conserved between homologous proteins are likely to be 
important for function and/or structure of a protein [382]. Conserved residues can be 
identified by producing a multiple sequence alignment of homologous proteins [383]. 
Figure 4.1 shows a multiple sequence alignment of representative members of the IpgB 
family of effectors including EspM [384], Map [153], EspT [385], IpgB1 and IpgB2 [159]. 
An alignment of 24 members of the family can be seen in Alto et al (2006) [159]. The 
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multiple sequence alignment reveals a number of conserved amino acid residues: Trp70, 
Glu74, Ser80, Leu118 and Asp119 (figure 4.1). In this study, Ser80, Leu118, Asp119 and 
Phe195 (non-conserved) were mutated by site directed mutagenesis to determine the 
contribution of these residues to effector function and targeting. The residues were 
substituted with alanine as it is a small amino acid, likely to preserve protein folding by 
conserving steric and hydrophobicity properties. Therefore any effect on protein function is 
more likely due to loss of amino acid side chain and not due to disruption of overall protein 
structure [386].  
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   MapEPEC  215488973 --LMINHGKLTTQLLQAVAKQTGSSDTQQWFKQEQITFLSRAVNKTVDDY 47-94 
   MapCIROD  15723928  --LMINHDKLTAQLLKAVAKQTGNGDTQQWFRQEQITFISKTVNKTVHDY 47-94 
   MapSAKAI  15833816  --FVINHGKLTNQLLQAVAKQTRNGDTQQWFQQEQTTYISRTVNRTLDDY 47-94 
   EspM2SAKAI 15832739  --ISFSVRKFSGNILETVRRQS-TKDIDEWIKDERIVYPSRVINQEIDNY 44-90 
   bfpT EPEC  4126789  --IHFSVRKFSGNILDTVNRQN-TKDINGWIKDERIVYPSRVINQEIDNY 44-90 
   EspM1SAKAI  15831079  --IRFNVNKFSGCILETVSRQS-TKDIHGWVSDERTVYPSRVINQEIDNC 44-90 
   EspM2CIROD  169788415 --VSFSTDHMNKQILSTVSRQS-TKDLLAWKKDEKVIYPSRLVNIGIDKY 40-86 
   IpgB2SF  32306996  --VKISSTKINTSILSSVSEQI-GENITDWKNDEKKVYVSRVVNQCIDKF 36-82 
   EspTCIROD  202957371 --ISFSYLRLESELMQCINLKN-EGKMNEWMREECICFVSRDVNKQLDIF 37-83 
   IpgB1SF  18462570  FGCPVNINKIRDSVIDKIKDSNSGNQLFCWMSQERTTYVSSMINRSIDEM 47-96 
                         
 
   MapEPEC  215488973 CMSNNSAISKETKCRIFKEVESAI-QQPLDMNCAQSSISHFLQSNKYFN- 142 
   MapCIROD  15723928  CINNNSTINKETKQHIFKAVESVI-QQPLDINCAQSSISHFLQSNKYFN- 142 
   MapSAKAI  15833816  CRSNNSVISKETKGHIFRAVENAL-QQPLDMNGAQSSIGHFLQSNKYFN- 142 
   EspM2SAKAI  15832739  CFQKNAKISTEERQRVFFLVSQEN-QLTLDVKAAQSSINHVIMGSASFG- 138 
   bfpTEPEC  4126789  CFQKNAKISTEERQRVFSLVRQRY-QLTLDVKAAQSSINHVIMGNASFG- 138 
   EspM1SAKAI  15831079  CLQKNAKISSEERKMVFSLVSKEF-ELTLDVKAAQSSINHIIIGNASFG- 138 
   EspM2CIROD  169788415 CAENNTNVTGRVRQRVFAMISKDF-GIKLDARSAQSSINHIITGNGSFG- 134 
   IpgB2SF  32306996  CAEHSRKIGDNLRKQIFKQVEKDY-HISLDINAAQSSINHLVSGSSYFK- 130 
   EspTCIROD  202957371 AKNNQTTIPGCVRERVFQRASFHC-GFSLDVRCAQTSTHHMILNSLYFQ- 131 
   IpgB1SF  18462570  AIHNGVVLTSDNKRNIFAAIEKKFPDIKLDEKSAQTSISHTALNEIASSG 146 
                              
 
   MapEPEC  215488973 QKVDEQCGKGVDPITRFNTQTKLIEQVSREIFEQNFST-AKISDIKALTE 191 
   MapCIROD  15723928  KIVDEQCGKGVDPITRFNTQTKMIDDVSCELFEKNFNS-TKVSDIKAITQ 191 
   MapSAKAI  15833816  QKVDEQCGKRVDPITRFNTQTKMIEQVSQEIFERNFSG-FKVSEIKAITQ 191 
   EspM2SAKAI  15832739  KKMDALC-DGMSRDVKNRTSDTIANLLADKFYQKHIDSDIDIVKLRNDIP 187 
   bfpTEPEC  4126789  KKIDTLC-DSMSRGCKNRTADCIANLLADKFYQKHIEPDIDIVKLRNEIP 187 
   EspM1SAKAI  15831079  KKMDALC-DGMSRAVKNSTTDYIANVLADKFYQKHIAPGVDIVKLRNEIP 187 
   EspM2CIROD  169788415 KKTASLC-EGMDRGVKNKAADMLANQLADIFFEKNISQDINIKKLQNDVK 183 
   IpgB2SF  32306996  KKMDELC-EGMNRSVKNDTTSNVANLISDQFFEKNVQY-IDLKKLRGNMS 178 
   EspTCIROD  202957371 KKMDTLF-GSADVEVRNQCVRTALSSLADIFFERNVNS-IDMNKFRDKVY 179 
   IpgB1SF  18462570  LRAKILKRYSSDMDLFNTQMKDLTNLVSSSVYDKIFNESTKVLQIEISAE 196 
                                          
 
   MapEPEC  215488973 KAIADNVQDTRL 203 
   MapCIROD  15723928  SVIADCVQDTRL 203 
   MapSAKAI  15833816  NAILEHVQDTRL 203 
   EspM2SAKAI  15832739  DYLMRAIQG--- 196 
   bfpTEPEC  4126789  DYLRCAIQA--- 196 
   EspM1SAKAI  15831079  GYMSRVIQG--- 196 
   EspM2CIROD  169788415 RYIIMANAMSA- 194 
   IpgB2SF  32306996  DYITNLESPF-- 188 
   EspTCIROD  202957371 DAIVQEAQRT-- 189 
   IpgB1SF  18462570  VLKAVYRQSNTN 208 
Figure 4.1 Alignment of WxxxE family members. Clustal alignment of 
EHEC EspM2 and other family members. Genbank ID# is listed. The WxxxE 
motif is highlighted in red. Conserved (yellow) and non-specific (blue) residues 
mutated in transfection experiments are highlighted. Consistent with P. 
syringae nomenclature, species/strain names are shown as subscript suffixes: 
EPEC (EPEC 69), CIROD (C. rodentium), SAKAI (EHEC O157:H7 Sakai), SF 
(S. flexneri).  
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4.2. Methods 
 
4.2.1. Gateway DNA cloning 
PCR 
Thirteen effectors were amplified by PCR (author and R Younis performed five reactions 
each, S.A. Beatson performed three reactions) as described in chapter 2. Primers used in this 
study are listed in table 4.1. 
TOPO cloning 
Thirteen effectors were cloned into pENTR-D-TOPO (no Shine-Dalgarno sequence). 
Author performed five Topo
 
cloning reactions as described in chapter 2 (R. Younis 
performed five reactions, S. A. Beatson performed three reactions). Entry vectors used in 
this study are listed in table 4.2 
LR recombination 
Thirteen effectors were recombined (as described in chapter 2) into Gateway mammalian 
cell expression vector pcDNA-DEST53 (figure 4.2). Destination vectors used in this study 
are listed in table 4.2. The author performed eight successful LR reactions, R. Younis 
performed five. Destination vectors were confirmed by DNA sequencing according to 
standard procedures described in chapter 2. Details of growth media, chemical 
transformation of TOP10 E. coli and plasmid preparation can also be found in chapter 2.  
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Figure 4.2: pcDNA DEST53. Gateway destination vector for mammalian 
expression of N-terminal GFP fusion. Expression of the GFP-effector fusion was 
controlled by a cytomegalovirus (CMV) promoter. 
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Primer Sequence (5’-3’) 
DNA sequencing  
 
GatewayM13F GTAAAACGACGGCCAG 
gwpDEST53GFPf GAGTTTGTAACTGCTGCTGGG 
gw.pDEST53_R2 GCTGATCAGCGGGTTTATCTT 
gw.pDEST53_R3 CCACTTTGTACAAGAAAGC 
 
Amplification of effector genes 
 
 
ECs0850.gwF CACCATGCGCCCTACGTCC 
nsGW.0850r AAGCAATGGATGCAGTCTTACC 
ECs1812.gwF CACCATGAACATTCAACCGACC 
ECs1812.gwR GACTCTTGTTTCTTGGAT 
ECs1815gwF CACCATGTTACCAACAAGTGGT 
ECs1815gwR TCCACATTGTAAAGATCC 
ECs1824.gwF CACCATGCCTGTCATATTAAAC 
ECs1824.gwR AATTCTAGTGCATATATTTTG 
ECs1994gwF CACCATGCCATTAACCTCAGAT 
ECs1994gwR ATTACCCTTTATAACGAA 
ECs1825.gwF CACCATGCCAGTAAATGCG 
nsGW.1825r CCCCTGTATAACACGACTC 
ECs2714.gwF CACCATGTCAATTATAAAAAAC 
ECs2714.gwR TTTTTTGAGAGGATATATG 
ECs3485.gwF CACCATGCCGATGAATACT 
nsGW.3485r TCCCTGTATAGCACGCATC 
ECs3486.gwF CACCATGCCAGTCATATTAAAT  
ECs3486.gwR AATACTGTTTTGTTGAAG  
ECs3487.gwF CACCATGCCCAAAATATCATCAG 
ECs3487.gwR ATTTCTAACCAAGGGGTCC 
ECs3488.gwF CACCATGGAGAGAAGGGCT 
ECs3488.gwR TTAAGCATCACTTGCAAC 
ECs3857.gwF CACCATGTTATCTTCATTAAATG 
ECs3857.gwR CCATGAACTGCAGGTATAC 
ECs3858.gwF CACCATGATTAATCCTGTTAC 
ECs3858.gwR CTCAATTTTAGAAAGTTTAT 
ECs4562.gwF CACCATGTTTAGTCCAATGACAATG 
ECs4562.gwR CAATCGGGTATCCTGTAC 
 
Table 4.1: DNA primers used in this study 
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Effector Sakai 
ID 
Entry vector Entry vector 
source 
GFP 
Destination 
vector (pcDNA 
DEST53) 
Destination 
vector source 
Map ECs4562 SME14a This study SM14.14a This study 
NleE ECs3858 SME20a This study SM14.20 This study 
NleB ECs3857 SME13.19a This study pDEST3857 R. Younis, this 
study 
NleG6-3 ECs3488 pENTR-D-
3488 
This study pDEST3488 R. Younis, this 
study 
EspW ECs3487 pENTR-D-
3487 
This study pDEST3487 R. Younis, this 
study 
NleG8-2 ECs3486 pENTR-D-
3486 
This study pDEST3486 R. Younis, this 
study 
EspM2 ECs3485 pR1.26b R. Younis, 
this study 
pDEST3485  R. Younis, this 
study 
EspJ ECs2714 SME4.3 This study SM16.4.3b This study 
NleG2-2 ECs1994 SME37a This study SM14.37a This study 
NleG ECs1824 pSB2.12A S.A.Beatson, 
this study 
SM3.6 This study 
NleF ECs1815 pSB10.10B S.A.Beatson, 
this study 
SM16.11a12 This study 
NleA ECs1812 pSB2.10B S.A.Beatson, 
this study 
SM14.10b This study 
NleD ECs0850 pR1.27a R. Younis, 
this study 
pDEST0850 This study 
 
Table 4.2: Vectors used in this study. 
 
 
Plasmid Purpose Source 
pDEST/GW-53/CAT GFP control Invitrogen 
pRK5 myc Expression of Rho (actin stress 
fibre formation) 
L. Machesky, University 
of Glasgow 
 
Table 4.3: Control vectors used in this study. 
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4.2.2. Site directed mutagenesis 
 
Primer design 
Mutagenic primers were designed using the primer design guidelines issued by Stratagene 
or by using the Quikchange Primer Design Program available at www.stratagene.com. 
Briefly, both mutagenic primers contained the mutation (in the middle of the primer) and 
annealed to the same sequence on opposite strands of the plasmid; primers were between 25 
and 45 bases long with a melting temperature >78°C and a minimum G+C content of 40%. 
Mutagenic primers (purified by polyacrylamide gel electrophoresis) were obtained from 
Eurogentec. Mutagenic primers used in this study are shown in table 4.4.    
ECs3485 mutagenesis (performed by R. Younis) 
Template plasmid DNA was obtained from a dam
+
 E. coli strain to ensure selection for 
mutated plasmids following treatment with Dpn I. The reaction mixture consisted of 5 µl of 
10x reaction buffer, 40 ng dsDNA template (pDEST53-3485), 125 ng each mutagenic 
primer, 1 µl dNTP mix, 1 µl PfuUltra DNA polymerase (2.5 U/µl) and 50 µl dH2O. 
The following reaction cycle was used: 
95°C 30 seconds 
95°C 30 seconds 
55°C 1 minute 
68°C 3 minutes 
4°C until use 
Cycle x 16 
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Dpn I digestion 
10 U Dpn I restriction enzyme was added to each reaction mix after amplification. The 
mixture was mixed by pipetting and then incubated for 1 hour at 37°C to digest the 
nonmutated, parental DNA. Dpn I treated DNA was then transformed into chemocompetent 
E. coli (strain XL-1 Blue) as outlined in chapter 2. Mutagenesis was confirmed by DNA 
sequencing as outlined in chapter 2.  
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Primer pair Sequence Mutation/s 
introduced 
3485.2afS 
3485.2arS 
5’ GATAGTATATCCCGCAAGGGTGATCAACCAG 3’ 
5’ CTATCATATAGGGCGTTCCCAGTAGTTGGTC 3’ 
S80A 
3485.3afQ 
3485.3arQ 
5’ GATGCGTGCTATAGCAGGATGAGGTGGGCGC 3’ 
5’ CTACGCACGATATCGTCCTACTCCACCCGCG 3’ 
Q195A 
3485.4xfLD 
3485.4xrLD 
5’ TCAACTAACCGCAGCAGTTAAGGCAGCACAAAG 3’ 
5’ AGTTGATTGGCGTCGTCAATTCCGTCGTGTTTC 3’ 
L118A D119A 
 
Table 4.4: Mutagenic primers used in site directed mutagenesis of EspM2. 
 
  
Table 4.5: Mutated EspM2 vectors created and used in this study. 
Effector Destination vector Source 
EspM2S80A pDEST53 3485 2a  R. Younis, 
this study 
EspM2Q195A pDEST53 3485 3a R. Younis, 
this study 
EspM2L118D119A pDEST53 3485 4x R. Younis, 
This study 
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4.2.3. Transfection 
Preparation of DNA for transfection (DNA maxiprep)   
To ensure high transformation efficiency, DNA used in mammalian cell transfection was 
required to be of a high quality, high concentration and endotoxin-free. Endofree Maxiprep 
(Qiagen, USA) kits were used for the preparation of plasmid DNA (all reaction vessels used 
for preparation of DNA were new/endotoxin-free). Briefly, single colonies of transformed 
TOP10 E. coli were picked and grown overnight (37°C, shaking at 200rpm) in 5 ml of LB 
broth supplemented with 100 µg/ml of ampicillin. 250 µl of this overnight culture was used 
to inoculate 250 ml LB broth supplemented with 100 µg/ml ampicillin. Cells were grown 
overnight at 37°C with shaking (200rpm). The bacterial culture was then centrifuged at 
6000 x g for 15 minutes at 4°C. Plasmid DNA was obtained by a standard alkaline lysis 
method using a commercially available maxiprep kit (Qiagen, USA) following the 
manufacturer’s instructions. Plasmid DNA was eluted in 300 µl elution buffer.  
Preparation of Lipofectamine-DNA complexes 
Transfection solutions were prepared by adding 6 l Lipofectamine 2000 (Invitrogen, UK) 
to 10 l PBS. Endotoxin-free DNA stocks of 0.025 g/ l were prepared in PBS. 16 l of this 
stock was added to the Lipofectamine solution and mixed by gentle pipetting. 
Lipofectamine is a cationic lipid with a positively charged head group that interacts with 
and condenses DNA [369] [370]. Lipofectamine-DNA complexes interact with negatively 
charged cell membranes to promote endocytosis of the complex [368]. Prior to transfection, 
Lipofectamine-DNA complexes were allowed to form for 15 minutes at room temperature. 
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Immediately before transfection, 200 l serum free DMEM was added to the 
Lipofectamine-DNA solution and mixed gently.   
Lipofectamine transfection 
HeLa cells were seeded on borosilicate glass coverslips (VWR, US) in 6-well tissue culture 
dishes (Invitrogen) and grown for 48 hours at 37°C to provide approximately 1 x 10
5
 cells 
for transfection.  Immediately before transfection, cells were washed twice with serum-free 
DMEM. 800 l of serum-free medium was then added to the cells. 232 l of the transfection 
solution containing 0.5 g DNA complexed to Lipofectamine was gently added to each 
well. Cells were then incubated for 6 hours at 37°C 5% CO2. The transfection medium was 
then removed and the cells washed twice in DMEM (10% FCS). 2.5ml DMEM (10% FCS) 
was added to each well and the cells incubated overnight at 37°C 5% CO2. R. Shaw and 
author performed 60% and 40% (respectively) of transfections of HeLa cells. 
 
4.2.4. Immunostaining 
 
Coverslips were washed 3 times in PBS before being fixed in 3% paraformaldehyde for 15 
minutes. Coverslips were then washed again (3 times in PBS) before cells were 
permeabilised for 4 minutes in PBS/0.1% Triton X-100. Coverslips were washed three times 
in PBS, quenched for 15 minutes in 50mM NH4Cl and washed again (3 times in PBS). 
Coverslips were placed on dental wax and 5 µg/ml of tetramethylrhodamine isothiocyanate 
(TRITC)-conjugated phalloidin was added to each to stain the actin cytoskeleton. Phalloidin 
is light sensitive and extremely toxic therefore great care must be taken when handling. 
107 
 
Coverslips were incubated in the dark for 40 minutes at room temperature. Coverslips were 
transferred to a darkened 24-well plate and washed 3 times with PBS. Coverslips were then 
mounted on microscopy slides using 2 µl Citifluor AF1 (Citifluor, UK) and sealed with nail 
varnish. 
 
4.2.5. Microscopy 
 
All samples were examined using a Leica DMR immunofluorescence microscope equipped 
with a DC200 digital camera. Green (GFP) and red (TRITC-Phalloidin) images were 
analysed and superimposed using Leica IM1000 software. This allowed visualisation of 
GFP-effector proteins as green and actin as red.   
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4.3. Results 
 
4.3.1. Gateway vectors 
 
Thirteen pENTR-D-TOPO entry vectors and pcDNA-DEST53 mammalian expression 
vectors containing selected effector genes were successfully created. Entry vectors will be 
able to be used in LR recombination reactions with alternative destination vectors in future 
studies.  
 
4.3.2. NleB, NleF, EspM2 and EspW diffusely localise within the host cell 
cytoplasm 
 
Human epithelial (HeLa) cells were transiently transfected with the Gateway mammalian 
expression vector pcDNA-DEST53. This allowed expression of individual GFP-effector 
fusion proteins within the mammalian cell. GFP localisation was followed using 
fluorescence microscopy. TRITC-phalloidin was also used to visualise the actin 
cytoskeleton of transfected cells. Transfections were repeated 3 times and 20 images of 
transfected cells were recorded per transfection. Representative images of transfected cells 
are shown in figures 4.3 to 4.14 (transfections and image acquisition were performed by the 
author unless otherwise stated). HeLa cells were transfected with pDEST/GW-53/CAT 
plasmid as a control. This plasmid allows expression of GFP alone and was used to 
determine transfection efficiency and the effects of GFP expression on the mammalian cell. 
In cells transfected with the control plasmid, GFP was diffusely localised throughout the 
cytoplasm and nucleus with areas of higher concentrations of GFP in vesicle-like structures. 
Cells transfected with the control also showed no other changes compared to untransfected 
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cells. EHEC O157:H7 T3SS effector Map was used as a positive control as this effector has 
been well characterised and is known to localise to mitochondria and induce filopodia [153]. 
GFP-Map showed a punctate perinuclear localisation and filopodia were induced (figure 
4.3). In cells expressing EspW, NleB1, NleD, NleF and EspM2, GFP was diffusely localised 
throughout the cytoplasm (figures 4.4 - 4.8, 4.13). Cells expressing NleD showed diffuse 
cytoplasmic GFP localisation (80% cells) and, occasionally, punctate GFP aggregates (20% 
cells) (figure 4.7). No changes in the actin cytoskeleton were observed in cells expressing 
NleF, EspW, NleB or NleD.   
110 
 
   
Figure 4.3: HeLa cell control transfections, stained with TRITC-phalloidin 
(A) non-transfected cells, (B) cells transfected with pcDNA CAT GFP, (C) 
cells transfected with Map (performed by R. Shaw). Filopodia are indicated. 
Scale bar represents 20 µm. 
A 
B 
C 
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Figure 4.4: HeLa cells transfected with EspW (ECs3487) (A) GFP 
only, (B) TRITC-phalloidin, (C) merged image. 
A B 
C 
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Figure 4.5: HeLa cells transfected with NleB1 (ECs3857). (A) 
GFP only, (B) TRITC-phalloidin actin stain, (C) merged image. 
A B 
C 
113 
 
 
 
 
Figure 4.6: HeLa cells transfected with NleB1 (ECs3857). (A) 
GFP only, (B) TRITC-phalloidin actin stain, (C) merged image. 
C 
B A 
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Figure 4.7: HeLa cells transfected with NleD (ECs0850). (A, B) GFP 
only, (C,D) TRITC-phalloidin actin stain, (E,F) merge showing 
differences in localisation patterns observed for the same effector. 
A B 
C D 
E F 
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Figure 4.8: HeLa cells transfected with NleF (ECs1815). (A) GFP 
only, (B) TRITC-phalloidin, (C) merge. 
A B 
C 
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4.3.3. NleA, NleE, NleG and EspJ show punctate localisation within the 
mammalian cell cytoplasm 
 
In contrast to the diffuse localisation patterns of EspM2, NleB1, NleD, NleF and EspW, 
several effectors: NleA, NleE, NleG and EspJ showed punctate localisation within the 
cytoplasm of transfected cells. EspJ appeared in spots around the cell nucleus suggesting 
that this effector may be targeted to a perinuclear organelle such as the ER or to secretory 
vesicles.  
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Figure 4.9: HeLa cells transfected with NleA (ECs1812). 
Transfection and images A, B and C performed by R. Shaw. 
A 
A B 
C D 
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Figure 4.10: HeLa cells transfected with EspJ (ECs2714) (performed by R. 
Shaw). Scale bar represents 20 µm. 
Figure 4.11: HeLa cells transfected with NleE (ECs3858) (performed by R. 
Shaw). Scale bar represents 20 µm.  
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Figure 4.12: HeLa cells transfected with NleG.  (A, B) NleG8-2 (ECs3486), (C, 
D) NleG6-3 (ECs3488), (E) NleG2-2 (ECs1994), (F) NleG (ECs1824). 
Transfections A-E performed and images taken by R. Shaw. 
A B 
C D 
F E F 
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4.3.4. EspM2 promotes actin stress fibre formation 
 
TRITC-phalloidin staining showed that actin stress fibres were formed in HeLa cells 
expressing wild type EspM2 (figure 4.13). Levels of actin stress fibre formation were 
comparable to cells expressing Rho, a small GTPase that regulates actin stress fibre 
assembly [387] as shown using Hela cells transfected with pRK5 myc (a Rho expression 
vector).  
 
4.3.5. EspM2 mutants show altered patterns of localisation and decreased 
stress fibre formation 
 
HeLa cells were transiently transfected with mutated EspM2. Localisation of EspM2S80A 
was similar to wild type i.e. diffuse cytoplasmic localisation. Actin stress fibres were also 
seen in cells expressing EspM2S80A mutant (comparable to levels caused by expression of 
wild type EspM2 and Rho). However, cells expressing EspM2Q195A and EspM2L118A/D119A 
showed altered localisation of GFP. GFP was no longer diffusely localised throughout the 
cytoplasm but appeared as small cytoplasmic aggregates (figure 4.14). No actin stress fibres 
were seen in cells transfected with EspM2Q195A and EspM2L118A/D119A (figure 4.14). 
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Figure 4.13: Hela cells transfected with EspM2. (A) GFP-EspM2 localisation, 
(B) TRITC-phalloidin actin stain, (C) merged image, (D) Hela cells transfected 
with pRK5-Myc to induce actin stress fibres. Actin stress fibres are indicated. 
A B 
C D 
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Figure 4.14: Hela cells transfected with EspM2 mutants. (A, B) EspM2S80A, 
(C, D) EspM2L118/D119A, (E) EspM2Q195A, (F) EspM2wt. Actin stress fibres are 
indicated. Scale bar represents 20 µm. 
A B 
C D 
E F 
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4.4. Discussion 
 
Transfection has been used successfully to study many T3SS effectors. In this study, 
transient transfection was used to study the localisation of selected novel EHEC O157:H7 
effectors. Effectors were expressed as N-terminal GFP fusions within human epithelial 
(HeLa) cells. The localisation of GFP was followed using fluorescence microscopy. Four 
effectors; EspM2, NleB1, NleF and EspW were diffusely localised within the host cell 
cytoplasm whereas seven effectors including effectors from the NleG family, NleA, NleE 
and EspJ were not diffusely localised and showed punctate localisation patterns within the 
host cell.  
 
Diffuse localisation of EspM2, NleB1, NleF and EspW suggests that these effectors are not 
targeted to a specific organelle or cellular compartment. Further studies of EspM2 [388] and 
NleF [300] have confirmed cytoplasmic localisation of these effectors. 
 
The non-diffuse patterns of localisation of NleA, NleE, EspJ and NleG are difficult to 
interpret as GFP localisation may indicate that the effectors are targeted to specific 
organelles or that there was poor transfection/expression or misfolding of the effectors 
within the mammalian cell. To determine the exact localisation of the effectors, cell 
compartment-specific dyes/antibodies could be used e.g. MitoTracker (Invitrogen)
 
for 
visualising mitochondria, DAPI for visualising DNA/nucleus. In agreement with the 
punctate localisation patterns seen in this study, NleA has been shown to localise to the 
Golgi [295] whereas a study by Zurawski et al (2008) showed that OspZ (a Shigella NleE 
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homologue) demonstrates similar localisation to EHEC NleE in infected cells [389]. The 
perinuclear punctate localisation of GFP-EspJ suggests that EspJ may localise to the 
ER/secretory vesicles [390]. These findings support those of Marches et al (2008) who also 
found that EspJ-FLAG showed punctate, endomembrane localisation in transfected COS-7 
cells. EspJ has since been shown to inhibit opsono-phagocytosis – possibly by blocking 
membrane/membrane-borne regulator trafficking [390].  
 
Transfection of cells with NleD (ECs0850) demonstrated inconsistent results i.e. diffuse 
patterns of GFP were seen in 80% of cells whereas aggregates of GFP were present in 20% 
of cells. This may have been due to degradation of the GFP-effector fusion protein perhaps 
due to cell stress caused by toxicity of the effector. Studies have shown that effectors 
introduced by transfection do not always localise to the same place as those introduced by 
bacteria. For example, SseG (Salmonella) targets the endoplasmic reticulum and 
microtubules when delivered by bacteria [391] [392] but targets the Golgi of transfected 
cells [393]. Therefore, transfection is not wholly reliable and may not accurately reflect 
effector localisation during an infection – infection studies should be undertaken to confirm 
the localisation of effectors. Infection studies would eliminate the possibility that 
localisation patterns are due to poor transfection or expression of the effector within HeLa 
cells.  
 
Transfected cells were stained with TRITC-phalloidin to visualise the actin cytoskeleton. 
There were no actin cytoskeletal changes observed in transfected cells except those 
expressing EspM2. In these cells, there was an increase in actin stress fibre formation. 
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Similar actin stress fibres are induced in cells over-expressing the small GTPase, Rho [394] 
[395].  This suggests that EspM2 might function by interfering with actin directly or by 
modulating actin cytoskeletal dynamics through activation of small GTPases. In similar 
experiments by Alto et al, a homologue of EspM2, IpgB2 from Shigella, induced the 
formation of actin stress fibres in transfected HEK293 cells. Alto et al showed that EspM2 
(and EspM1) belong to a family of effectors that contain an invariant Trp-xxx-Glu (WxxxE) 
motif. This family contains T3SS effectors from Shigella (IpgB1, IpgB2), Salmonella (SifA, 
SifB) and EPEC (Map) [159]. Work by Alto et al [159] has shown that these effectors 
appear to mimic the GTP-active forms of Rho-family GTPase. Map mimics Cdc42, IpgB2 
mimics RhoA and IpgB1 mimics Rac-1 to promote filopodia, stress fibre formation and 
membrane ruffles respectively [159]. Arbeloa et al have since confirmed that EspM2 causes 
global parallel stress fibre formation in a RhoA-dependent mechanism [388].  
 
Mutation of Leu118/Asp119 and Phe195 to alanine affected GFP-effector localisation and 
stress fibre formation within HeLa cells. This may have been caused by protein misfolding 
and degradation. However, Arbeloa et al found that mutagenesis of L114 and D115 of 
EspM3 resulted in the formation of local parallel stress fibres instead of radial stress fibres 
[388]. Leu118 and Asp119 of EspM2 may therefore be important in controlling the 
conformation of actin stress fibres in host cells. Arbeloa et al also showed that mutagenesis 
of other conserved residues in EspM3 did not have any effect on stress fibre formation – 
similarly, results of this study showed that mutation of Ser80 to alanine did not affect 
effector localisation or stress fibre formation. Structural studies may help to elucidate the 
mechanism by which EspM2 promotes the formation of stress fibres. 
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In evaluation, transfection of Hela cells with GFP-effector fusions has provided an insight 
into the localisation of twelve EHEC O157:H7 non-LEE encoded T3SS effectors. 
Transfection also provided an insight into the function of EspM2. However, the localisation 
pattern of a small number of effectors, especially NleD, was also inconsistent. This 
highlights some of the limitations of the approach used. For example, expression of 
effectors was driven by a powerful viral promoter (CMV) – it is possible that high level 
expression of effector proteins may have led to aberrant targeting within the transfected cell. 
Also, localisation of effectors was observed at only one time point (12 hours) after 
transfection. A number of T3SS effectors are known to move between cellular 
compartments e.g. YopM moves to the nucleus by a mechanism that requires vesicular 
trafficking [359]. The subcellular localisation of the novel effectors should therefore be 
investigated at more time points after transfection e.g. at 6 and 24 hours to confirm that the 
correct subcellular localization (or movement of the effector through the cell) has been 
observed. As mentioned in chapter 3, there are limitations to studying T3SS effectors in 
isolation. During infection, effectors may interact inside host cells which may affect the 
localisation of each individual effector e.g. Tir and EspFu co-localise to the pedestal during 
infection [263]. The localisation of novel effectors should therefore also be investigated and 
confirmed using other methods (e.g. infection) and model systems. Yeast provides an ideal 
alternative model in which to study T3SS effectors – yeast cell culture is simple and less 
time-consuming that mammalian cell culture and there are many techniques that can be used 
to investigate T3SS effector function. Chapter 5 documents investigations into effector 
localisation and function using a yeast cell model.   
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CHAPTER FIVE 
Expression of effectors in Saccharomyces 
cerevisiae 
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5.1. Introduction 
 
The Saccharomyces cerevisiae model is increasingly being used to study T3SS effectors as 
it is simple and can provide valuable insights into effector localisation and function within 
eukaryotic cells. There are a variety of assays and techniques using the yeast cell model that 
have been used to dissect T3SS effector function. In this chapter, selected effectors were 
screened using a yeast growth inhibition assay to identify effectors with deleterious effects 
on yeast. The localisation of selected effectors within yeast cells was investigated using 
yeast reporter strains. The effect of effector expression on chitin localisation and cell 
morphology was also investigated. Finally, an attempt was made to dissect sequence-
activity relations for effectors EspM2 and NleG8-2.   
 
5.1.1. Expression of proteins in yeast  
De novo expression of proteins e.g. T3SS effectors, in yeast is relatively straightforward as 
yeast can be easily transformed with plasmid DNA in the form of shuttle vectors that are 
easy to propagate in E. coli and transform into yeast [159, 396]. In this study, effector 
proteins were expressed as V5/6x His fusions from the Gateway shuttle vector pYES 
DEST52 (Invitrogen, UK). This high copy number plasmid is able to replicate in both E. 
coli and yeast. Yeast are transformed with the vector by an established lithium acetate 
method [397]. Expression of effector-V5/6xHis fusion proteins from pYES-DEST52 is 
controlled by the GAL1 promoter. This promoter is repressed by glucose [398] and activated 
by galactose [399]. Therefore, expression of effectors can be induced by the addition of 
galactose to the growth media. Effector-V5/6xHis fusion proteins can be detected using 
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commercially available anti-V5 [400] or anti-His [401] antibodies. V5 is a small (4 kDa) 
epitope tag derived from Simian virus 5 [400]. The His tag is comprised of 6 histidine 
residues and is useful in protein purification [402]. 
 
5.1.2. Yeast growth as an indicator of protein toxicity 
Yeast growth inhibition due to expression of T3SS effectors has been shown to be a 
sensitive and specific indicator of bacterial protein activity [403] [378]. Experimental 
evidence has shown that very few non-translocated bacterial proteins affect yeast growth 
[403] [378] whereas T3SS effectors from EPEC [404] [405], Salmonella [157, 406] [407], 
Shigella flexneri [159, 378], Yersinia [408] [157], Pseudomonas aeruginosa [409] [410] 
[411], Pseudomonas syringae [412] [413] and Chlamydia trachomatis [414] inhibit yeast 
growth. Slagowski et al (2008) showed that 19 translocated Shigella proteins significantly 
inhibited yeast growth whereas none of the 20 non-translocated Shigella proteins tested had 
an effect on yeast growth [378].  
 
Growth inhibition caused by expression of proteins confined to the bacterial cytoplasm 
appears to be rare [336]. However, when this does occur it does not appear to be due to a 
non-specific effect of overexpression of a bacterial protein but is more likely due to 
interference with conserved cellular processes [336]. For example, in a study by 
Campodonico et al (2005), expression of Legionella sterol desaturase inhibited yeast growth 
– this was likely due to the bacterial protein being highly similar to an essential yeast 
protein, ERG25, required for membrane synthesis [403].  
130 
 
Yeast growth assays are inexpensive and simple to set up and measure. Therefore, the 
approach is amenable to high-throughput screens and has been used to screen >1000 
Francisella proteins for toxicity [378]. There are several methods that can be used to 
monitor yeast growth including plating serial dilutions of yeast culture onto inducing media 
[157] [414], measuring the optical density of liquid cultures [378] or using dyes to measure 
cellular respiration [414]. In this study, yeast growth was monitored by plating serial 
dilutions of saturated culture onto solid media and comparing the growth of yeast on 
inducing and non-inducing media. 
 
Differential yeast growth is the basis of many assays including overexpression screens and 
pathogenic genetic arrays (see Chapter 6). It has also been used to screen drugs/identify 
drug targets [415] and screen novel small molecule inhibitors of type-III secretion and T3SS 
effectors [415]. Inhibitors of type-III secretion can be identified by applying small 
molecules to yeast (that are expressing an effector that causes growth retardation): if growth 
is restored, the small molecule is likely to inhibit the effector (and not damage the 
eukaryotic cell itself). This screening technique was recently used to identify six compounds 
(from an initial 56,000) that inhibited the P. aeruginosa effector ExoS [415]. 
 
5.1.3. Localisation of effectors in yeast gives clues as to effector function 
Many eukaryotic cell processes and components are highly conserved between yeast and 
mammalian cells [416] – therefore it is predicted that effector targeting will also be 
conserved when effectors are expressed de novo in yeast [336]. There is mounting evidence 
131 
 
to suggest that localisation of effectors in yeast is representative of effector localisation 
during the course of an infection. For example, effectors that localise to the actin 
cytoskeleton [405], nucleus [157], plasma membrane [414] and mitochondria [359] in 
mammalian cells also localise to these compartments within yeast [417]. Therefore, 
localisation of effectors within yeast cells can give valuable clues as to effector targeting 
within host cells. However, localisation is not as specific as growth assays – Siggers et al 
observed that a small number of bacterial proteins localised to specific yeast cell 
compartments even though the proteins do not normally contact host cells [336]. 
 
Visualisation of effector proteins in fixed/live yeast has been achieved using indirect 
immunofluorescence and fluorescent tags/fusions (e.g. GFP) [418]. This study uses indirect 
immunofluorescence of fixed yeast cells to determine the localisation of selected effector-
V5 fusion proteins. Fluorescein isothiocyanate (FITC)-conjugated anti-V5 antibodies 
(Invitrogen, UK) were used to stain effector-V5 fusions to determine the subcellular 
localisation of the effectors. FITC is a fluorescent molecule (fluoresces at 530 nm) often 
used for fluorescence microscopy [419]. In addition to fluorescent antibodies, yeast reporter 
strains that constitutively express monomeric red fluorescent protein (mRFP) fusion 
proteins were used to help determine the localisation of effectors in the yeast cell. 
Monomeric RFP fluoresces at 605 nm; therefore fluorescence of RFP and FITC can be 
easily distinguished [420]. There are many yeast strains available that express RFP-fusions 
that localise to specific subcellular compartments/structures e.g. nucleolus, Golgi apparatus, 
lipid particles etc. [421]. This study makes use of four reporter strains (outlined in table 5.5) 
in which the RFP-reporter protein localises to the actin cytoskeleton, endoplasmic reticulum 
(ER) membrane, spindle pole body or microtubule cytoskeleton. These reporter strains were 
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chosen as they would allow visualisation of cell components/processes e.g. cytoskeleton, 
secretory pathway, that are often targeted by T3SS effector proteins. 
 
5.1.4. Morphology of yeast cells can give clues as to effector function 
Observing the overall morphology of the yeast cell, budding patterns, organelles and 
cytoskeleton using differential interference contrast (DIC) microscopy can also give clues as 
to effector function [405]. For example, vacuole fragmentation in cells expressing the P. 
aeruginosa effector, ExoU, led investigators to believe that the effector disrupted vacuolar 
membranes – they subsequently demonstrated that ExoU acted as a phospholipase [410]. 
Also, Rodriguez-Escudero et al found that expression of EPEC effector Map caused the 
formation of large unbudded yeast cells - this pointed to depolarisation of the actin 
cytoskeleton [405]. The effector was subsequently shown to mimic activated Cdc42, a 
GTPase involved in regulating the actin cytoskeleton. Another significant morphological 
change that may be observed is filamentous yeast growth. This indicates perturbation of the 
filamentous growth pathway – a MAPK pathway also controlled by Cdc42 [160] [422]. The 
morphology of live yeast cells expressing selected effector proteins was observed using DIC 
microscopy. 
 
Yeast chitin localisation can also provide insight into effector function. Chitin is a linear 
polymer found in the yeast cell wall and is composed of β-1,4-linked N-acetyl glucosamine 
(GlcNAc) [423]. Although chitin is a minor constituent of the cell wall, a high density of 
chitin is found at the bud neck and septum where it provides stretching resistance during 
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budding to ensure cell integrity [423]. Deposition at these sites is tightly controlled (both 
temporally and spatially) by the cell according to cell cycle and site of bud emergence 
[423]. Chitin present in bud necks and scars can be stained using calcofluor white (a 
fluorophore that binds specifically to chitin) [424]. The location/morphology of bud 
necks/scars can be used as reporters of effector function i.e. abnormalities may indicate that 
the effector disrupts MAPK signaling pathways, the secretory pathway or disrupts the 
cytoskeleton – all of which are essential for chitin deposition. In this study, the localisation 
of chitin within the cell wall of live yeast expressing selected effectors was investigated.        
 
5.1.5. Truncation of NleG8-2 
NleG8-2 is 216 amino acids in length. A RPS-BLAST search using the conserved domain 
database shows that residues 18-206 of NleG8-2 correspond (E-value = 5 x 10
-50
) to 
DUF1076 (pfam06416) – a domain/family comprising several bacterial proteins exclusive 
to E. coli and Salmonella, of unknown function. To localise the activity within the protein, 
truncated versions of NleG8-2 were constructed. DNA primers were designed to amplify 
150, 360 and 618 nucleotides of the NleG8-2 gene so that expression would result in 
expression of 1 – 50, 1 – 120 and 1 – 206 amino acids of NleG8-2 respectively. The effect 
on yeast growth inhibition was then tested. Rodriguez-Escudero et al used a similar 
approach to study the contribution of the C-terminus of Map to Map-induced toxicity [405]. 
They showed that the 15 C-terminal amino acids of Map were involved in Map-mediated 
inhibition of yeast growth [405]. 
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Figure 5.1: Truncated NleG8-2 proteins expressed in yeast.
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5.1.6. Targeting residues of EspM2 and NleG8-2 for mutagenesis 
Multiple alignments of novel effector proteins and their homologues show that there are 
conserved amino acid residues and motifs in a number of effector families. It was speculated 
that these conserved residues may be important for effector function and that substitution of 
the residues with alanine may disrupt effector function and attenuate effector toxicity. The 
importance of three conserved residues of EspM2 was previously investigated using a 
mammalian cell model (Chapter 4). This study concentrates on the highly conserved WxxxE 
motif found in IpgB-like effectors [159] [388] and four residues that are conserved in the 
NleG family of effectors.  
 
All effectors of the IpgB family of effectors contain an invariant WxxxE motif [159] (see 
figure 5.2). Secondary structural analysis by Alto et al suggests that these effectors have a 
common protein fold and that each effector is composed of 6 to 8 helices [159]. Site-
directed mutagenesis was used to mutate Trp70 and Glu74 to alanine. The effect of 
substitution on effector toxicity was assayed using the yeast growth assay. 
 
Within NleG family members there are four conserved residues: Cys136, Asp162, His176 
and Cys194 (see figure 5.3). Significantly, these residues are often found in catalytic active 
sites [425]. This has led to speculation that NleG T3SS effectors may function 
enzymatically [2]. Site-directed mutagenesis was used to mutate each residue (individually) 
to alanine. Effector toxicity was then investigated using the yeast growth assay. The 
localisation of mutated effectors in yeast was also investigated.     
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GB# 
MapEPE69  215488973  INHGKLTTQLLQAVAKQTGSSDTQQWFKQEQITFLSRAVNKTVDDYCMSN 48-98 
MapSTEC O92:NM 221361477  INHGKLTTQLLQAVAKQTGSSDTQQWFRQEQITFLSRAVNKTVDDYCMSN 48-98 
MapSTEC O111:NM 221361419  INHGKLTNQLLQAVAKQTGSSDTQQWFKQEQITFLSRTVNKTVDDYCMSN 48-98 
MapAEPEC   193070392  INYGKLTNQLLQAVAKQTRSGDIQQWFQQEQTTYISRTVNRALDDYCMSN 1-51 
MapAEPEC 0181-6/89 54311620  INYGKLTNQLLQAVAKQTRSGDTQQWFQQEQTTYISRTVNRALDDYCMSN 48-98 
MapSTEC O103:H2 57434451  INHGKLTNQLLQAVAKQTRSGDTQQWFKQEQITYISRTVNRAIDDYCMSN 48-98 
Orf19REPEC O15:H- 13447722  INHGKLTNQLLQAVAKQTRSGDTQQWFKQEQITYISRTVNRAIDDYCMSN 48-98 
EcE22_2869EPE22 193062205  INHGKLTNQLLQAVAKQTRSGDTQQWFKQEQITYISRTVNRAIDDYCMSN 6-56 
MapEHEC 33264 195957629  INHGKLTNQLLQAVAKQTRNGDTQQWFQQEQTTYISRTVNRTLDDYCRSN 48-98 
MapEHEC EC4196 187775716  INHGKLTNQLLQAVAKQTRNGDTQQWFQQEQTTYISRTVNRTLDDYCRSN 6-56 
ST30Ealb  170766827  INYGKLTNQLLQTVAKQTRGGDTQQWFHQERITFTSRTVNKTLDEYCMSN 8-58 
EspTAEPEC O2:H49 223636058  FSYPRLESELIQCINLKN-EGKKNEWMKEESICFVSRDVNKLLDMFAKNN 35-84 
EspTCIROD  202957371  FSYLRLESELMQCINLKN-EGKMNEWMREECICFVSRDVNKQLDIFAKNN 38-87 
trcASflex  13448971  ISSTKINTSILSSVSEQI-GENITDWKNDEKKVYVSRVVNQCIDKFCAEH 40-89 
IpgB2Sdys  194435299  ISSTKINTSILSSVSEQI-GENITDWKNDEKKVYVSRVVNQCIDKFCAEH 7-56 
IpgB2Sflex  56404000  ISSTKINTSILSSVSEQI-GENITDWKNDEKKVYVSRVVNQCIDKFCAEH 37-86 
IpgB2Sson  74314861  ISSTKINTSILSSVSEQI-GENITDWKNDEKKVYVSRVVNQCIDKFCAEH 37-86 
IpgB2Sboy   82524696  ISSTKINTSILSSVSEQI-GENITDWKNDEKKVYVSRVVNQCIDKFCAEH 37-86 
rorfJREPEC  18140091  LSTNTLNNRILTSVARQS-TKDINAWKRDERTVYPSRVINQGIDKYCAEN 41-90 
Orf31REPEC  6090819  LSTNTLNNRILTSVARQS-TKDINAWKRDERTVYPSRVINQGIDKYCAEN 26-75 
EspM2CIROD  169788415  FSTDHMNKQILSTVSRQS-TKDLLAWKKDEKVIYPSRLVNIGIDKYCAEN 39-90 
IpgB2Ealb  170768423  FSVNQMNKIILNTVTRQS-TKDISAWKSDERIVYPSRLINMGIDKHCSEN 7-56 
EspM/TrcAEPEC2  195182811  FSVRKFSGNILDTVNRQN-TKDINGWIKDERIVYPSRVINQEIDNYCFQK 45-94 
EspM/TrcAEHEC EDL933  15803143  FSVRKFSGNILETVRRQS-TKDIDEWIKDERIVYPSRVINQEIDNYCFQK 45-94 
EspM/TrcAEHEC EC4024  195939673  FSVRKFSGNILETVRRQS-TKDIDEWIKDERIVYPSRVINQEIDNYCFQK 43-92 
EspM2SAKAI  15823739  FSVRKFSGNILETVRRQS-TKDIDEWIKDERIVYPSRVINQEIDNYCFQK 45-94 
IpgB2EHEC EC4196 187776009  -------------MRRQS-TKDIDEWIKDERIVYPSRVINQEIDNYCFQK 1-36 
IpgB2EHEC EC4501 189404141  -------------MRRQS-TKDIDEWIKDERIVYPSRVINQVIDNYCFQK 1-36 
EspM3CIROD  169788413  FSVQKVSDNILSLVTRQS-TKDIDGWIKDEQKVYPSRVVNQEIDKFCLEN 41-90 
IpgB1Sson  74314929  VNINKIRDNVIDKIKDSNSGNQLFCWMSQERTSYVSSMINRSIDEMAIHN 50-100 
IpgB1Sflex  31983578  VNINKIRDSVIDKIKDSNSGNQLFCWMSQERTTYVSSMINRSIDEMAIHN 50-100 
IpgB1Sboy  187734448  VNINKIRDSVIDKIKDSNSGNQLFCWMSQERTSYVSSMINRSIDEMAIHN 50-100 
IpgB1Sdys  82524574  VNINKIRDSVIDKIKDSNSGDQLFCWMSQERTSYVSSMINRSIDEMAIHN 50-100 
Propen_03987Ppen 226330074  ---------------MKKIDKDISGWWKDEKKILPSSIINRTIDNLYKRD 1-35 
Consensus 100%   -------------------------W---E-----S---N---D------ 
 
Figure 5.2: Alignment of IpgB family members. Homologues of EHEC O157:H7 Sakai EspM2 were identified by BLASTP. Conserved 
amino acids targeted for mutagenesis are highlighted in yellow. GenBank ID# is shown. Strain/species names are shown: CIROD (C. 
rodentium), REPEC (rabbit EPEC), Sson (S. sonnei), Sflex (S. flexneri), Sboy (S. boydii), Sdys (S. dysenteriae), Ppen (Proteus penneri), 
AEPEC (atypical EPEC E110019), EPEC2 (EPEC B171), EPE22 (EPEC22), EPE69 (EPEC 69), Ealb (E. albertii).
137 
 
 
 
 
 
 
 
NleG1CROD   LQTRISECTFSVSQEKLQCPEEEMRCPVTLETPEKGVFVKNSGDSSVCTLFDSSSFSRLVRDGGVHPLTREPIKASMIVSSDKCVYDNAKGNFVIKNS--- 97-194 
NleG1 EPEC2   LQARISECAFSVSQENLQCPEEGKRCPVTLETPETGVFVKNSEGSLVCTLFDSVSISRLVREGGVHPLTRETITPSMIVKPEDCIFDSSKGNFIIKDG--- 92-189 
NleG2-4SAKAI   IEGKISQCKFSVNTESLQCPSEAVRCPIILDKPEEGVFVKNSEGSLVCTLFDSVSFSHLVRDGGKHPLTREPITSSMIVSQEQCIYDQTKGNFVIKDK--- 94-191 
NleG2EPE69   IEGKISQYKFSVNTQSLQCPSEAVRCPIILDKPEEGVFVKNSEDSLVCTLFDSVSFSHLVRDGGRHPLTREPITSSMIVSPEQCIYDQAKGNFVIKDK--- 95-192 
NleG2-1 EPE22   PQDKIYQCKFSVNTESLQCPSDATRCPIILETPEEGVFVKNSDSSAVCTLFDVDALSRVVNDGSVHPLTRTPITPSMIVKPEECKYDPARGSFIIKDS--- 96-193 
NleG2-2EPE22   IQSKISQYKFSVCPERLQCPPESAQCPITLEIPEEGVFIKNSGDSVVCSLFDVTAFSRLVSEKSPHPLTREKLTASMVVSADKCFYDHGKGSFVIKDS--- 94-191 
NleG2-4EPE22   IEGKISQCKFSVNTESLQCPSEAVRCPIILDKPEEGVFVKNSEGSLVCTLFDSVSFSHLVRDGGKHPLTREPITSSMIVSQEQCIYDQTKGNFVIKDK--- 94-191 
NleG2-5EPE22   IEGKISQCKFSVNTESLQCPSEEVRCPIILDKPEEGVFVKNSEGSLVCTLFDSISFSHLVRDGGKHPLTREPITSSMIVSQEQCIYDQTKGNFVIK----- 94-189 
NleG3-1EPE22   LQAKISECTFTVDIEKLHCPGEVLQCPITLEQPEKGIFVKNSDGSDVCTLFDAAAFSRLTGEGLPHPLTREPITASIIVKHEECIYDDTRGNFVIKGN--- 98-195 
NleG3-2EPE22   LQAKISECTFTVDIEKLHCPGEVLQCPITLEQPEKGIFVKNSDGSDVCTLFDAAAFSRLTGEGLPHPLTREPITSSMIVSQEQCIYDQTKGNFVIK----- 98-193 
NleG4EPE22   ICYKILSSSFPVHSEEVFFPKEHLKCPIILDAPDNGVFIKNSVSAKVCNLYDKNAMLKLVISGSPHPLSREPITESMIMRKDECYFDPKTESFVVNDV--- 99-196 
NleG5SAKAI   LLDKIEVCAFNVEHAQLQVPESLRTCPVTLCEPEDGVFMRNSMNSNVCMLYDKMALIHLVKTRAAHPLSRESIAVSMIVGRDNCAFDPDRGNFVLKN---- 117-213 
NleG6-1SAKAI   LMEKINSCLFRPDSNHFSCPESFLTCPITLDTPETGVFMRNSRGAEICSLYDKDALVQLVETGGAHPLSREPITESMIMRKDECHFDTKREAFCCK----- 114-209 
NleG6EPE22   LMEKINSCVFRPDSNHFSCPESFLTCPITLDTPENGVFMRNSRGAEICSLYDKDALVQLVETGGAHPLSREPITESMIMRKDECHFDSKKEAFVASDA--- 114-211 
NleG7SAKAI   LKNKIHSHSFVVNPDEFSCDTQFLKCPITLCVPEKGVFVKNALNSNICTLYDKSAFMNLTREHLPHPLSREKIVKEMIIERNMCYFDTISQHFIIMDA--- 111-216 
NleG7AEPEC   LMNAIHSHSFNVNTDEFSCDKQFLECPITLCIPKQGIFVKNTLNSNICTLYDKSAFMNLTREHLPHPLSREKIVKEMIIERNMCYFDTISQHFIIMDA--- 111-216 
NleG7CROD   LKSKIHSHAFIVNPDEFTCSKQYLECPITFCIPENGVFVKNSMDSKVCSLYDKSAIMQLIRKHHPHPLSREKIAKEMIIDKNNCYFDIMNQHFRILDTD-- 111-209 
NleG8-1SAKAI   IQNKINSHAFTVSHQDFSCHEQHLNCPITLCIPETGVFVRNAKNSEICSLYDHNALTELIRRNAPHPLSREPFVPEMIVSKDECHFNLIEQYFCILAT--- 111-215 
NleG8-2SAKAI   LLDRINSNAFPVSLQDFSCTEEHLNCPITLHIPETGVFVRNARNSEICALYDQEALTELILRNALHPLSRDPFAPEMIISKDKCHFNITKQCFYALPI--- 111-216 
NleG8CROD   VQSRVNSYAFSVNPGDFPCSVLHLSCPITLCVPETGVFVKNARCSKVCSLYDISALTEMLRRNASHPLSREAFTPGMIVHKEECNFNTTEQHFCILPR--- 111-213 
NleG8EPE22   VQTRINSHAFTVNPGDFPCCEQHLSCPITLCIPKTGVFVKNALHSKVCSLYDKDALSEAIRHNVFHPLSREAFSPEMIVGREECYFDLTDQRFCIISG--- 110-212 
NleG8 EPEC2   VQTRINSHAFTVNPGDFPCCEQHLSCPITLCIPKTGVFVKNALHSKVCSLYDKDALSEAIRHNVFHPLSREAFSPEMIVGREECYFDLTDQRFCIISG--- 110-212 
NleG10-1 SBONG   ISWKIDLCNFQVESGSFACSEEYLTCPITMAIPTNGIFVKASSRSDVCHLFDKEAFFNVLSLELRHPLSQEPIRSDMIVRKSECYFNTERDCFTLR----- 97-192 
NleG10-2 SBONG   ISWKIDLCNFQVESGSFACSEEYLTCPITMAIPTNGIFVKASSRSDVCHLFDKEAFFNVLSLELRHPLSQEPIRSDMIVRKSECYFNTERDCFTLR----- 97-192 
NleG11 SBONG   LVDKVDLCSFRPCVDELSCSEDNLMCPVMLAVPEKGVFVKTSSQSDICQLFDEAALIQLIIDGAVHPVSRAPLSADMIISKDECCFDSTKGSFIIP----- 126-221 
NleG12 SBONG   VLGKIDACLFATEPTGFQIPGVHLTCPITLNIPERGVFARTSLQSDVRCLYDSTALKELVSRRLPHPISREAITAAHIVPKEQCHFDPEKGAFIHSASQ-- 20-118 
Consensus100%  .........................C......P..................D.............HP................C..... ........... 
 
Figure 5.3: Alignment of NleG homologues. Conserved amino acid residues targeted for mutagenesis are highlighted in yellow. Figure 
adapted and used with permission from Tobe et al (2006) [2]. Homologues of Citrobacter rodentium NleG were identified using TBLASTN. 
Species/strain names are shown: CIROD (C. rodentium), EPE22 (EPEC E22), SAKAI (EHEC O157:H7 Sakai), EPE69 (EPEC 69), EPEC2 
(EPEC B171), AEPEC (atypical EPEC E110019), SBONG (S. bongori).
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5.2. Methods 
 
5.2.1. DNA Cloning 
PCR 
NleG8-2 was amplified by PCR to contain no stop codon so that expression of a V5 and 
6xHis (C-terminal) fusion was possible. Reaction mix and cycle used are shown in chapter 
2. Primers used are shown in table 5.1. 
PCR for truncated versions of ECs3486 NleG8-2 
The reaction mix consisted of: 1 µl genomic DNA template (EHEC O157:H7 Sakai), 0.5 µl 
ExTaq DNA polymerase (Takara), 4 µl dNTP mix, 5 µl 5x ExTaq buffer (Takara), 10 µl 
forward primer (2 µM), 10 µl reverse primer (2 µM) and 19.5 µl dH2O. 
The reaction cycle was as follows: 
95 °C 2 minutes 
95 °C 30 seconds 
Annealing temperature (50 – 60 °C) 30 seconds 
72 °C 2 minutes 
72 °C 5 minutes 
4 °C until use 
  
Cycle x 30 
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5.2.2. Site directed mutagenesis 
Primer design 
Mutagenic primers were designed using the primer design guidelines issued by Stratagene 
or by using the Quikchange Primer Design Program available at www.stratagene.com. 
Mutagenic primers used in this study are shown in table 5.1.    
Mutant strand synthesis 
Template plasmid DNA was obtained from a dam
+
 E. coli strain to ensure selection for 
mutated plasmids following treatment with Dpn I. 
EspM2 mutagenesis 
The reaction mixture consisted of 5 µl of 10x reaction buffer, 5-50 ng dsDNA template 
(pENTR-SD-3485ns), 125 ng each mutagenic primer, 1 µl dNTP mix, 1 µl PfuUltra DNA 
polymerase (2.5 U/µl) and 50 µl dH2O. The following reaction cycle was used: 
95°C 30 seconds 
95°C 30 seconds 
55°C 1 minute 
68°C 3 minutes 
4°C until use 
Cycle x 18 
140 
 
NleG8-2 mutagenesis (performed by R. Younis) 
The reaction mixture consisted of 3 µl 25 mM MgSO4, 5 µl 2 mM dNTP, 125 ng each 
mutagenic primer, 5 – 50 ng dsDNA template (pENTR-SD-3486ns), 1 µl (1 U/µl) KOD hot 
start polymerase (Merck, USA), 5 µl 10x KOD reaction buffer, 31 µl H2O and 1 µl DMSO. 
Reaction cycle: 
94°C 2 minutes 
94°C 15 seconds 
60°C 30 seconds 
72°C 1 minute 
72°C 5 minutes 
Dpn I digestion 
10 U Dpn I restriction enzyme was added to each reaction mix after amplification. The 
mixture was mixed by pipetting and then incubated for 1 hour at 37°C to digest the 
nonmutated, parental DNA. Dpn I treated DNA was then transformed into chemocompetent 
E. coli (strain XL-1 Blue) as outlined in chapter 2. Mutagenesis was confirmed by DNA 
sequencing as described in chapter 2. 
  
Cycle x 18 
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Primer Sequence (5’-3’) Mutation 
introduced 
ECs3486.gwF CACCATGCCAGTCATATTAAAT N/A 
ECs3486revNS AATACTGTTTTGTTGAAGTGGG N/A 
Truncation primers   
ECs3486_50aaR ACCATCCATAAACTGGATATAATG N/A 
ECs3486_120aaR AAATGCATTCGAATTTATTCG N/A 
ECs3486_206aaR TAATGCGTAAAAACATTG N/A 
Mutagenic primers   
NleG8-2   
New_QC3486_C136A ACTTTTCCTGTACTGAGGAACATCTTAATGCTCCGATAACGCTACA NleG8-2 C136A 
New_QC3486_C136Ar TGTAGCGTTATCGGAGCATTAAGATGTTCCTCAGTACAGGAAAAGT NleG8-2 C136A 
D162A_f_new GAAATTCAGAAATATGTGCATTATATGCTCAGGAAGCATTGACTGA NleG8-2 D162A 
D162A_r_new TCAGTCAATGCTTCCTGAGCATATAATGCACATATTTCTGAATTTC NleG8-2 D162A 
H176A_f_new GCGTAACGCTCTCGCCCCCCTCAGCCGT NleG8-2 H176A 
H176A_r_new ACGGCTGAGGGGGGCGAGAGCGTTACGC NleG8-2 H176A 
C194A_f_new TTGCTCCAGAAATGATTATAAGCAAAGACAAGGCTCATTTTAATATAACA
-AAACAATGTTTTT 
NleG8-2 C194A 
C194A_f_new AAAAACATTGTTTTGTTATATTAAAATGAGCCTTGTCTTTGCTTATAATC
-ATTTCTGGAGCAA 
NleG8-2 C194A 
EspM2   
3485.5afW CAGAGTACTAAAGATATTGATGAGGCGATAAAAGA EspM2 W70A 
3485.5arW CGTTCATCTTTTATCGCCTCATCAATATCTTTAGTACTCTG EspM2 W70A 
3485.5bfE GAGTGGATAAAAGATGCACGGATAGTATATCCCTC EspM2 E74A 
3485.5brE GAGGGATATACTATGCCTGGATCTTTTATCCACTC EspM2 E74A 
Sequencing primer   
pDEST52f CCTCTATACTTTAACGTC N/A 
Table 5.1: Primers used in this study.  
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5.2.3. TOPO cloning 
Purified PCR product (NleG8-2) was cloned into pENTR-SD/D-TOPO (Invitrogen, UK) 
according to procedures outlined in chapter 2. Entry vectors produced earlier in the study 
(see chapter 3) were also used. Entry vectors used are listed in table 5.2. 
 
5.2.4. LR recombination 
In this study, fifteen effectors were expressed within yeast from the pYES-DEST52 
Gateway vector (Invitrogen, UK). Expression vectors used in this study are shown in table 
5.2. pYES DEST52 contains a URA3 auxotrophic marker for selection of yeast 
transformants and a GAL1 promoter for high-level, galactose-inducible protein expression in 
S. cerevisiae. This promoter is induced in the presence of galactose [399], repressed in the 
presence of glucose [398] and not affected by raffinose.  The carbon source added to the 
SC-Ura media therefore allows control over effector gene expression. The vector also has a 
2µ origin for high copy replication in yeast and a pUC origin for high copy replication in E. 
coli. The vector contains a V5 epitope and 6xHis tag; recombination between entry vector 
and pYES-DEST52 allows expression of an effector- V5/6xHis fusion protein that can be 
easily detected using anti-V5 [400] or anti-His [401] antibodies (see figure 5.4). 
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Figure 5.4: pYES DEST52.
Gateway destination vector for expression of V5/6x His fusion proteins in yeast. 
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5.2.5. Plasmid constructs 
 
Effector Sakai ID Entry vector Source Destination vector Source 
EspY4 ECs4653 pSB10.22B S. Beatson, 
this study 
pYES DEST52 4653 This study 
Map ECs4562 SME14a This study pYES DEST52 Map This study 
NleB1 ECs3857 pENTR-SD-3857 This study pYES DEST52 3857 This study 
NleG8-2 ECs3486 pENTR-SD-3486ns 
fp3 
This study pYES DEST52 3486 This study 
EspM2 ECs3485 pENTR-SD-3485ns R.Younis, 
this study 
pYES DEST52 3485 This study 
EspJ ECs2714 pENTR-SD-2714 This study pYES DEST52 2714 This study 
NleG2-3 ECs2156 pENTR-SD-2156 This study pYES DEST52 2156 This study 
NleG6-2 ECs2155 pSB3.31 S. Beatson, 
this study 
pYES DEST52 2155 This study 
EspM1 ECs1825 pENTR-SD-1825 This study pYES DEST52 1825 This study 
NleF ECs1815 pSB10.10B S. Beatson, 
this study 
pYES DEST52 1815 This study 
NleH ECs1814 SME46b This study pYES DEST52 1814 This study 
EspO1-1 ECs1567 pENTR-SD-1567 This study pYES DEST52 1567 This study 
EspX7 ECs1560 pENTR-SD-1560 This study pYES DEST52 1560 This study 
NleD ECs0850 pR1.27a This study pYES DEST52 0850 This study 
EspY1 ECs0061 pSB3.47a S. Beatson, 
this study 
pYES DEST52 0061 This study 
Control vector (Gateway cassette removed)      
N/A N/A N/A N/A pYES DEST52e This study 
 
 
 
Table 5.2: Entry and destination vectors used in this study. 
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Effector Entry vector Source Destination vector Source 
Mutated EspM2     
EspM2W70A pENTR-SD 3485 5a This study pDEST52 3485 5a This study 
EspM2E74A pENTR-SD 3485 5b This study pDEST52 3485 5bE This study 
Truncated NleG8-2     
NleG8-21-50 pENTR-SD-3486 50 This study pDEST52 3486 50 This study 
NleG8-21-120 pENTR-SD-3486 120 This study pDEST52 3486 120 This study 
NleG8-21-206 pENTR-SD-3486 206 This study pDEST52 3486 206 This study 
Mutated NleG8-2     
NleG8-2C136A pENTR-SD-C136A R. Younis, 
this study 
pDEST52 C136A2 This study 
NleG8-2D162A pENTR-SD-D162A R. Younis, 
this study 
pDEST52 D162A This study 
NleG8-2H176A pENTR-SD-H176A R. Younis, 
this study 
pDEST52 H176A2 This study 
NleG8-2C194A pENTR-SD-C194A R. Younis, 
this study 
pDEST52 C194A1 This study 
 
Table 5.3: Vectors containing mutated/truncated effector genes used in this study. 
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5.2.6. High-efficiency Transformation of Yeast 
 
Yeast strains used in this study are outlined in table 5.4  
 
Strain Genotype Source 
FY833 MATα his3Δ ura3Δleu2Δ lys2Δ trp1Δ GAL2  S. Dove, University of Birmingham 
BY4741 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 S. Dove, University of Birmingham 
 
Table 5.4: Yeast strains used in this study. 
 
 
Reporter yeast strains used in this study are outlined in table 5.5 
 
Strain 
BY4741 
RFP Localisation Source 
RFP-Sac6 Actin. Sac6p is an actin bundling protein 
homologous to fimbrin [426]. 
S. Dove, University 
of Birmingham 
RFP-Sec66 ER membrane. Sec66 is a component of the 
Sec63p complex required for translocation of 
presecretory proteins into the ER [427].  
S. Dove, University 
of Birmingham 
RFP-Kip3 Microtubule. Kip3p is a kinesin microtubule 
motor required for normal spindle assembly 
and microtubule-cortical interactions [428]. 
S. Dove, University 
of Birmingham 
RFP-Spc42 Spindle pole. Spc42 is a major component of 
the spindle pole body anchored within the 
nuclear membrane [429]. 
S. Dove, University 
of Birmingham 
Table 5.5: Yeast reporter strains used in this study. 
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Buffers for yeast transformation 
Polyethylene glycol (PEG; 50% w/v) was made by dissolving polyethylene glycol (MW 
3350; Sigma) in dH2O to make a 50% w/v solution. The solution was sterilised by filtration 
through a 0.22 µm filter (Millipore, UK). 
 
Single-stranded carrier DNA (2 mg/ml) consisted of 200 mg of high-molecular weight DNA 
(Sigma D1626) dissolved in 100 ml of TE buffer (pH 8.0). The solution was mixed 
vigorously with a magnetic stirrer at 4°C o/n. Aliquots were stored at -20°C until needed.  
Transformation of Yeast 
5 ml of YPD or SC media was inoculated with the desired strain and incubated with shaking 
(200rpm) overnight at 30°C. Cells were pelleted at 3000g for 5 minutes and the supernatant 
was removed. Cells were resuspended in 2.5 ml of sterile H2O and centrifuged again. H2O 
was removed and cells were resuspended in 1.0 ml of 100 mM lithium acetate (LiAc). Cells 
were pelleted at 13000g for 5 seconds and the LiAc was removed. Cells were resuspended 
in 400 µl of 100 mM LiAc (cell density was approximately 2 x 10
9
 cells/ml). 50µl samples 
of the cell suspension were added to sterile microfuge tubes. The cells were again pelleted 
by centrifugation at 13000rpm for 5 seconds and the LiAC was removed. The 
‘transformation mix’ was then added (in the order listed): 240 µl of PEG (50% w/v), 36 µl 
of 1.0 M LiAc, 25 µl of boiled and chilled single-stranded carrier DNA (2.0 mg/ml), 50 µl 
of sterile H2O and plasmid DNA (0.1-10 µg). The microfuge tube was then vortexed 
vigorously for approximately 1 minute until the cell pellet was completely mixed. Cells 
were incubated for 30 minutes at 30°C then heat shocked for 20-25 minutes at 42°C. Cells 
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were pelleted at 6000rpm using a microfuge and the transformation mix removed. Cell 
pellets were resuspended in 400 µl of sterile H2O. 200µl aliquots were plated onto selective 
SC agar plates.  
 
5.2.7. Yeast immunofluorescence 
Based on protocol described by Pringle et al [430]. 
Solutions for yeast immunofluorescence 
Phosphate buffer consisted of 40 mM KPO4 (pH 6.5) plus 500 µM MgCl2 in dH2O. Sorbitol-
phosphate buffer consisted of 40 mM KPO4 (pH 6.5) plus 500 µM MgCl2 plus 1.2 M 
sorbitol in dH2O. Blocking solution consisted of 0.5% (w/v) BSA in 1 x phosphate buffered 
saline (PBS) (pH 7.4). 
Zymolyase solution contained 10 mg zymolyase, a β-1,3-glucanase enzymatic preparation 
(AMS Biotechnology, UK), dissolved in sorbitol-containing phosphate buffer. The solution 
was mixed by vortexing frequently for 1 hour (incubated on ice between vortexing). The 
solution was then centrifuged at 13000 rpm for 10 minutes then frozen in liquid nitrogen 
and stored at -80°C. 
Polylysine solution. High molecular weight polylysine (>300,000 MW; Sigma) was 
dissolved as a 1% stock solution in dH2O and frozen in liquid nitrogen (stored at -80°C).   
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Slide preparation:  
All solutions were spun at 13000 rpm for 10 minutes immediately before use to reduce dust 
and other particle contamination of the slides. The wells of Teflon-faced slides 
(Polysciences) were coated with 20 µl of a 0.1% polylysine solution and slides were 
incubated in a moist chamber at room temperature for 10 minutes. The wells were then 
washed five times with 20 µl dH2O, dried and stored in a dust-free environment.  
  
2 ml SC-Ura + glucose was inoculated with desired strain and incubated with shaking (200 
rpm) overnight at 30°C. The overnight culture was then diluted 1:200 into fresh SC-Ura + 
glucose and grown at 30°C with shaking for 3 hours. Cells were then washed twice in dH2O 
and resuspended in 5 ml SC-Ura + galactose. Cells were incubated for 4 hours at 30°C with 
shaking. 3.4 ml of 10% formalin was added and the cells incubated for a further 10 minutes 
at 30°C with shaking. Cells were centrifuged at 2000 rpm for 3 minutes and resuspended in 
0.6 ml of phosphate buffer and 0.4 ml 10% formalin. Cells were incubated for 1 hour at 
30°C. Cells were washed twice in the phosphate buffer (no formalin) and then again (gently) 
in the sorbitol phosphate buffer. Cells were resuspended in 0.5 ml sorbitol buffer and stored 
overnight at 4°C. Cells were treated for 15 minutes with 30 µl of 10 mg/ml Zymolyase 
(100T) at 37°C. Cells were washed once in sorbitol buffer and resuspended (very gently 
using low vortex speeds) in 200µl sorbitol buffer. Cells were placed on ice. 20 µl of the cell 
suspension was spotted onto each well of the prepared Teflon-faced slides and incubated at 
room temperature for 10 minutes. Liquid was aspirated from the wells and the slide was 
immersed in cold methanol for 6 minutes and then cold acetone for 30 seconds. Excess 
acetone was immediately removed from the slide and the slide allowed to dry quickly on a 
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warm surface. Cells were blocked by adding 20 µl blocking solution to each well. Slides 
were incubated in a moist chamber at room temperature for 1 hour. Blocking solution was 
then removed and 20 µl blocking solution containing FITC-conjugated anti-V5 antibody 
(Invitrogen) 1:200 was added to each well. Slides were incubated for 1 hour in a moist 
chamber at room temperature. The cells were then washed 4 times for 10 minutes with 20 
µl/well of fresh blocking solution. Excess blocking solution was removed from the wells 
and 5 µl citifluor AF1 (Citifluor, UK) an anti-bleaching mounting solution was added. A 
square coverslip was then placed over 4 wells (no bubbles). Excess citifluor was removed 
and the coverslip sealed in place with nail polish. The slides were allowed to dry and were 
then either viewed immediately or stored at -20°C until use.    
Fluorescence microscopy 
Fixed and stained cells were viewed using a Nikon E600 microscope (with a Nikon 100x 
objective) fitted with an XF100-3 filter cube (Omega Optical, US). Images were captured 
with an ORCA digital camera (Hamamatsu, US). Images were processed using Simple PCI 
(Hamamatsu) software.   
 
5.2.8. Calcofluor staining 
Calcoflour (Sigma) was added to yeast cells growing in SC-Ura+glucose or SC-
Ura+galactose (OD600 = 0.5) to a final concentration of 100 µg/ml. Cells were incubated for 
5-10 minutes at 30°C, washed twice with dH2O and observed with a DAPI-compatible filter 
set. 
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5.2.9. Yeast protein extraction 
5ml SC-Ura+raffinose (2%) was inoculated with 10μl stationary phase FY833 (transformed 
with pDEST52-effector construct that had been grown in SC-Ura+glucose) and incubated 
overnight at 30°C 200rpm. 2.5ml of overnight culture (OD600 =1) was induced with 2% 
galactose for 2 hours 30°C 200rpm. 2.5 OD600 units of induced and non-induced cells were 
harvested by centrifugation 13000rpm 15 min. Supernatant was removed and pellets frozen 
at -80°C overnight.  Pellets were resuspended in 100μl dH2O. NaOH was added to a final 
concentration of 0.1M and the suspension vortexed to mix. The suspension was then 
incubated at room temperature for 5 min before being centrifuged at 13000rpm for 1 min.  
The supernatant was removed and the pellet resuspended in 50μl 2x SDS loading buffer. 
The proteins were boiled for 3 min and briefly centrifuged to remove cell wall debris. 6μl 
was then loaded onto a 12% SDS-PAGE gel for separation and analysis.   
 
5.2.10. Western blotting 
Protein was extracted from induced and non-induced yeast cells as described above. The 
proteins were separated by SDS-PAGE and electrophoretically transferred onto Hybond-P 
membranes as described in chapter 2. Membranes were probed with horse radish peroxidase 
(HRP) conjugated anti-V5 antibodies (at a dilution of 1:200) to detect effector-V5 fusions as 
described in chapter 2. 
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5.2.11. Growth retardation assay 
Single colonies of transformed FY833 (carrying desired effectors in pYES DEST52) were 
used to inoculate 2ml SC-Ura+raffinose (2%) broth. These were then incubated at 30°C 
200rpm overnight. The optical density OD600 of each culture was measured and normalised 
to OD600=1. A 10-fold dilution series was prepared from the normalised cultures and 10μl of 
each dilution applied to both SC-Ura+glucose agar (non-inducing) and SC-Ura+galactose 
agar (inducing). Both plates were incubated at 30°C for 48 hours. Growth of yeast on 
inducing and non-inducing plates was then compared. To acquire images of plates, plates 
were placed onto a scanner and a piece of black card was placed on top to provide a dark 
background. Plates were then scanned and images were processed using Microsoft 
Powerpoint software. 
 
   
 
  
153 
 
5.3. Results 
 
5.3.1. Confirmation of expression of effectors in yeast 
 
  
Figure 5.5: Western blot of yeast cell lysates from cells expressing (A) NleH1-2, 
(B) NleB1, (C) EspJ, (D) NleF, (E) EspY1. Proteins were visualised using HRP-
conjugated anti-V5 antibody (Invitrogen). M = prestained protein marker (Sigma). 
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Figure 5.6: Western blot of yeast cell lysates from cells expressing (A) EspX7, (B) 
EspO1-1, (C) NleG6-2, (D) NleG2-3, (E) EspY4, (F) NleD. Proteins were visualised 
using HRP-conjugated anti-V5 antibody (Invitrogen). M = prestained protein marker 
(Sigma). 
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5.3.2. Yeast growth inhibition 
 
Yeast strain FY833 was successfully transformed with Gateway destination vectors (pYES 
DEST52) carrying novel effector genes. Sixteen transformants were obtained. Expression of 
effector-V5 fusion proteins was controlled by the carbon source used in the growth media 
(galactose induced expression, glucose repressed expression). Growth of 10-fold serial 
dilutions of yeast culture on inducing and non-inducing media was compared. No growth 
inhibition was seen for yeast grown on non-inducing media i.e. yeast grew to comparable 
levels as yeast carrying empty vector pYES DEST52e. An exception to this was yeast 
carrying EspM2 which showed slight growth inhibition on non-inducing plates (figure 5.8). 
In contrast, severe growth inhibition was seen for yeast carrying EspM2 (ECs3485), NleG8-
2 (ECs3486) and NleG2-3 (ECs2156) grown on inducing SC-Ura+galactose media. This 
shows that expression of these effectors is toxic to yeast.  
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Figure 5.7: Yeast growth assay. 10-fold serial dilutions of saturated yeast culture (10 µl) were 
plated onto non-inducing (glucose) and inducing (galactose) SC-Ura media. Plates were 
incubated at 30°C for 48 hours. Yeast carrying pYES DEST52e vector were used as a negative 
control. Effectors carried by the yeast are indicated. Expression of NleG2-3 caused growth 
retardation on inducing media.  
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Figure 5.8: Yeast growth assay. 10-fold serial dilutions of saturated yeast culture (10 µl) 
were plated onto non-inducing (glucose) and inducing (galactose) SC-Ura media. Plates 
were incubated at 30°C for 48 hours. Yeast carrying pYES DEST52e vector were used as 
a negative control. Effectors carried by the yeast are indicated. Expression of EspM2 and 
NleG8-2 caused growth retardation on inducing media. 
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SC-Ura + Galactose 
(effector expressed) 
157 
 
5.3.3. Amino acid substitution of the EspM2 WxxxE motif decreases the 
toxicity of EspM2 
Yeast carrying EspM2 showed growth inhibition on both non-inducing and inducing media 
(figure 5.8), although growth inhibition was most severe on inducing media (no detectable 
growth). In contrast, yeast carrying mutated EspM2, in which the conserved tryptophan (W) 
and glutamic acid (E) residues of the WxxxE motif were substituted with alanine, did not 
show growth inhibition on non-inducing media (similar growth as the control). Yeast 
carrying EspM2W70A and EspM2E74A did show growth inhibition when grown on inducing 
media but inhibition was not as severe as that caused by expression of EspM2wt – growth 
inhibition was only visible at higher dilutions of plated culture (figure 5.9). Expression of 
mutated EspM2 was therefore not as toxic to yeast as expression of EspM2wt.  
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Figure 5.9: Mutant EspM2 yeast growth assay. 10-fold serial dilutions of saturated 
yeast culture (10 µl) were plated onto non-inducing (glucose) and inducing (galactose) 
SC-Ura media. Plates were incubated at 30°C for 48 hours. Yeast carrying pYES 
DEST52e vector were used as a negative control. EspM2wt causes growth retardation on 
both non-inducing and inducing plates. EspM2W70A and EspM2E74A cause less severe 
growth retardation than EspM2wt on both types of plate.  
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5.3.4. Truncation of NleG8-2 
Expression of NleG8-2 was found to inhibit yeast growth (figure 5.8). In an attempt to 
determine sequence-activity relations for NleG8-2, truncated versions of NleG8-2 were 
tested using the yeast growth inhibition assay. Truncation of NleG8-2 to lengths of 1-50, 1-
120 amino acids appeared to decrease toxicity of the effector in the yeast growth assay i.e. 
yeast carrying NleG8-21-50 and NleG8-21-120 showed similar levels of growth as the control 
when grown on inducing media. Expression of NleG8-21-206 caused growth inhibition 
similar to that caused by expression of wild type NleG8-2 (figure 5.10).   
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Figure 5.10: Truncated NleG8-2 yeast growth assay. 10-fold serial dilutions of 
saturated yeast culture (10 µl) were plated onto non-inducing (glucose) and inducing 
(galactose) SC-Ura media. Plates were incubated at 30°C for 48 hours. Yeast carrying 
pYES DEST52e vector were used as a negative control. Expression of NleG8-2wt and 
NleG8-2206 caused growth retardation. 
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5.3.5. Mutant NleG8-2 growth assay 
Further investigations into sequence-activity relations of NleG8-2 included yeast growth 
inhibition assays of yeast expressing mutated NleG8-2. Yeast carrying NleG8-2wt, NleG8-
2C136A, NleG8-2D162A, NleG8-2H176A and NleG8-2C194A showed no growth inhibition on non-
inducing plates (all showed similar growth to control). Growth inhibition was observed in 
yeast expressing NleG8-2wt and NleG8-2C194A on inducing plates – expression of NleG8-
2C194A caused similar growth inhibition as expression of NleG8-2wt. No growth inhibition 
was observed in yeast expressing NleG8-2C136A, NleG8-2D162A or NleG8-2H176A. Substitution 
of Cys136, Asp162 and His176 to alanine therefore decreased toxicity of NleG8-2 (figure 
5.11). Western blotting confirmed that equal amounts of protein were expressed by all 
clones (figure 5.12). Therefore, differences in growth were not caused by differences in 
levels of protein expression.   
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Figure 5.11: Mutant NleG8-2 yeast growth assay. 10-fold serial dilutions of saturated 
yeast culture (10 µl) were plated onto non-inducing (glucose) and inducing (galactose) SC-
Ura media. Plates were incubated at 30°C for 48 hours. Yeast carrying pYES DEST52e 
vector were used as a negative control. Expression of NleG8-2wt and NleG8-2C194A caused 
growth retardation. 
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Figure 5.12: Western blot of NleG8-2. Proteins from yeast cell lysates of cells 
grown in SC-Ura+galactose media were separated by SDS-PAGE and analysed 
for NleG8-2 by western blot using HRP-conjugated anti-V5 antibody 
(Invitrogen). FY833 yeast strain expressing: (A) NleG8-2C136A, (B) NleG8-
2D162A, (C) NleG8-2H176A, (D) NleG8-2C194A, (E) NleG8-2wt. Yeast BY4741 
reporter strains (F) Sac6, (G) Kip3, (H) Sec66 expressing NleG8-2wt. Ppm – 
broad range prestained protein marker (Sigma), marker protein sizes are 
indicated (kDa). 
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5.3.6. Localisation of effectors in yeast 
Yeast cells expressing V5-tagged effectors were fixed and stained with FITC conjugated 
anti-V5 antibody (Invitrogen). Images are shown in figure 5.13. Map-V5 was detected 
around the cell periphery in crescent-like structures whereas NleG8-2 was detected as 
punctate structures at the cell periphery. EspM2 appeared to localise to both the cell 
periphery (70% of cells) and throughout the cytoplasm (30% of cells). Tir showed strong 
staining of the yeast cell cytoplasm.  
 
In an attempt to identify the subcellular localisation of NleG8-2, the effector was expressed 
in four separate yeast reporter strains. In these strains, RFP-tagged proteins; Kip3 (localises 
to microtubules), Spc42 (localises to the spindle pole body), Sec66 (localises to the ER 
membrane) and Sac6 (localises to actin) were used to identify cellular components. NleG8-2 
did not co-localise with any of the RFP-tagged proteins and did not alter the localisation of 
these proteins (figures 5.14 and 5.15). 
 
Mutation of conserved residues C136, D162, H176 and C194 did not appear to affect 
NleG8-2 localisation within yeast cells – the effector localised to punctate areas of the cell 
periphery (figure 5.16).  
  
165 
 
Figure 5.13: Localisation of effectors in yeast. Effector-V5 
fusions were visualised in fixed yeast cells using FITC-conjugated 
anti-V5 antibody and fluorescence microscopy. 
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Figure 5.14: Localisation of NleG8-2 in yeast reporter strains. FITC-conjugated anti-V5 antibody was used to stain fixed yeast cells to 
show localisation of NleG8-2-V5 fusions (V5 FITC). RFP shows fluorescence of RFP-tagged protein constitutively expressed by reporter 
strain i.e. Sac6 (actin), Kip3 (microtubules). Merged image shows both FITC and RFP fluorescence. DIC image of stained cell is also 
shown. Localisation of RFP-tagged proteins expressed by yeast reporter strains in cells carrying control vector pYES DEST52e is also 
shown. 
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Figure 5.15: Localisation of NleG8-2 in yeast reporter strains. FITC-conjugated anti-V5 antibody was used to stain fixed yeast cells to 
show localisation of NleG8-2-V5 fusions (V5 FITC). RFP shows fluorescence of RFP-tagged protein constitutively expressed by reporter 
strain i.e. Sec66 (ER), Spc42 (spindle pole body). Merge shows both FITC and RFP fluorescence. DIC image of stained cell. Localisation 
of RFP-tagged proteins expressed by yeast reporter strains in cells carrying control vector pYES DEST52e is also shown. 
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Figure 5.16: Localisation of NleG8-2 and mutated NleG8-2 in yeast cells. 
Effector-V5 fusions were detected in fixed yeast cells using FITC conjugated anti-V5 
antibody (Invitrogen). 
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5.3.7. Yeast cell morphology and chitin localisation 
Live yeast cells expressing selected effectors or carrying pYES DEST52e control vector 
were viewed using DIC microscopy. Cells expressing Map and NleG8-2 showed normal 
morphology and budding patterns whereas approximately 25% of cells expressing NleG2-3 
were elongated and had unconstricted bud necks (figure 5.18). Cells expressing EspM2 also 
showed morphological changes including elongated cells and unusual bud necks (figures 
5.17) although the changes were less severe than those changes caused by NleG2-3. 
 
The chitin-specific fluorophore calcofluor white was used to stain chitin in the cell walls of 
live yeast cells. Chitin was localised to bud scars only in cells carrying pYES DEST52e 
control vector and cells expressing Map, NleG8-2 and EspM2. However, in cells expressing 
NleG2-3 abnormal cell morphology and budding patterns were accompanied by unusual 
chitin localisation (figure 5.18). Chitin was more diffusely localised within the yeast cell 
wall around the unconstricted bud necks.   
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Figure 5.17: Yeast cell morphology and chitin localisation of cells 
expressing EHEC O157:H7 T3SS effectors. Cells were grown in 
SC-Ura+galactose for 4 hours to induce expression of effectors. Cells 
were viewed using DIC microscopy, chitin was visualised using a 
DAPI filter. Vector only (A, B); Map (C, D); NleG8-2 (E, F); EspM2 
(G, H). Scale bar represents 5 µm. 
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Figure 5.18: Morphology and chitin localisation of 
yeast cells expressing NleG2-3. Cells were grown in SC-
Ura+galactose for 4 hours to induce expression of NleG2-3. 
Cells were viewed using DIC microscopy, chitin was visualised 
using a DAPI filter. Abnormalities in morphology/chitin 
localisation are indicated. Images A and B show cells 
containing vector only. Scale bar represents 5 µm. 
A B 
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5.4. Discussion 
 
5.4.1. EspM2, NleG8-2 and NleG2-3 cause yeast growth inhibition 
Yeast strain FY833 was transformed with pYES DEST52 containing selected EHEC 
O157:H7 T3SS effectors. The effect of effector expression on yeast growth was then tested 
by comparing growth of yeast on inducing and non-inducing media. As a control, yeast 
carrying (non-recombined) pYES DEST52e were used to show that growth inhibition was 
due to effector expression (yeast carrying this vector grew similarly on inducing and non-
inducing media). All effector proteins were expressed at similar levels by yeast grown in 
inducing media.  
 
Yeast expressing EspM2, NleG8-2 and NleG2-3 showed growth retardation suggesting that 
these effectors are toxic. It was difficult to obtain yeast transformants for EspM2 and 
colonies of transformants obtained were small. This problem was probably due to the 
toxicity of the effector – Alto et al could not recover yeast transformants for the EspM2 
homologue, IpgB2 [159]. Interestingly, expression of EspM2 in yeast was so toxic that 
growth inhibition was seen in cells grown on glucose media whereby expression of the 
effector is repressed. This effect may be caused by leaky expression of effector from the 
GAL1 promoter as was found by Slagowski et al (2008) [378] and Stirling et al (2006) 
[411]. Future studies of EspM2 expression in yeast may benefit from using an alternative, 
tightly controlled promoter such as tetO [417] [431].  
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Relatively few effectors were seen to affect yeast growth. It is possible that a number of 
effectors target cellular processes that are not normally rate-limiting for growth. In order to 
identify these effectors, the growth assay could be improved by the use of ‘stressors’ such as 
caffeine in the growth media. Such ‘stressors’ are added to the media at doses that do not 
affect the normal growth of yeast but do increase sensitivity to effectors [414] e.g. Shigella 
effector OspB only affects yeast growth when caffeine is added to the growth media [378]. 
Conditional sensitivity in the presence of stressors (known to affect certain cell processes) 
may give clues as to effector function [336]. For example, greater sensitivity to an effector 
in the presence of nocodazole (a drug that inhibits microtubule polymerisation [432]) may 
suggest that the effector targets the microtubule network [433].  
 
Usually, protein tags and fusion to GFP does not interfere with effector function [378]. 
Surprisingly however, Map-V5 did not affect yeast growth, chitin localisation or cell 
morphology when tested in this study. This was unexpected as expression of Map has been 
shown by Rodriguez Escudero et al and Alto et al to cause the accumulation of large 
unbudded cells and growth retardation [405] [159]. However, in these studies Map was 
expressed with an N-terminal tag (GST or GFP). Interestingly, in accordance with results of 
this study, Rodriguez Escudero et al found that expression of C-terminally tagged Map 
(Map-GFP) did not cause severe growth inhibition even though the effector was still 
targeted to mitochondria [405]. These results suggest that addition of a C-terminal tag 
masks the effect of a toxic domain present at the C-terminus of Map – the toxicity of Map 
has subsequently been shown to depend on the last three amino acids of the protein, a TRL 
motif [159] [388]. In contrast to findings that tags/reporter proteins may decrease effector 
toxicity, Slagowski et al found that a small number of effectors were more toxic when 
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expressed as GFP fusions e.g. IpgB1 only caused growth inhibition when expressed as a 
GFP fusion [378]. The effect of expressing the effectors with a C-terminal V5/His tag must 
therefore be considered – the toxicity of novel effectors may have been masked/augmented 
by the C-terminal V5/His tag. To confirm the toxicity of novel effectors in yeast, each 
should be screened again using alternative tags/reporter proteins (e.g. myc, GFP). Effectors 
should also be tested using N-terminal tags. Currently pYES DEST52 is the only Gateway 
compatible yeast expression vector available, conversion of other yeast expression vectors 
to Gateway would be highly useful. 
  
5.4.2. Localisation of effectors 
Localisation of T3SS effectors within yeast can provide valuable insights into effector 
function. For example, the Salmonella effector SipA colocalised with actin when expressed 
in yeast [157]. SipA was subsequently shown to bundle actin filaments in the host cell 
which promotes formation of membrane ruffles and uptake of Salmonella [434]. In a study 
by Rodriguez-Escudero et al, Map-GFP localised to yeast mitochondria. Here, Map-V5 
showed a similar localisation pattern to Map-GFP. However, mitochondrial markers (e.g. 
DAPI, Mitotracker) should be used to confirm that Map-V5 is also targeted to mitochondria. 
NleG8-2 was localised to punctate regions near the cell periphery and did not appear to co-
localise with or disrupt the localisation of any of the RFP-tagged cellular proteins produced 
by any reporter strain. Other reporter strains/cell dyes specific for the Golgi, secretory 
vesicles and vacuole should be used to see if NleG8-2 is targeted to these cellular 
compartments. In a study by Li et al EPEC NleG localised to both the cytoplasmic and 
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membrane fraction of transfected HeLa cells and was not involved in the formation of the 
pedestal [435].  
 
Unfortunately, the low level of fluorescence of RFP and rapid photobleaching of RFP when 
exposed to UV light meant that images obtained were of a poor quality and somewhat 
difficult to interpret. Confocal microscopy could have improved this and would have 
allowed visualisation of greater detail of subcellular structures and localisation of effectors. 
Localisation studies could also be improved through the use of antibody markers and dyes 
for specific compartments e.g. Mitotracker (Invitrogen) for mitochondria. Also, the use of a 
fluorescent reporter protein e.g. GFP would improve upon indirect immunofluorescence as 
effectors could be visualised within live cells. Procedures involved in preparing cells for 
staining for immunofluorescence (i.e. digestion of the cell wall with Zymolyase) were 
difficult and may have introduced artifacts. For example, over digestion made cells too 
fragile whereas under-digestion did not allow sufficient antibody into the cell. Digestion of 
the cell wall may also have resulted in cell distortion.  
 
The results of this study and other studies into the localisation of T3SS effectors in 
mammalian and yeast cells suggests that factors other than effector sequence/structure are 
involved in determining the localisation of effectors within the host cell. These factors may 
include the context of effector delivery, the presence of other effectors and host responses to 
the effector [364]. 
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5.4.3. Morphology and chitin localisation 
Interestingly, NleG2-3 caused abnormal growth of yeast cells. The elongation of cells and 
disruption of budding may indicate that this effector perturbs the MAPK signaling pathway 
controlling filamentous growth [436]. The use of DAPI staining would have been useful to 
visualise nuclei within the cells to determine whether there was a loss of co-ordination 
between morphogenetic and nuclear events in the cell. 
 
Patterns of chitin localisation in cells expressing NleG2-3 are unusual and it appears that the 
cells have been unable to form a tight ring of chitin at the bud neck. This may indicate that 
localisation of septin (essential for promoting cell wall synthesis at the bud neck through the 
recruitment of chitin synthases [423]) has been disrupted. In a study by Rodriguez-Escudero 
et al, a similar phenotype was observed in cells expressing EspF – expression of septin-GFP 
fusion proteins confirmed that septin was mislocalised in cells expressing EspF. Use of a 
reporter stain in which a septin-RFP protein is expressed may help to elucidate the 
mechanism by which NleG2-3 causes aberrant chitin localisation and cell morphology.  
 
To investigate whether NleG2-3 affects MAPK signal cascades involved in morphogenesis 
and cell integrity, specific antibodies could be used to detect phosphorylation (activation) of 
components of the signal cascade. This was attempted using antibodies against the 
phosphorylated domain of p42/44 MAPK but neither phosphorylated or unphosphorylated 
proteins could be detected.   
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5.4.4. Mutant EspM2 
EspM effectors contain a conserved WxxxE motif [159]. In order to determine whether 
these residues were required for EspM2 function, Trp70 and Glu74 were mutated to alanine 
by site directed mutagenesis. Interestingly, yeast grown on media containing galactose 
(expression of effector induced) showed reduced growth comparable with that caused by 
expression of wild type EspM2. However, yeast grown on glucose media (expression of 
effector is repressed) grew better than yeast carrying wild type NleG8-2. These results 
suggest that the toxicity of EspM2 was reduced but not abolished when W70 and E74 were 
mutated to alanine. This contrasts with results of Alto et al who showed that IpgB2 yeast 
toxicity was abolished when the WxxxE motif was mutated to alanine [159]. Further 
characterisation of EspM2 by Arbeloa et al has shown that the WxxxE motif is required for 
the function of EspM2 and other effectors (e.g. EspT) belonging to the IpgB family [388]. 
Results of this study suggest that the WxxxE motif is required for inhibition of yeast growth 
and may be important in the function of EspM2 but that other sequences/functions may 
mediate the severe growth retardation caused by EspM2.  
 
5.4.5. Mutant NleG8-2 
Results of growth assays of yeast expressing truncated versions of NleG8-2 suggested that 
the C-terminus, specifically amino acids 120-216 were important for effector function. It 
was found that within this region lay four residues; Cys136, Asp162, His176 and Cys194 
that were conserved in all NleG family members. Residues C136, D162, H176 and C194 
were mutated to alanine by site directed mutagenesis. Expression of NleG8-2C136A, NleG8-
2D162A, NleG8-2H176A abolished inhibition of yeast growth associated with expression of 
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wild type NleG8-2. Expression of NleG8-2C194A caused similar levels of yeast growth 
inhibition as expression of wild type NleG8-2. It is therefore likely that residues Cys136, 
Asp162 and His176 are important for the function of NleG8-2. Mutation of these residues of 
NleG8-2 did not appear to affect the localisation of NleG8-2–V5 within the yeast cell. These 
residues are therefore unlikely to form part of a targeting motif or be involved in effector 
targeting within the host cell. 
 
Interestingly, cysteine, aspartic acid and histidine are amino acids often found in the 
catalytic triad of cysteine proteases [425]. A number of T3SS effectors from animal and 
plant pathogens have been shown to act as cysteine proteases including Yersinia and 
Pseudomonas effectors YopT and HopPtoN [371] [437]. YopT cleaves Rho GTPases 
(releasing them from the host cell membrane) to cause actin cytoskeletal disruption [371]. 
The proteolytic activity of these effectors is dependent on invariant C/H/D residues found in 
all YopT family members. It is possible that NleG8-2 functions as a cysteine protease with 
Cys136, Asp162, and His176 forming the catalytic triad. In order to confirm this, proteolytic 
activity of NleG8-2 must be demonstrated. Purification of an NleG8-2–His fusion protein 
was attempted but was unsuccessful; therefore the effector could not be assayed for protease 
activity in vitro in this study. We have shown that NleG8-2 has a toxic phenotype when 
expressed in yeast. Members of the NleG family of effectors have not been well 
characterised or focused upon, unlike EspM2 and other IpgB-like effectors that have been 
characterised by Arbeloa et al [388] and Alto et al [159]. I therefore decided to concentrate 
on characterising and investigating NleG8-2 further using yeast genetic-based approaches – 
this work is presented in chapter 6.  
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CHAPTER SIX 
Analysis of NleG8-2 function using a 
microarray and a yeast gene high copy 
suppression screen 
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6.1. Introduction 
 
In addition to using yeast physiology to study candidate EHEC O157:H7 T3SS effectors, I 
decided to use yeast genetics to study effectors in more detail. This chapter describes the use 
of DNA microarrays and a high-copy suppression (HCS) screen to study NleG8-2.  
 
The yeast genome was sequenced in 1996; so far more than 75% of yeast CDSs have a 
known or predicted function [438]. A variety of databases allow easy access to this 
information [439]. There are many tools and resources available for genome-wide and small 
scale experiments using yeast as a model e.g. comprehensive yeast DNA [440, 441] and 
protein [442] microarrays. Other powerful resources include isogenic strain collections 
where each strain carries a CDS that is either: 
 deleted. 
 fused to other proteins [443] e.g. fusions to green fluorescent protein (GFP) allow 
for localisation studies [421].  
 fused to a tandem affinity tag (useful for co-immunoprecipitation and expression 
studies [444]).  
 fused to the GAL4-binding domain –  can be used in two-hybrid assays to 
investigate protein interactions [445]. 
 over-expressed (see below) [446] [447].   
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6.1.1. Over-expression and gene-deletion screening 
 
There are two tools in particular that have been used to study type-III secretion and T3SS 
effector function: isogenic strain collections in which each CDS is deleted and plasmid-
based libraries that allow over-expression of individual genes [159] [163] [336]. Such strain 
collections and libraries allow the identification of proteins that (when over-expressed or 
absent) confer resistance to effectors and restore yeast growth [446] [448]. The protein or 
pathway targeted by the effector can then be inferred (see below). 
 
Synthetic genetic array (SGA) is a gene-deletion based approach that gives insights into the 
functions and protein-protein interactions of proteins encoded by mutated yeast genes [449] 
[450]. SGAs have been adapted to pathogenic genetic arrays (PGAs) to screen for mutants 
that are resistant to the effects of T3SS effectors. In this approach, effector genes (under the 
control of an inducible promoter) are introduced into a set of yeast deletion strains – each 
strain is deleted for a non-essential CDS. Strains that are hypersensitive to the effects of the 
T3SS effector or alternatively those strains that are resistant to the effector (growth restored) 
can then be isolated. The mutated gene of each strain can be identified to give clues as to the 
target of the T3SS effector. For example, Alto et al successfully used a PGA in addition to 
DNA microarrays to investigate the Shigella effector IpgB2 (the expression of which was 
found to be toxic to wild type yeast) [159]. The IpgB2 gene was integrated into the genome 
of over 5000 viable gene-deletion mutant yeast strains. Results showed that only strains 
carrying deletions in genes encoding components of the cell wall integrity (CWI) 
Rho1p/MAPK pathway were able to grow [159]. Therefore, it was predicted that IpgB2 
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targets the CWI MAPK signalling pathway – IpgB2 was subsequently shown to act as a Rho 
mimic [159] [388]. 
 
Over-expression screening has also been used to investigate protein function and was first 
used by Kasahara et al (1994) to identify a yeast gene (HKR1) responsible for resistance to 
HM-1 killer toxin, a Hansenula mrakii toxin that inhibits glucan synthesis [451]. The main 
use of this type of screening has been screening for drug resistance to facilitate 
identification of drug targets [452]. The principle of this approach is straightforward: over-
expression of a gene results in increased protein product. If the over-expressed protein is the 
target of the drug, the yeast cell should be resistant to the drug. The gene being over-
expressed can then be isolated and identified. Over-expression screening can also be used to 
study deleterious T3SS effectors. Shao et al found that yeast Cdc42 (a Rho GTPase) was a 
multicopy suppressor for the Yersinia effector YopT [371]. YopT was subsequently found 
to disrupt Rho GTPase localisation [371].  
 
The study described here used a plasmid library-based approach (summarised in figure 6.1) 
to investigate the eukaryotic target of NleG8-2. Yeast strain FY833 carrying the NleG8-2 
expression vector (or empty vector as negative control) was transformed with a genomic 
DNA library constructed on a high copy number vector (pYE13). Both NleG8-2 and the 
genes carried by the library plasmid were expressed when the yeast was grown on media 
containing galactose. Yeast that were able to grow under these conditions i.e. resistant to the 
effects of NleG8-2, were then selected. The library plasmid DNA was isolated from the 
resistant transformant and the over-expressed gene/s identified. The principle of this 
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approach denotes that the proteins encoded by these genes are likely to be targets of the 
effector or involved in resistance to the effector. It was proposed that this approach, used in 
conjunction with a DNA microarray, would give valuable clues as to the target/function of 
NleG8-2 (as has been achieved for other effectors [159] [163]).  
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Figure 6.1: Summary of high copy suppression screen. Yeast transformed with pYES 
DEST NleG8-2 show growth retardation when grown on galactose media due to expression of 
NleG8-2. Yeast are then transformed with pYE13 genomic library. Both NleG8-2 and genes 
contained within the pYE13 insert are expressed when yeast is grown on galactose media. 
Yeast able to grow on galactose media (i.e. resistant to NleG8-2) are selected, the pYE13 
clone isolated and the genes contained within the pYE13 insert identified.  
185 
 
6.1.2. DNA Microarrays 
 
DNA microarrays have revolutionised genetic investigations as they are able to measure the 
expression of thousands of genes in parallel [453]. Microarrays are commonly used to 
identify genes that are differentially expressed in one set of cells relative to another e.g. 
wild-type versus mutant strains [454] [455], treated versus untreated cells [456] [457] or 
diseased versus healthy tissue [458] [459].  
 
Microarrays have been used to study T3SS [3] and EHEC O157:H7 [460]. Transcriptional 
analysis of eivF and etrA mutant strains of EHEC O157:H7 using whole genome 
microarrays (based on the EHEC O157:H7 genome) revealed that LEE genes were up-
regulated compared to the parent EHEC O157:H7 Sakai strain [3]. This showed that EivF 
and EtrA, proteins from a second T3SS locus, ETT2, influence transcription of the LEE [3]. 
Microarrays have also been used to investigate bacterial and host cell responses to bacterial 
attachment. Recent analysis of the transcriptomes of EHEC O157:H7 and epithelial cells 
(HT-29) showed that over 300 HT-29 genes (including immune regulatory genes such as IL-
8 and interferon-related genes) and over 900 EHEC O157:H7 genes (including an activator 
of the LEE1 promoter, tryptophanase [322]) were differentially regulated during bacterial 
attachment [461]. In another study, transcriptome analysis of attaching EHEC found 
upregulation of a gene encoding a protease that mediates inhibition of the IFN signal 
transduction cascade [462]. Identification of up-regulated genes such as these may provide 
novel targets for strategies aimed at interrupting the infection process [462].  
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Yeast genome microarrays have previously been used to investigate the function of T3SS 
effectors [159] [163]. The transcriptional profile of yeast expressing an effector may give 
insights into effector function i.e. genes may be up/down regulated in response to effectors 
which may in turn give clues as to the pathways targeted by the effector. Alto et al used 
yeast DNA microarrays to analyse the transcriptome of yeast cells expressing IpgB2 [159]. 
They found that IpgB2 affected the expression of 351 transcripts and that the overall 
transcriptional profile of yeast expressing IpgB2 correlated with that of a cell over-
expressing activated Rho1p. This showed that IpgB2 stimulates small G-protein signalling 
in a similar way to GTP-bound Rho1p [159]. In order to gain an insight into the function of 
NleG8-2, the transcriptome of yeast expressing NleG8-2 was compared to the transcriptome 
of yeast expressing an empty vector to identify those genes that were up/down-regulated in 
response to NleG8-2.    
 
6.1.3. Microarray methodology 
 
This study used GeneChip Yeast Genome 2.0 arrays (Affymetrix, US). These microarrays 
are constructed by photolithography and contain 5744 probe (25-mer oligonucleotide) sets 
for 5841 of the 5845 genes present in the Saccharomyces cerevisiae genome. The 
microarray methodology used in this study is summarised in figure 6.2 and is as follows 
[463]:  
1. RNA is harvested from yeast cells expressing NleG8-2 (or empty vector, negative 
control).  
2. Reverse transcriptase is used to make cDNA from the RNA. 
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3. An in vitro transcription reaction is then used to create cRNA from the cDNA.  
4. cRNA is biotinylated and fragmented.  
5. Fragmented biotinylated cRNA is then allowed to hybridise to probes on the 
microarray.  
6. Arrays are washed and stained with streptavidin-phycoethrythrin (SAPE).  
7. The signal is amplified by washing the array with biotinylated anti-streptavidin 
(goat) antibody and staining with SAPE.  
8. The microarray slide is scanned using fluorescence microscopy.  
 
The intensity of phycoerythrin fluorescence (caused by SAPE binding to biotinylated cRNA 
attached to individual probes) is used as a measure of transcription of the gene (represented 
by the probe) under the conditions/treatment of the cell. In order to determine whether 
changes in gene expression are significant, data are statistically analysed (e.g. using  
Student’s t-test) [464].        
 
RNA hybridisation to the microarrays was performed and results were analysed at the 
Consortium for the Functional Genomics of Microbial Eukaryotes (COGEME) at The 
University of Manchester, UK. 
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Figure 6.2: Affymetrix microarray methodology
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6.2 Materials and Methods 
 
6.2.1. Whole genome microarray 
Harvesting yeast cells for RNA extraction 
5 ml SC-Ura+glucose was inoculated with a single yeast colony (either FY833 pYES 
DEST52 or FY833 NleG8-2). Cells were incubated in a shaking (200rpm) water bath 
overnight at 30°C. 100 µl of stationary phase yeast culture was added to 200 ml fresh SC-
Ura+glucose and incubated overnight at 30°C (200rpm). The log phase culture was washed 
twice in sterile dH2O by centrifuging for 10 minutes at 12000rpm in a Beckman-Coulter 
centrifuge using a JA-20 rotor. Four sterile 50 ml Oak ridge centrifuge tubes (Nalgene) were 
used per culture. Cell pellets were resuspended in 1 ml SC-Ura and inoculated into 200 ml 
fresh SC-Ura+galactose (2%). Cells were incubated in 1 l conical flasks for 4 hours at 30°C 
and 200rpm. The cell density of each culture was measured. Cells were placed on ice and 
transferred to pre-cooled centrifuge tubes. Cells were centrifuged at 4000rpm (at 4°C) for 3 
minutes. The supernatant was removed. The cell pellet was resuspended in 1 ml supernatant 
and slowly pipetted into liquid nitrogen using a Pasteur pipette so that spheres (5 mm) of 
frozen culture were formed. Spheres were collected into a pre-chilled 50 ml Falcon tube and 
stored at -80°C. RNA extraction, cRNA preparation, microarray hybridisation and data 
analysis was carried out by B. Rash and A. Hayes at the COGEME facility, University of 
Manchester.   
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RNA extraction (performed by B. Rash, University of Manchester) 
A 5 ml Teflon vessel was pre-cooled in liquid nitrogen. The frozen cells and a 7 mm 
tungsten carbide bead were added to the vessel and the vessel shaken at 1200 rpm for 2 
minutes in a Micro-Dismembrator to break the cells. 2 ml TRIzol (Invitrogen) was added to 
the frozen powder (cells) and the mixture split into two microcentrifuge tubes. The samples 
were homogenised by vortexing for 1 minute. The samples were kept at room temperature 
for 5 minutes to allow dissociation of nucleoprotein complexes. The samples were then 
centifuged at 12000 rpm for 10 minutes to remove polysaccharides and high molecular 
weight DNA. 0.4 ml chloroform was added to each sample and the samples shaken 
vigorously by hand for 15 seconds. The samples were left for 5 minutes at room temperature 
then centrifuged at 12000 rpm for 5 minutes. The aqueous phase (containing RNA) was 
transferred to a fresh microfuge tube and 0.5 ml isopropyl alcohol (IPA) was added to 
precipitate the RNA. Samples were kept at room temperature for 10 minutes. The RNA was 
then pelleted at 12000 rpm for 10 minutes. The supernatant was carefully removed and the 
RNA pellet was washed with 1 ml 70% ethanol by vortexing and centrifugation at 12000 
rpm for 10 minutes. The pellet was allowed to air dry for 5 minutes. The RNA pellet was 
then dissolved in 500 µl DEPC-treated dH2O. 500 µl LiCl buffer was added to the RNA 
sample and the RNA allowed to precipitate for 1 hour at -20°C. The pellet was washed 
twice more (as before) with 70% ethanol, air dried for 5 minutes and dissolved in 100 µl 
DEPC treated dH2O. RNA was visualised and the quality of RNA checked by running 5 µl 
on a 1% agarose gel. RNA was quantified using an Agilent Bioanalyser. cDNA and 
biotinylated, fragmented cRNA were prepared following the manufacturer’s instructions.  
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Hybridisation was also performed according to the manufacturer’s instructions 
(www.affymetrix.com/support/downloads/manuals/expression_analysis_technical_manual.p
df). 
Data Analysis 
Arrays were scanned at the COGEME facility (University of Manchester, UK) using a 
GeneChip scanner – fluorescence of phycoerythrin was detected at 570 nm. GeneChip 
Operating software (GCOS) was used for initial analysis of microarray slides i.e. 
bad/absent/falsely identified spots were filtered out. Dr. A. Hayes (University of 
Manchester) then analysed the data generated by GCOS using Genespring GX (Agilent, US) 
software. The data were normalised to allow the comparison of three independent replicates 
performed for each condition. Genes showing significantly different levels of expression 
(P<0.05) in yeast expressing NleG8-2 were identified using a paired t-test. Genes identified 
by this test were then filtered using a multiple testing correction. This process attempts to 
decrease the number of false positives that may appear to be statistically significant when 
using P-values. The Benjamini-Hochberg false discovery rate was used in this study. The 
false discovery rate is the proportion of genes expected to occur by chance relative to the 
proportion of identified genes. The Benjamini-Hochberg FDR was applied to the normalised 
data with a significance cut-off of 0.75. The reliability of microarray results can also be 
improved by performing more replicates to decrease the number of false positives and false 
negatives identified.    
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6.2.2. Yeast high copy suppression (HCS) screen 
Media 
M9 minimal medium consisted of 200 ml M9 (2x) salts, 1.6 g/l yeast synthetic drop out 
media supplement without leucine (Sigma), 400 µl 0.1M CaCl2, 2 ml glucose (40%), 400 µl 
1M MgSO4, supplemented with 100µg/ml ampicillin. For agar plates 200ml water agar 
(3%) was added. 
Yeast plasmid based library preparation 
Yeast genomic library AB320 in pYE13 was obtained from the American Type Culture 
Collection (ATCC). This library consists of 5 – 20kb genomic inserts in the shuttle vector 
pYE13 (a high copy number plasmid 25-80 copies/cell). The library was supplied in E. coli 
RR1 in a glycerol stock at a titre of 2.0 x 10
7
 cells/ml. 10000 clones are needed to represent 
all genes in the library. I decided to collect at least three times this amount to make sure all 
clones were represented i.e. 30000 clones. Optimum plating density is 20000 colonies per 
plate therefore 1µl of the glycerol stock was diluted in 1 ml of LB broth and spread onto a 
large (20 cm x 20 cm) plate (total of 3 plates). Cells were allowed to grow overnight at 
37°C. The next day, 25 ml LB broth (supplemented with ampicillin) was added to each plate 
and the plate rocked gently for 1 hour at room temperature to release colonies from the agar 
surface. Cell suspension from each plate was collected into a 1 l flask and 300 ml LB + 
Ampicillin was added. The cells were allowed to grow for a further 2 hours at 37°C 180rpm. 
Plasmid DNA was extracted from cells and precipitated using a Qiagen maxiprep kit 
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according to the manufacturer’s instructions. DNA was resuspended in 1 ml TE buffer (10 
mM Tris-HCl, 1 mM EDTA, pH 8.0). 
 
 
Yeast transformation with library 
5 ml SC-Ura+glucose was inoculated with a single yeast colony. Cells were incubated in a 
shaking (200rpm) water bath overnight at 30°C. 500µl of this overnight culture was then 
used to inoculate 200 ml fresh SC-Ura+glucose. Cells were incubated overnight at 30°C 
(200rpm). Cells were centrifuged for 5 minutes at 3000 x g in 50 ml Falcon tubes and the 
supernatant removed. Cells were resuspended in a final volume of 25 ml 0.1M LiAc 
solution. Cells were again centrifuged at 3000 x g for 5 minutes and the supernatant was 
discarded. The following transformation mix was added (in the order listed): 2.4 ml 50% 
PEG 3350, 0.36 ml of 1.0M LiAc, 0.5 ml ssDNA and 0.25 ml sterile dH2O (containing 20 
µl DNA library). The cells and transformation mix were thoroughly mixed by vortexing for 
2 minutes. 400 µl cell suspension was added to sterile microcentrifuge tubes and cells were 
heat shocked for 22 minutes at 42°C. Cells were centrifuged at 100 x g for 30 seconds and 
resuspended in a final volume of 20 ml SC-Ura-Leu. Cells were grown for 3 hours at 18°C. 
Strain Genotype Source 
RR1 (recA+ 
HB101 E. coli 
derivative) 
F
- 
supE44 lacY1 ara-14 galK2 xyl-5 mtl-1 
leuB6 proA2 Δ(mcrC-mrr) recA+ rpsL20 thi-
1 λ- 
American Type 
Culture Collection  
(ATCC) 
KC8 E. coli hsdR, leuB600 trpC9830 pyrF::Tn5 hisB463 
lac ΔX74 strA galU,K 
Clontech 
Table 6.1: E. coli strains used in the propagation of pYE13 
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A volume of cell suspension sufficient to obtain 2000 colonies per plate was plated onto SC-
Ura-Leu+galactose in large 20 cm x 20 cm plates (Corning). Cells were incubated for 3 days 
at 25°C.   
Plasmid rescue from yeast 
400µl of glass beads (450 µm diameter) were added to a 1.5ml microcentrifuge tube. 200µl 
of extraction buffer was added to the beads. Yeast cells were then added to the tube: yeast 
cells were scraped from the patch on the selective plate using a 1ml pipette tip (cells coated 
2mm of the tip) and added to the tube. 200µl of phenol/chloroform mix was added to the 
tube and cells were vortexed vigorously for 7 minutes. Tubes were centrifuged for 10 
minutes at 13000rpm. 140µl of the supernatant was transferred to a sterile microcentrifuge 
tube and 500µl ethanol/NH4Ac was added. Tubes were vortexed for 30 seconds. Tubes were 
then centrifuged for 15 minutes at 13000rpm at 4°C. The supernatant was removed and the 
pellets washed with 250µl 70% ethanol. Pellets were air dried for 10 minutes and 
resuspended in 10µl dH2O. 
Electroporation  
Electroporation cuvettes (2 mm electrode gap) were cooled on ice for 30 minutes prior to 
electroporation. Electrocompetent E. coli strain KC8 (20 µl; Clontech) were added to the 
cuvette, followed by 2µl recovered plasmid. Cells were electroporated at 2.5kV.  
Immediately following electroporation, 200µl SOC medium was added to the cuvette. The 
cell suspension was transferred to a sterile microcentrifuge tube and incubated at 37°C for 1 
hour. 150µl of the cell suspension was pipetted onto M9 – Leu agar plates and spread 
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evenly around the plate using a plastic spreader. Plates were incubated for 2 days at 37°C. 
Plasmids were obtained from transformed KC8 by standard miniprep procedures as detailed 
in chapter 2. DNA sequencing (using the primers listed in table 6.2) was used to obtain the 
sequences of the yeast genomic inserts of the plasmids. 
 
 
 
  
Primer Sequence 
pYEp13seq-40 5’ CGCTACTTGGAGCCACTATCG 3’ 
pYEp13seq-60 5’ CCGCCGCCCAGTCCTGCTCG 3’ 
pYEp13seqrev 5’ GTGATGCCGGCCACGATGC 3’ 
Table 6.2: pYE13 DNA sequencing primers used in this study. 
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6.3. Results 
6.3.1. Yeast library transformation 
 
Transformation of FY833 pYES DEST-3486 with the pYE13 plasmid-based library was 
repeated 3 times. Yeast FY833 pYES DEST52e was transformed with the plasmid based 
library as a control. 20000 colonies per SC-Ura-Leu plate were obtained for the control 
transformation showing that transformation with the pYE13 plasmid library was successful. 
21 colonies of FY833 pDEST-3486 yeast were able to grow on SC-Ura-Leu+galactose (i.e. 
suppression of growth inhibition). Each colony was picked. Of the 21 colonies picked from 
the original plates only 16 grew on SC-Ura-Leu+galactose when streaked onto fresh plates. 
It is likely that the remaining five colonies (that did not grow when restreaked) were 
anomalous, perhaps growing on top of transformation debris, not directly on galactose 
media therefore not expressing NleG8-2 at the same levels as other colonies. Recovery of 
the library plasmid was attempted for each of the 16 isolates. Ten library plasmids were 
successfully recovered. No plasmids could be recovered from the six remaining colonies 
indicating that resistance to the effector was probably due to a chromosomal mutation. KC8 
E. coli were transformed with yeast cell extracts in order to amplify the library plasmid. 
Successful transformation of KC8 with the 10 recovered plasmids was seen with between 1 
and 42 colonies obtained on each plate. One colony of transformed KC8 was picked from 
each plate. The plasmid was amplified and purified by miniprep. To confirm that resistance 
to the effects of NleG8-2 were dependent on the library plasmids, fresh yeast FY833 pYES 
DEST-3486 were transformed with each of the recovered plasmids. More than 1000 
colonies were obtained per transformation when plated on SC-Ura-Leu+glucose and all 
strains grew as well as FY833 pYES DEST52e when restreaked onto SC-Ura-
Leu+galactose.        
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6.3.2. Genes identified by high copy suppressor screen 
 
Sequences of pYE13 plasmid inserts were obtained through DNA sequencing using primers 
listed in table 6.2. Sequences were identified using the BLAST facility on the 
Saccharomyces genome database (SGD) website (www.yeastgenome.org). Genes contained 
within the inserts are shown in table 6.3.  
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Transformant Chromosome Region Genes 
1 XVI 92482-96878 CIN2 
 
2 VI 146481-150679 LOC1, DEG1 
 
3 XIV 519318-562724 VAC7, MSG5, COX5A, COG5, 
YNL050C, SFB2, ALG11, SLM2, 
YNL046W, LAP2, YIP3, BOP3, COG6, 
YNL040W, BDP1, GPI15, IDH1, 
NCE103  
 
4 XII 85387-87909 ISA1 (partial), TPO1 
 
5 VII 719785-723935 SPT6 (partial), DAM1 
 
6 X 207119-213767 CCT7, GZF3 
 
10 III 27365-31919 KAR4, YCL056C 
 
12 VIII 170201-174000 SLT2 (partial), RRM3, YHR032W 
(partial) 
 
15 XVI 923239-929949 OPT2, YPR196W 
 
16 XVI 52665-61750 THI21, YPL257W (partial) 
 
Table 6.3: Genes present in yeast genomic inserts of pYE13 obtained from yeast pYE13 
transformants resistant to NleG8-2. 
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6.3.3. Results from microarray 
 
Statistical analysis of 3 biological replicates (normalised) showed that 33 yeast genes were 
significantly up/down regulated when NleG8-2 was expressed compared to empty vector 
pYES DEST52e. Table 6.4 shows those 20 genes that were significantly up regulated when 
NleG8-2 was expressed. Table 6.5 shows those 13 genes that were significantly down 
regulated when NleG8-2 was expressed.  
 
Gene  NleG8-2  
log2 change in 
expression  
Control 
log2 change in 
expression  
FDR corrected 
P value 
Un-corrected P 
value 
ATG14 0.24396355 -0.25174126 0.54066426 2.47E-04 
ADP1 0.21325588 -0.18376286 0.7418809 0.0036259 
LDB17 0.15847778 -0.18701713 0.69583017 0.0026743 
SPG3 0.23451614 -0.20057519 0.624788 0.0014056 
RPL2A 0.080376625 -0.09576479 0.7215294 0.0033673 
VPS62 0.21762784 -0.2945741 0.6932907 0.0023974 
PHB2 0.099705376 -0.12216377 0.5721855 5.51E-04 
DOG2 0.068860054 -0.108840145 0.5721855 6.41E-04 
HPF1 0.09053389 -0.11002779 0.5721855 0.0010252 
MRPL8 0.14485581 -0.09985542 0.624788 0.00136 
BET4 0.21451695 -0.39233527 0.6932907 0.0025639 
VPS70 0.17858696 -0.18124802 0.6932907 0.0023418 
MRP49 0.056836445 -0.07747873 0.5721855 8.15E-04 
CWP2 0.030136744 -0.031445503 0.624788 0.0015776 
TUL1 0.0804224 -0.07997767 0.18507534 2.06E-05 
LOT6 0.06335894 -0.07263056 0.6932907 0.0022296 
RPS31 0.063635506 -0.059439022 0.7418809 0.003666 
CST9 0.063355125 -0.10863749 0.6932907 0.0026011 
SLZ1 0.27074432 -0.22138388 0.5721855 9.79E-04 
GDH1 0.14543247 -0.16374111 0.7215294 0.0032961 
     
Table 6.4: Yeast genes that were upregulated in yeast expressing NleG8-2. FDR 
– false discovery rate.  
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Table 6.5: Yeast genes that were down regulated in yeast expressing NleG8-2. FDR – 
false discovery rate. 
Gene  NleG8-2  log2 
change in 
expression 
Control  log2 
change in 
expression 
FDR corrected 
P value 
Un-corrected P 
value 
POP5 -0.07967726 0.057573635 0.54066426 2.47E-04 
PHO11/PHO12 -0.090715885 0.12421814 0.5721855 7.02E-04 
PRS4 -0.15346973 0.11938318 0.624788 0.0061008 
CCT6 -0.06419722 0.1024119 0.7215294 0.003043 
NPY1 -0.053647995 0.026236853 0.18507534 3.39E-05 
POP3 -0.18177192 0.30887666 0.5721855 6.28E-04 
AAH1 -0.31523672 0.46882185 0.645003 0.0017707 
NCS2 -0.22807248 0.46882185 0.7215294 0.0032698 
YIP3 -0.098649345 0.100541115 0.5721855 4.93E-04 
PRS5 -0.12467575 0.2036918 0.7418809 0.0035366 
RPB8 -0.17324512 0.10171763 0.6932907 0.0022402 
ELP4 -0.09937986 0.161686262 0.5721855 5.28E-04 
ARO7 -0.14434178 0.2225523 0.624788 0.001466 
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6.3.4. Functions of the genes identified 
 
Table 6.6 shows the functions of the proteins encoded by the genes identified by 
transcriptome analysis and the high copy suppressor screen. Data for protein function was 
obtained from gene annotation in SGD. The genes are grouped according to their product’s 
role in the yeast cell e.g. proteins localised to or necessary for the correct functioning of the 
mitochondria are grouped together under ‘Mitochondria’. Evidence for each gene product is 
shown next to gene name i.e. up - up regulated in microarray, down - down regulated in 
microarray. If the protein is encoded by a high copy suppressor encoded within pYE13, the 
plasmid isolate is shown: ‘S3’ – suppressor from transformant 3. 
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Gene Function 
Secretory pathway/cell wall  
 
COG5/COG6 (S3) Components of the conserved oligomeric Golgi complex, a cytosolic tethering 
complex that functions in protein trafficking to mediate fusion of transport vesicles to 
Golgi compartments. 
YIP3 (S3, down) Protein localized to COPII vesicles, proposed to be involved in ER to Golgi 
transport; interacts with members of the Rab GTPase family and Yip1p; also interacts 
with Rtn1p. 
SFB2 (S3) Probable component of COPII coated vesicles that binds to Sec23p; homologous to 
Sec24p; involved in ER to Golgi transport and in autophagy. 
BET4 (up) Subunit of Type II geranylgeranyltransferase required for vesicular transport between 
the ER and Golgi; provides a membrane attachment moiety to Rab-like proteins 
Ypt1p and Sec4p. 
TUL1 (up) Golgi-localized RING-finger ubiquitin ligase (E3), involved in ubiquitinating and 
sorting membrane proteins that contain polar transmembrane domains to 
multivesicular bodies for delivery to the vacuole. 
ATG14 (up) Autophagy-specific subunit of phosphatidylinositol 3-kinase complex I (with 
Vps34/15/30p); Atg14p targets complex I to the phagophore assembly site (PAS); 
required for localizing additional ATG proteins to the PAS. 
GPI15 (S3) Protein involved in the synthesis of N-acetylglucosaminyl phosphatidylinositol 
(GlcNAc-PI), an intermediate in the synthesis of glycosylphosphatidylinositol (GPI) 
anchors. 
CWP2 (up) Covalently linked cell wall mannoprotein, major constituent of the cell wall; plays a 
role in stabilizing the cell wall; involved in low pH resistance; precursor is GPI-
anchored. 
ALG11 (S3) Alpha-1,2-mannosyltransferase, involved in asparagine-linked glycosylation in the 
ER. 
PHO11 (down) One of three repressible acid phosphatases, a glycoprotein that is transported to the 
cell surface by the secretory pathway; induced by phosphate starvation and 
coordinately regulated by PHO4 and PHO2. 
VPS62 (up) Vacuolar protein sorting (VPS) protein required for cytoplasm to vacuole targeting of 
proteins. 
VPS70 (up) Protein of unknown function involved in vacuolar protein sorting. 
 
VAC7 (S3) Integral vacuolar membrane protein involved in vacuole inheritance and morphology; 
activates Fab1p kinase activity under basal conditions and also after hyperosmotic 
shock. 
RNA/DNA 
 
 
LOC1 (S2) Nuclear protein involved in asymmetric localisation of ASH1 mRNA; binds dsRNA 
in vitro; constituent of 66S pre-ribosomal particles. 
DEG1 (S2) Non-essential tRNA pseudouridine synthase, important for translation efficiency and 
cell growth. 
BDP1 (S3) Essential subunit of RNA polymerase III transcription factor (TFIIIB). 
SPT6 (S5) Transcriptional RNA pol II subunit. 
RRM3 (S12) DNA helicase for DNA replication and Ty transposition. Related to Pif1p. 
RPL2A (up) Protein component of the large (60S) ribosomal subunit. 
RPS31 (up) Fusion protein that is cleaved to yield a ribosomal protein of the small (40S) subunit 
and ubiquitin; ubiquitin may facilitate assembly of the ribosomal protein into 
ribosomes; interacts genetically with translation factor eIF2B. 
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Gene Function 
RNA/DNA (cont.)  
  
RPS31 (up) Fusion protein that is cleaved to yield a ribosomal protein of the small (40S) subunit 
and ubiquitin; ubiquitin may facilitate assembly of the ribosomal protein into 
ribosomes; interacts genetically with translation factor eIF2B. 
POP3/POP5 
(down) 
Subunits of both RNase MRP, which cleaves pre-rRNA, and nuclear RNase P, which 
cleaves tRNA precursors to generate mature 5' ends. 
NCS2 (down) Protein required for thiolation of the uridine at the wobble position of Lys(UUU) and 
Glu(UUC) tRNAs; has a role in urmylation and in invasive and pseudohyphal 
growth. 
RPB8 (down) RNA polymerase subunit ABC14.5, common to RNA polymerases I, II, and III. 
ELP4 (down) Subunit of Elongator complex, which is required for modification of wobble 
nucleosides in tRNA; required for Elongator structural integrity. 
Cytoskeleton  
 
CIN2 (S1) GTPase activating protein (GAP) for Cin4p; tubulin folding factor C for β-tubulin 
(Tub2p) folding. 
DAM1 (S5) Kinetochore protein involved in microtubule binding. 
CCT6 (down) 
CCT7 (S6) 
 
Part of the TCP1/CCT complex that folds actin and tubulin. 
Part of the TCP1/CCT complex that folds actin and tubulin. 
Signalling 
 
 
MSG5 (S3) Dual-specificity protein phosphatase; required for maintenance of a low level of 
signaling through the cell integrity pathway, adaptive response to pheromone; 
regulates and is regulated by Slt2p; dephosphorylates Fus3p. 
SLM2 (S3) Phosphoinositide PI4,5P(2) binding protein, forms a complex with Slm1p; acts 
downstream of Mss4p in a pathway regulating actin cytoskeleton organization in 
response to stress; phosphorylated by the TORC2 complex. 
SLT2 (S12) Serine threonine MAP kinase. Cell integrity pathway signalling. 
PRS4/PRS5 
(down) 
5-phospho-ribosyl-1(alpha)-pyrophosphate synthetase, synthesizes PRPP, which is 
required for nucleotide, histidine, and tryptophan biosynthesis. Has a role in 
remodelling of the cell wall and cell integrity signalling.  
YHR032W (S12) Unknown protein (putative substrate of cAMP-dependent protein kinase (PKA). 
CST9 (up) SUMO E3 ligase; required for synaptonemal complex formation; localizes to 
synapsis initiation sites on meiotic chromosomes; potential Cdc28p substrate. 
 
Mitochondria 
 
 
COX5A (S3) Subunit Va of cytochrome c oxidase, which is the terminal member of the 
mitochondrial inner membrane electron transport chain; predominantly expressed 
during aerobic growth.  
IDH1 (S3) Subunit of mitochondrial NAD(+)-dependent isocitrate dehydrogenase, which 
catalyzes the oxidation of isocitrate to alpha-ketoglutarate in the TCA cycle. 
ISA1 (S4) Mitochondrial matrix protein involved in iron-sulphur cluster biosynthesis. 
PHB2 (up) Subunit of the prohibitin complex (Phb1p-Phb2p), a 1.2 MDa ring-shaped inner 
mitochondrial membrane chaperone that stabilizes newly synthesized proteins; 
determinant of replicative life span; involved in mitochondrial segregation. 
MRPL8 (up) Mitochondrial ribosomal protein of the large subunit. 
MRP49 (up) Mitochondrial ribosomal protein of the large subunit. 
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Gene Function 
Transporters/permease 
 
 
ADP (up) Putative ATP-dependent permease of the ABC transporter family of proteins. 
OPT2 (S15) Oligopeptide transporter. 
TPO1 (S4) Polyamine transporter. 
 
Other 
 
 
LAP2 (S3) Leucyl aminopeptidase yscIV (leukotriene A4 hydrolase) with epoxide hydrolase 
activity, metalloenzyme containing one zinc atom. 
BOP3 (S3) Protein of unknown function, potential Cdc28p substrate; overproduction confers 
resistance to methylmercury. 
NCE103 (S3) Carbonic anhydrase; involved in non-classical protein export pathway. 
GZF3 (S6) Transcription factor for nitrogen catabolite repression. 
KAR4 (S10) Transcription factor required for karyogamy and meiosis. 
YPR196W (S15) Maltose activator. 
THI21 (S16) Encodes protein involved in thiamine biosynthesis. 
YPL257W (S16) Unknown protein; may have 3 TMDs and may associate with heat shock protein. 
LDB17 (up) Protein of unknown function. 
SPG3 (up) Protein required for survival at high temperature during stationary phase. 
LOT6 (up) FMN-dependent NAD(P)H:quinone reductase, may be involved in quinone 
detoxification; expression elevated at low temperature; sequesters the Cin5p 
transcription factor in the cytoplasm in complex with the proteasome under reducing 
conditions. 
DOG2 (up) 2-deoxyglucose-6-phosphate phosphatase, member of a family of low molecular 
weight phosphatases, similar to Dog1p, induced by oxidative and osmotic stress, 
confers 2-deoxyglucose resistance when overexpressed. 
SLZ1 (up) Sporulation-specific protein with a leucine zipper motif. 
GDH1 (up) NADP(+)-dependent glutamate dehydrogenase, synthesizes glutamate from ammonia 
and alpha-ketoglutarate; expression regulated by nitrogen and carbon sources. 
NPY1 (down) NADH diphosphatase, hydrolyzes the pyrophosphate linkage in NADH and related 
nucleotides. 
AAH1 (down) Adenine deaminase; involved in purine salvage; transcriptionally regulated by 
nutrient levels and growth phase. 
ARO7 (down) Chorismate mutase, involved in aromatic amino acid biosynthesis. 
  
Table 6.6: Genes identified in the HCS screen and microarray. Up: up-regulated in 
cells expressing NleG8-2; down: down-regulated in cells expressing NleG8-2. Potential 
suppressors (S) are shown with the number of the pYE13 transformant e.g. S3: 
suppressor from transformant 3. 
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6.4. Discussion 
 
A high copy plasmid suppressor (HCS) screen was performed. Toxicity of NleG8-2 
expression was rescued by high copy number suppressors from a S. cerevisiae pYE13-based 
library. Plasmids (pYE13) were isolated from colonies able to grow when NleG8-2 was 
expressed. Isolated plasmids were retested for their ability to suppress the growth inhibition 
caused by NleG8-2 by plasmid purification and retransformation. Table 6.3 shows the 
genomic inserts of each recovered pYE13 plasmid and lists the genes (i.e. potential 
suppressors) present in the inserts. Transcriptome analysis of yeast expressing NleG8-2 and 
yeast expressing empty vector pYES DEST52 showed that 33 genes were significantly 
up/down regulated when NleG8-2 was expressed. Tables 6.4 and 6.5 show those genes that 
were significantly up/down regulated respectively. Table 6.6 lists suppressors and 
differentially regulated genes according to their function/localisation within the yeast cell.  
 
6.4.1. The yeast secretory pathway 
 
A large number of the genes identified by the HCS screen and microarray appear to be 
involved in the secretory pathway and cell wall biosynthesis. A further 18 gene products are 
involved in protein modification, trafficking and cell wall integrity (CWI) signalling. Cell 
surface expansion and cell wall biosynthesis/remodelling are key processes in growth, 
division, mating and the response to environmental changes in budding yeast [423]. The 
secretory pathway is integral to these processes as cell wall components and plasma 
membrane proteins involved in cell wall remodelling are delivered to the plasma membrane 
by the secretory pathway. Disruption of the secretory pathway hinders cell wall biosynthesis 
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and reduces cell wall integrity [423]. Yeast cells detect changes in cell wall biosynthesis and 
integrity using sensor proteins such as Mid2 and Wsc. These proteins transmit signals via 
kinase cascades to activate transcription factors such as Rlm1 thus inducing a transcriptional 
response e.g. to promote cell wall remodelling [465]. It is possible that NleG8-2 affects the 
secretory pathway which in turn disrupts cell wall biosynthesis/integrity and triggers CWI 
signalling. Interestingly, in a study by Grose et al, the Ugp1 overexpression phenotype (i.e. 
sensitivity to cell wall integrity stress conditions) [466] was suppressed by a similar 
complement of genes as found in this study. This indicates that NleG8-2 may cause cell wall 
stress.  
 
A basic graphical representation of the yeast secretory pathway, its interactions with cell 
wall synthesis and CWI MAPK signalling pathways is shown in figure 6.3. The localisation 
of potential suppressors or up/down regulated gene products involved in this pathway is also 
shown. 
 
 
207Figure 6.3: The yeast secretory pathway and its interactions with the cell wall. Potential suppressors identified in the HCS 
screen are shown in red lettering, up-regulated genes (microarray) in green and down-regulated genes (microarray) in purple. Ub -
ubiquitin. Steps of the secretory pathway (indicated by numbers) are explained in the text.
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The yeast secretory pathway and cell wall integrity: 
1. ER. Proteins intended for secretion are translocated into the ER. Proteins may be 
modified e.g. glycosylphosphatidylinositol (GPI) modified or mannosylated [423] in 
the ER [467] by proteins such as GPI15 and ALG11. Proteins are selectively packaged 
into COPII coated vesicles for anterograde transport to the Golgi [468]. Selective 
packaging of proteins into COPII vesicles from the ER depends on multiple factors 
including components of the COPII coat and the Rab GTPase Ypt1p [469]. GPI-
modified proteins depend on Ypt1p for selective packaging [469]. 
 
2. COPII vesicles travel to the Golgi where they are tethered to the Golgi membrane to 
promote membrane fusion. Accurate fusion requires the COPII coat, Rab GTPases, 
tethering factors and SNARE complexes [470]. 
 
 
3. Proteins are modified (e.g. glycosylated) as they move through the Golgi (anterograde 
transport) [471]. Golgi-resident/ER-resident proteins are transported back to the 
correct compartment in COPI coated vesicles (retrograde transport) [472]. 
 
4. Proteins intended for secretion are delivered to the plasma membrane in endocytic 
vesicles via early/late endosomes using the endocytic pathway [423]. 
 
  
5. Proteins may also be directed from the Golgi to the vacuole either directly (ALP 
pathway) or indirectly (CPY pathway) via intermediate multivesicular bodies (MVB) 
[473]. Proteins with polar residues in their transmembrane domains e.g. misfolded 
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proteins may be ubiquitinated (by Tul1) and transported to the vacuole for degradation 
[473].  
 
6. Proteins are secreted. GPI-modified proteins are anchored in the plasma membrane by 
the GPI anchor [474]. Alternatively the GPI anchor may be cleaved to release the 
proteins into the periplasm/cell wall [475, 476]. Proteins such as Gas1p contribute to 
cell wall biosynthesis [477] [478]. Cell wall stress (caused by osmotic 
shock/biosynthesis disruption/oxidative stress etc.) is detected by cell wall sensor 
proteins such as Wsc [479]. Wsc sensors also detect metabolic disturbances via PRS4 
and PRS5 [480]. 
 
7. Cell wall stress causes sensor proteins to trigger a MAPK signalling cascade via the 
Slt2 pathway to effect transcriptional changes via activation of transcription factors 
such as Swi4/Swi6 [481] and Rlm1 [482] [436].   
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6.4.2. ER to Golgi vesicle trafficking  
 
As highlighted in figure 6.3, potential suppressors/up/down regulated genes from each stage 
of the secretory pathway/CWI signalling pathway were identified. Notably, five of these 
genes (SFB2, COG5, COG6, YIP3 and BET4) are involved in COPII-mediated vesicular 
transport between the ER and Golgi: 
SFB2 (suppressor)  
SFB2 is a homologue of Sec24, a component of the COPII coat [483]. The COPII coat is 
composed of numerous Sec complexes plus a GTPase [484] and is required for selective 
packaging of proteins into transport vesicles destined for the Golgi [485]. SFB2 is specifically 
required for secretion of the plasma membrane protein Gas1p, an essential enzyme involved 
in cell wall synthesis [486]. 
COG5 and COG6 (suppressors)  
Both COG5 and COG6 form part of the evolutionarily conserved oligomeric Golgi complex 
(COG) [487] which acts to tether Golgi/vesicle membranes to promote membrane fusion. 
Cytosolic COG interacts with the Golgi membrane via Rab GTPases Ypt1p and Ypt6p [488] 
[489], SNARE proteins and the COPI coat [471].  
211 
 
YIP3 (potential suppressor and down-regulated gene)  
YIP3 is a Rab-GDI displacement factor (GDF) that forms complexes with Ypt1p [490]. Rab 
GTPases are continually distributed to different parts of the cell as a consequence of their role 
in directing vesicular transport. Therefore, an important process within the cell is Rab 
recycling, whereby inactive Rabs (Rab-GDI) are retrieved and delivered back to their resident 
organelle e.g. Golgi. Rab-GDI displacement factors are involved in reloading Rabs back onto 
their target membranes [490]. YIP3 ensures that Ypt1p is delivered back to the ER membrane 
to promote COPII budding [490]. YIP3 is prenylated to facilitate membrane attachment. 
Interestingly, overproduction usually inhibits growth and causes the ER to proliferate (this is 
thought to be due to deficient COPII budding) [490].  
BET4 (upregulated) 
BET4 is part of a geranylgeranyltransferase that catalyses the prenylation of Rab-like 
GTPases, Ypt1p and Sec4p [491]. Prenylation of Rabs enables them to attach to 
vesicular/organelle membranes and direct movement of vesicles within the cell [492].  
 
Interestingly, all of the products of the suppressor genes mentioned above interact with or are 
necessary for the correct functioning/localisation of Ypt1p. This suggests that NleG8-2 may 
affect the Rab GTPase (and associated vesicular targeting). In addition to the functions 
described above, Ypt1p is required for selection of GPI-anchored proteins into COPII vesicles 
[469]. GPI15, an enzyme involved in the synthesis of GPI anchors was also identified as a 
potential suppressor of NleG8-2. GPI is a complex glycoplipid that can anchor cell surface 
proteins to membranes [493]. A large number of cell wall proteins are GPI-modified [494]. 
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These proteins would most likely be affected by disruption of Ypt1p as they depend on Ypt1p 
for selection into COPII vesicles and vesicle-mediated transport to the plasma membrane 
[495]. Mislocalisation of GPI-modified cell wall proteins in this way would likely diminish 
the integrity of the cell wall (as has been shown to occur in yeast with a non-functioning 
secretory pathway [496]). We might therefore expect to see evidence of disruption of the cell 
wall and associated MAPK signalling pathways in cells expressing NleG8-2.  
 
6.4.3. Disruption of the secretory pathway affects the yeast cell wall and CWI 
signalling 
 
Numerous suppressors and differentially regulated genes are involved in cell wall synthesis 
and CWI signalling (see below). Significantly, a number of these have been shown to be able 
to compensate for cell wall defects caused by impaired delivery of membrane and cell wall 
precursors.  
 
6.4.4. Cell wall biosynthesis 
 
CWP2 was upregulated in cells expressing NleG8-2. CWP2 is a major cell wall mannoprotein 
and is GPI-modified. CWP2 is transported to the plasma membrane via the secretory pathway 
and has been shown to act as a multicopy suppressor for cells in which the bud neck is 
weakened by impaired delivery of membrane and cell wall precursors [496]. Increased CWP2 
may compensate for the loss of cell wall strength caused by NleG8-2-mediated disruption of 
the secretory pathway. ALG11, a mannosyltransferase essential for N-linked glycosylation of 
proteins [497] was identified in the HCS screen. The outer cell wall is composed of highly 
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glycosylated mannoproteins [498] thus ALG11 may provide mannoproteins for the outer cell 
wall layer to improve cell wall strength. Also, N-glycosylation of Mid2p is required for 
Mid2p to perceive changes in the cell wall [499] – ALG11 might therefore increase the ability 
of the cell to sense cell wall stress.  
 
6.4.5. CWI signalling 
 
The CWI pathway is involved in cell wall remodelling. Slt2 is the MAP kinase of this route 
and activates the transcription factor Rlm1. CWI signalling can be triggered by; heat stress, 
hypo-osmotic shock, oxidative stress, cell wall stressing agents and impairment of cell wall 
biosynthesis [500]. Delocalisation of signalling components can also activate the CWI 
pathway [501]. A number of components of the CWI signalling pathway were identified as 
suppressors (MSG5 and Slt2) or were up/down regulated in the microarray (PRS4 and PRS5). 
PRS4/5 signals through MSG5 and Slt2 in the CWI MAPK signalling pathway [480]. A role 
for Slt2 in assembly of the chitin ring at the bud neck has recently been demonstrated by 
Gomez et al. [502]. Slt2 was shown to affect septin localisation at the bud neck causing bud 
neck fragility. Notably, overexpression of CCT7 (another potential suppressor of NleG8-2) 
was shown to reduce bud neck fragility in an Slt2 mutant [502]. It is possible that CCT7 may 
act as a suppressor of NleG8-2 by compensating for mislocalised membrane proteins that are 
involved in cell wall/chitin synthesis.  
 
The genes identified in this study suggest that CWI MAPK signalling in cells expressing 
NleG8-2 is triggered by the cell integrity sensor Wsc. This plasma membrane protein 
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responds to cell wall stress, PRS4/5 and a plasma membrane protein, Gas1p (although the 
nature of the signals received and mechanism of signal transduction are poorly understood 
[423]). Gas1p is a 1-3 β-glucan synthase and is involved in construction of the cell wall. 
Interestingly, Gas1p is GPI-modified and as such relies on Ypt1p for sorting into COPII 
vesicles. Gas1p is also directed to COPII vesicles by SFB2. SFB2 and GPI15 (potential 
suppressors) are integral to the trafficking and localisation of Gas1p to the plasma membrane. 
It seems likely therefore that Gas1p is mislocalised in cells expressing NleG8-2 leading to cell 
wall stress (sensed by Wsc/Mid2 causing CWI signalling). Overexpression of SFB2 may 
compensate for loss of Ypt1p-mediated sorting of Gas1p into COPII vesicles whereas GPI15 
may increase the amount of Gas1p-GPI in the cell (thereby increasing the probability of 
Gas1p reaching the plasma membrane). Gas1p was not however, identified in the screens 
therefore we may only speculate that activation of the CWI pathway is by this route. Slt2 and 
MSG5 may act as suppressors of NleG8-2 by increasing signalling through the CWI pathway 
thereby preparing the cell for cell wall stress caused by aberrant protein trafficking. 
 
6.4.6. Disruption of vacuolar protein sorting 
 
The yeast vacuole(s) is similar to the mammalian lysosome and has three main functions: 
protein degradation, ion and metabolite storage and detoxification [473]. Multiple vesicular 
pathways transport proteins to and from the vacuole. There are a number of genes encoding 
vacuolar proteins that have been identified by the screens. These include VPS62, VPS70 and 
Vac7. The functions of VPS62 and VPS70 are poorly understood although it is presumed that 
they are involved in regulation of vacuole fusion and fission as mutants demonstrate unusual 
vacuole morphology [503]. Vac7p is involved in generating phosphoinositides (e.g. 
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PtdIns[3,5]P2) on vacuolar membranes. Phosphoinositide signalling is crucial for vesicle 
trafficking and fusion between vacuolar membranes [473]. VPS62, VPS70 and Vac7 point to 
a role for NleG8-2 in regulating/disruption of vacuole fusion/fission. Fusion of vesicles and 
small vacuoles to the main vacuole, like ER and Golgi-derived vesicles, requires SNARE 
proteins, tethering factors and Rab GTPases whereas fission requires COPI and COPII coat 
proteins. It is therefore highly likely that vacuolar function and/or morphology would be 
affected if NleG8-2 disrupted vesicular transport by affecting Rab GTPase or COPII function. 
Another upregulated gene product involved in Golgi-vacuole protein trafficking is ATG14. 
ATG14 associates with VPS34 a protein required for regulation of retromer function i.e. helps 
to retrieve late Golgi proteins from the endosome [503]. ATG14, VPS62, VPS70 and Vac7 
may compensate for NleG8-2-mediated disruption of vacuolar protein sorting. 
 
6.4.7. NleG8-2 does not appear to target the cytoskeleton or mitochondria 
 
Surprisingly, only four cytoskeleton-related genes were identified by the HCS screen or 
microarray. These were: Cin2, Dam, CCT6 and CCT7. Interestingly all are involved in 
binding/folding tubulin. CCT6 and CCT7 form part of the Cct double ring chaperonin 
complex in yeast which helps to fold actin and tubulin [504]. Cin2 is involved in activating 
tubulin folding whereas Dam1 is involved in chromosome segregation by binding chromatids 
to the kinetochore. The Golgi is usually found at the same site as the centrosome (the major 
microtubule organising centre) and organisation of Golgi cisternal stacks depends on 
microtubules [505]. However, disruption of microtubules has only a minor effect on protein 
trafficking [506]. NleG8-2 appears to have a significant effect on protein trafficking therefore 
it is unlikely that NleG8-2 disrupts microtubules. CCT7, as mentioned above is a suppressor 
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of yeast growth defects associated with mislocalised cell wall proteins and weak cell walls 
[502].  
 
Surprisingly, no actin related genes were identified in this study. T3SS often target the actin 
cytoskeleton and associated Rho GTPases [507] [508] [356]. We may have expected to see 
some perturbation of the actin cytoskeleton/function as a result of CWI signalling. However, 
experimental evidence suggests that the CWI pathway drives polarisation of the actin 
cytoskeleton and is not involved in actin depolymerisation [501]. Therefore any 
depolymerisation caused by cell wall stress would be transient as CWI signalling would 
restore localisation [465]. Actin-related genes would not be expected to act as suppressors of 
NleG8-2 or be up/down regulated in cells expressing NleG8-2.  
 
A small number of mitochondria-related genes were identified in the HCS screen and 
microarray including COX5A, ISA1, PHB2, IDH1, MRPL8 and MRP49. These genes encode 
a variety of proteins involved in unrelated processes e.g. ribosomal subunits and respiratory 
enzymes. It does not appear therefore that NleG8-2 targets mitochondria or mitochondrial 
processes. Correct mitochondrial function is dependent on proper functioning of the secretory 
pathway [509] therefore the mitochondrial-related suppressors may rescue mitochondrial 
dysfunction caused by a perturbed secretory pathway. 
 
Other genes identified by the microarray and HCS screen encode a variety of enzymes, 
transcription factors and unknown proteins. Their significance in resistance to NleG8-2 
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mediated growth retardation is unclear. They likely represent non-specific genes that would 
also enhance growth in the control or genes that have been isolated by being encoded next to a 
suppressor. This highlights the need for each potential suppressor to be tested individually. 
 
6.4.8. Effect of NleG8-2 on the host cell 
 
Overall the genes identified by the yeast genomic screens appear to point to a role for NleG8-
2 in regulating protein trafficking within the host cell. In yeast, it seems that NleG8-2 disrupts 
protein selection into secretory vesicles and intracellular vesicular transport (most likely ER 
to Golgi protein transport). We predict that disruption of vesicular transport leads to a 
decrease in the delivery of enzymes such as Gas1p that are involved in cell wall synthesis to 
the plasma membrane. Delivery of cell wall precursors (glucans, chitin etc) may also be 
reduced. This affects cell wall integrity leading to activation of the CWI MAPK signalling 
pathway. Transcriptional changes are thus induced by activated transcription factors which 
results in growth inhibition.  
 
The effect on the yeast cell wall is likely to be a side-effect of NleG8-2 disruption of the 
secretory pathway. In mammalian cells, disruption of protein trafficking and secretion by 
NleG8-2 might lead to subversion of the cell or the immune response i.e. by preventing GPI-
anchored proteins such as cell surface receptors, cell adhesion molecules, complement 
regulatory proteins and hydrolases reaching the cell surface [510]. Alternatively, disruption of 
secretion may prevent ingestion of bacteria by predatory protozoa or prevent fusion of 
deleterious vesicles with EHEC-containing vacuoles within bacterivorous cells. Notably, 
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NleA was shown by Kim et al (2007) to bind Sec24 and disrupt COPII coat function thereby 
reducing the efficiency of cellular secretion [511]. This shows that disruption of COPII 
function and disruption of the host cell secretory pathway may contribute to EHEC O157:H7 
virulence. It would be interesting to dissect the relationship between NleG8-2 and NleA to 
determine whether they act cooperatively (or are reciprocally redundant) to perturb the 
secretory pathway of host cells to contribute to cellular subversion. 
  
6.4.9. Possible molecular mechanism of NleG8-2 
 
As mentioned in the introduction to this thesis, T3SS effector proteins often target/mimic host 
cell GTPases [507]. Many T3SS effectors target Rho-like GTPases involved in regulating the 
host cell cytoskeleton, although a number of effectors have been found to target Rab GTPases 
(see below). Rab GTPases are at the forefront of vesicular trafficking within the cell and as 
such, represent a probable T3SS effector target [512]. For example, Pseudomonas aeruginosa 
effector ExoS possesses ADP-ribosyltransferase activity which results in inhibition of Rab 
activity; this interferes with clathrin-coated vesicle maturation [512]. Pseudomonas syringae 
effector AvrPto interacts with two Rab proteins to decrease extracellular vesicle trafficking 
and secretion of plant defence proteins [513]. Many intracellular T3S organisms target Rab 
GTPases using T3SS effectors to control which types of (i.e. beneficial/deleterious) vesicles 
can fuse with the pathogen-containing compartment. For example, Chlamydia spp have been 
shown to recruit Rabs to facilitate fusion of Golgi-derived host vesicles with the inclusion 
membrane [514]. Similarly, Salmonella containing vacuoles (SCVs) mature in a Rab7-
dependent manner but avoid lysosomal fusion [515]. 
219 
 
As discussed in chapter 5, NleG8-2 contains 3 invariant residues that are similar to the C/H/D 
catalytic triad found in cysteine proteases. We found that yeast growth inhibition caused by 
NleG8-2 was dependent on these residues (see chapter 5). It is possible therefore that NleG8-2 
may function as a novel form of cysteine protease. Other T3SS effectors that have cysteine 
protease activity include SseL, a Salmonella effector that acts as a deubiquitinase to kill 
macrophages [155] and the Yersinia effector YopT which disrupts the cytoskeleton. 
Interestingly, YopT causes cytoskeletal changes by disrupting the localisation of Rho-like 
GTPases by removing their prenyl modification [371]. Removal of prenyl groups from the 
Rho GTPases is dependent on the cysteine protease catalytic triad (C/H/D residues) [371]. 
Prenyl groups are essential for small GTPase targeting and localisation within eukaryotic cells 
as they allow the GTPase to attach to membranes [492].    
 
We could speculate that NleG8-2 has a similar function to YopT i.e. that cysteine protease 
activity removes the prenyl moiety from GTPases, except that NleG8-2 targets Rab GTPases 
(most likely Ypt1p) to disrupt vesicle trafficking within the host cell. This hypothesis is 
supported by the types of suppressors identified by the HCS screen - many potential 
suppressors were involved in the secretory pathway, particularly processes controlled by 
Ypt1p. A mechanism for the suppressor activity of the four Ypt1p interacting proteins would 
be as follows: Bet4 may increase the prenylation of Ypt1p thereby compensating for the loss 
of prenyl groups caused by NleG8-2. Overexpression of COG subunits may increase the 
probability of prenylated Ypt1p interacting with COG thereby increasing the number of 
successful Golgi-vesicle fusion events. Overexpression of YIP3 may increase Rab/Ypt1p 
recycling and ensure that any remaining prenylated Rabs are available for directing vesicular 
transport/protein secretion. Ypt1p was not identified in either the microarray or HCS screen 
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therefore its identification as the target of NleG8-2 is far from certain. An alternative target 
may be YIP3 which is also prenylated. Disruption of YIP3 function might cause similar 
effects on the yeast cell as loss of Ypt1p function. More research (as described in chapter 7) is 
required to investigate the function of NleG8-2 and the possibility that this effector acts as a 
cysteine protease to de-prenylate Rab GTPases/Rab accessory proteins.  
 
6.4.10. Validation of HCS screen results 
 
In order to confirm which of the genes identified through the HCS screen are involved in 
suppression of NleG8-2-mediated growth inhibition there are a number of issues that must be 
resolved. Firstly, the level of expression of NleG8-2 must be quantified in each suppressor 
strain to show that the level of NleG8-2 expression is the same as FY833-NleG8-2. This will 
ensure that no suppressors were isolated simply because they diminished expression of 
NleG8-2. Also, most HCS plasmids contained multiple genes. Therefore each gene must be 
tested individually in FY833-NleG8-2 to find the gene responsible for suppression of growth 
inhibition.  For example, at present it is impossible to say which gene present in pYE13 from 
transformant 3 is the true suppressor. Unfortunately there was insufficient time in this study to 
complete this aspect of the assay. In addition, the suppressor activity of each suppressor gene 
identified should also be quantified as the efficacy of a suppressor may give clues as to the 
target of NleG8-2. Another issue that must be resolved is the use of the GAL1 promoter for 
NleG8-2 expression. Growth on galactose is known to stress cells [516] and alters the 
synthesis of UDP-glucose (a substrate for cell wall polymers and glycoproteins). It is 
therefore possible that the genes involved in cell wall and glycoprotein synthesis may be 
involved in a general response to growth on galactose i.e. these suppressors may act by 
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relieving the stress caused by galactose and not NleG8-2. In order to determine if this is the 
case, NleG8-2 could be expressed from an alternative expression vector containing a different 
promoter (e.g. tetO promoter).    
 
Further studies could also make use of stress-inducing conditions e.g. caffeine, high 
temperature to determine if yeast cells expressing NleG8-2 are more sensitive to the effects of 
the effector under these conditions and also to see if the suppressor activity of a given gene is 
lost under these conditions. For example, changes in suppressor activity in the presence of 
Brefeldin A (a drug that disrupts the Golgi [517]) might indicate that the suppressor functions 
by relieving stress on the Golgi caused by NleG8-2. There are numerous methods that could 
be used to detect secretory stress. A block in membrane trafficking from the ER causes a 
slowing of phospholipid synthesis in the ER and can be detected by increased triacylglycerol 
synthesis using fluorescence-activated cell sorting (FACS) [518].      
 
6.4.11. Validation of microarray results and issues raised 
 
The Affymetrix microarray is, like other types of microarray, subject to limitations. Statistical 
settings and filters may lead to different conclusions as changes in gene expression may 
appear to be significant (or not) based on the test/P-value used. To ensure the statistical 
validity of the microarray results several steps were taken during the course of the experiment 
to reduce discrepancies. Three biological replicates of yeast expressing NleG8-2 and yeast 
expressing pYES-DEST52e (empty vector control) were performed; yeast cells were 
harvested at the same growth rate and yeast were frozen immediately after harvest to prevent 
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alterations in gene expression due to changes in environmental conditions. However, the 
possibility of differences in gene expression due to expression of an exogenous protein i.e. 
non-specific effects, should be considered. The variance in transcription for all probes should 
also be considered in order to assess whether the differentially regulated genes as listed in 
tables 6.4 and 6.5 were the only genes to show transcriptional changes when NleG8-2 was 
expressed. Unfortunately, graphical data showing the variance in transcription across all 
probes was not available. Microarray results could be validated further by performing more 
replicates. Also, performing a microarray on mammalian enterocytes infected with EPEC 
expressing NleG8-2 and enterocytes infected with an EHECΔNleG8-2 mutant may provide 
further evidence for the role of NleG8-2 in EHEC O157:H7 infection (although redundancy 
between NleG effectors as discussed in chapter 1 may affect interpretation of results). 
 
6.4.12. Evaluation of the techniques used 
 
The two approaches, microarray and high copy suppression screen complemented each other. 
Results from the HCS screen validate results from the microarray. For example, YIP3 was 
identified in the HCS screen and was seen to be down-regulated using the microarray. This is 
evidence to suggest that NleG8-2 affects YIP3 or a pathway requiring YIP3. Results from this 
study imply that NleG8-2 affects vesicular trafficking in the host cell, possibly through 
disruption of Rab GTPase membrane targeting. Future investigations into the effects of 
NleG8-2 should therefore concentrate on characterising the ER, Golgi and the secretory 
pathway in mammalian/yeast cells expressing NleG8-2.   
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CHAPTER SEVEN 
Discussion 
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7.1. Discussion 
 
7.1.1. Summary of findings 
 
Type III secretion is an important virulence factor of EHEC O157:H7. T3SS effectors 
encoded within the LEE have been well characterised. However, many effectors that are 
encoded outside the LEE are only just beginning to be investigated. The work presented in 
this thesis investigated several novel EHEC O157:H7 Sakai T3SS effectors that had been 
predicted in silico by PSI-BLAST homology searches.  
 
Work began by investigating the translocation of putative effectors through the LEE encoded 
T3SS. Evidence that candidate effectors were secreted via type III secretion was provided by 
a β-lactamase translocation assay. The results from this assay, plus several other 
secretion/translocation assays performed by collaborators, confirmed that 39 candidate 
effectors were T3SS effectors. This exciting result confirms that the repertoire of T3SS 
effectors in EHEC O157:H7 is much larger than previously imagined.  
 
Investigations into the localisation of effectors in mammalian cells revealed that novel 
effectors localise to various cellular compartments and organelles. Observation of the actin 
cytoskeleton in cells expressing novel effectors revealed that the EspM2 effector caused the 
formation of actin stress fibres in mammalian cells.   
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A yeast cell model was also employed to investigate the effects of selected effectors on cell 
growth, shape and physiology. Expression of a small number of effectors was toxic to yeast 
and inhibited yeast growth. Effects of effector expression also included redistribution of chitin 
in yeast cell walls and unusual cell morphology. Mutagenesis of EspM2 revealed that the 
conserved WxxxE motif is required for effector toxicity but that other regions and residues of 
the proteins may also be important.   
 
Finally, work focused on the effector NleG8-2. Transcriptomics and a high copy suppression 
screen were used to investigate disruption of yeast cellular physiology. Results from both 
screens were promising and showed that NleG8-2 might target vesicular trafficking within the 
cell. Dissection of sequence-activity relations for NleG8-2 was also attempted, revealing that 
yeast growth inhibition was dependent on three conserved C/H/D residues. This finding 
supports the hypothesis that NleG8-2 functions enzymatically. This is the first time that an 
NleG family member has been shown to have an effect on host cells. In conclusion, the results 
summarised above satisfy the aims of the thesis listed in chapter one. 
  
7.1.2. Re-evaluation of thesis 
 
In re-evaluating this thesis, a number of issues are raised. For example, during transfection 
experiments it may have been productive to try other cationic lipid-based transfection 
reagents to improve transfection efficiency and reliability. Despite the problems associated 
with transfection, mammalian cells appear to be better than yeast for localisation studies as 
they are much larger - thus enabling subcellular structures to be visualized more easily.  
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Overall, the yeast cell model was useful for initial screening of effector toxicity – the yeast 
were easy to handle and the system allowed effectors to be screened simultaneously. 
However, more insight into effector function would have been gained through the use of 
‘stressors’ in yeast growth assays as discussed in chapter 5. More insight into cellular 
localisation of effectors in yeast may also have been gained through the use of additional 
reporter strains and confocal microscopy, unfortunately these were not available during this 
study.  
 
7.1.3. Further work arising from this thesis 
 
Results from this thesis provide many avenues for further work. A pressing issue is to provide 
a definitive function/target of NleG8-2. Firstly, as discussed in chapter six, genes identified 
from the high copy suppression screen must be investigated for suppressor activity 
individually to define which are true suppressors. Secondly, the secretory system of yeast 
expressing NleG8-2 should be investigated to determine whether vesicular trafficking is 
disrupted. Although, no definitive function for NleG has been found in this study, the 
expansion of the NleG family in EHEC O157:H7 and the presence of numerous functional 
NleG genes in EHEC O157:H7 suggests that this effector is a significant player in EHEC 
O157:H7 virulence or colonisation. In order to determine the role of NleG in EHEC 
pathogenicity or colonisation, NleG could be knocked out and the effects of EHEC O157:H7 
ΔNleG investigated using a bovine infection model, bIVOC or human IVOC. Alternatively 
EHEC NleG genes could be introduced into EPEC (possesses one NleG) and the effects on 
EPEC pathogenicity investigated. 
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Further questions regarding NleG8-2 include:  
 What is the structure of NleG8-2? 
 With which eukaryotic proteins does NleG8-2 interact? Purification of NleG8-2 was 
attempted during this study but was unsuccessful. Further work using alternative 
expression vectors may enable pull down/co immunoprecipitation studies to be 
performed and eukaryotic target proteins to be identified. 
 How are the conserved Cys136, Asp162 and His176 residues involved in effector function 
– is NleG8-2 a cysteine protease? 
 Is NleG8-2 necessary for colonisation of humans or cattle? 
 
In addition to questions regarding NleG8-2, there remain further questions regarding EHEC 
T3SS, effectors and pathogenicity in general: 
 What are the functions of the remaining novel effectors? 
 How much redundancy is there between the T3SS effectors of EHEC O157:H7? 
 Are effectors involved in colonisation of cattle/humans or are they involved in 
bacteria-protozoa interactions e.g. do they offer defence against predation? 
 Do effectors act in combination with other effectors – is the combination of effectors 
more important than each individual effector (as has been proposed by Kenny et al 
[357])?  
 Does the combination of effectors define host specificity as shown for P. syringae 
[356]? 
  
228 
 
Interestingly, recent work by Asadulghani et al [294] demonstrated that although many Sakai 
prophages, that carry effectors in their passenger compartments, are defective (with the 
exception of NleA and Stx harbouring phage), many were able to excise themselves from the 
host genome, replicate, package phage DNA and be released from O157:H7 cells. Transfer of 
these apparently defective prophage to other E. coli was also demonstrated, probably due to 
interactions between defective prophage resulting in formation of functional phage [294]. 
These findings have exciting implications for T3SS effector research and our understanding 
of EHEC O157:H7 evolution. The use of next generation DNA sequencing technology and 
the increase in the number of sequenced bacterial genomes will undoubtedly reveal the 
existence of other T3SS effectors and provide insight into the vast metagenome to which 
EHEC O157:H7 phage-encoded effectors belong. Type-III secretion systems and their 
effectors will provide stimulus for exciting research for years to come.  The mid-throughput 
approaches to effector confirmation, localisation and functional characterisation described in 
this thesis provide a useful framework for investigating novel T3SS effector repertoires.  
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